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Abstract
Adenosine 5’-triphosphate (ATP) has been shown to be an important extracellular signaling 
molecule that mediates various physiological activities via the P2 (P2X and P2Y) receptors. 
However, information on the expression patterns of the P2 receptors during mammalian 
embryogenesis is limited. We therefore examined the expression patterns of different P2 
receptor subtypes in rat embryos. In the hindbrain neural tube, the P2 X3 receptor was 
transiently expressed at embryonic day E ll in the cranial motor neurons and the outgrowing 
axons. ATP significantly inhibited neurite outgrowth from neural tube explants. P2 X3 
receptors were also prominently expressed in sensory ganglia at this early stage and were 
coexpressed with P2 X2  receptors in E l6.5 embryos. Other P2X receptor subtypes were 
observed in different brain regions such as subventricular zones, the site of postnatal 
neurogenesis. In addition, the P2Y receptor expression was detected in the somites and 
subsequently in the developing skeletal muscle but was downregulated as development 
proceeded. While the P2 Y 1 receptor was no longer expressed in the adult skeletal muscle, the 
expression of P2 Y2  receptor was present, although restricted in the satellite cells and the P2 Y4  
receptor showed reduced expression in adult skeletal muscle. Likewise, the expression of the 
P2Y receptors was initially expressed throughout the myocardium (E l2) but was gradually
•  9 -1-restricted to the trabeculated myocardium (E l4-18). Studies on Ca influx showed that
particular P2 receptor subtypes of P2X2, P2 X4 , P2Yi, P2 Y2 , P2 Y4  and P2Y6 receptors 
responded to nucleotides in E l4 cardiomyocytes. P2 X7 receptor expression was detected in 
developing pancreatic islet cells and later coexpressed with glucagon in a-cells. In addition, 
transient expression of the P2 X7 receptor in insulin-expressing cells was observed in the 
embryonic, but not in adult, islet cells. Together, the results indicated that widespread and 
dynamic expression of P2 receptors was found in the three-germ layer-derived embryonic 
tissues, particularly in some transient embryonic structures during development, which 
suggested they may be important in embryonic organogenesis
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Chapter I General Introduction
I. General Introduction
1.1 Brief historical perspective on purinergic signaling
Ll.a ATP as an extracellular signaling molecule
Adenosine triphosphate (ATP), a molecule which belongs to the purine family, was first
identified in muscle cells independently by Fiske and Subbarow and by Lohmann in 1929
(see Schlenk, 1987; Maruyama, 1991). The chemical structure of ATP is made of a
nitrogenous base (adenine), a sugar (ribose) and a chain of three ionized groups (phosphates)
bound to the ribose (see Bodin and Bumstock, 2001a). In the field of biochemistry, the
most important value of ATP lies on its phosphate groups, which can undergo hydrolytic
release in aqueous solution with large negative free energy changes. Therefore ATP was
thought of largely as a store of free energy in the cell soon after its discovery, and even till
now. Hydrolysis of ATP is used to drive innumerable biochemical reactions, including
♦
many that are not phosphorylations. It is a source of energy for cell motility, muscle 
contraction, and the specific transport of substances across membranes (Mathews and van 
Holde, 1990). ATP was generated during anaerobic glycolysis in the cytoplasm, within the 
citric cycle and predominantly during oxidative phosphorylation in the mitochondria 
(Kalckar, 1969). Hydrolysis of ATP can proceed in either of two ways. Either the terminal 
phosphate can be cleaved off to produce adenosine diphosphate (ADP) and phosphate (Pj), or 
cleavage may occur at the second phosphodiester bond to yield adenosine monophosphate
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(AMP) and pyrophosphate (PPi). The former reaction is the more common one in vivo, but 
the free energy yield is about the same for both. As a result, ATP soon appeared as the most 
fundamental of all biomolecules and the universal source of readily available chemical 
energy for all living cells. It has been estimated that ATP participates in more chemical 
reactions than any other compound on the earth’s surface, except water (Bumstock, 1996).
Because of this essential intracellular role, there was a considerable resistance to the 
concept that ATP could exert any extracellular physiological action, the main argument being 
that cells would not release a bio-molecule so fundamental to life, a line of thought which 
was reinforced by the fact that a molecule the size and charge of ATP could not cross the 
plasma membrane by simple diffusion (Glynn, 1968; Chaudry, 1982). Very soon after the 
discovery of ATP, however, it became apparent that purine nucleotides were able to exert 
profound extracellular effects on different organs and tissues.
In the same year of ATP discovery, Drury and Szent-Gyorgyi (1929) reported the first 
time that extracellular purines were responsible for a negative chronotropic effect on the 
heart, a dilatation of coronary vessels and an inhibition of the spontaneous activity of the 
intestinal smooth muscle, though the crude tissue extracts used contained mostly AMP (see 
Vassort, 2001). In 1959, Holton showed that ATP was released to the rabbit ear artery
2
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during antidromic stimulation of sensory nerve, resulting in vasodilatation. Hughes and 
Vane (1967, see Bumstock, 1979) also noted that the responses of the rabbit portal vein to 
ATP resembled the inhibitory responses to the nonadrenergic, noncholinergic (NANC) 
intramural nerve stimulation. The NANC nerves, which were characterized by the 
responses upon the stimulation in the presence of adrenergic and cholinergic neuron blocking 
agents (or in the absence of adrenergic and cholinergic stimulation), were first defined in 
1963 (Bumstock et al, 1963, 1964; Martinson and Muren 1963), although atropine-resistant 
responses of the urinary bladder were described as far back as 1895 by Langley and 
Anderson (see Bumstock, 1986). Before ATP was identified to be the actual transmitter for 
NANC stimulation, other biochemicals were explored as possible candidates, e.g. 
catecholamines, 5-hydroxytryptamine, cyclic adenosine monophosphate (cAMP), histamine, 
prostaglandins, amino acids such as glycine and y-aminobutyric acid (GABA), and 
polypeptides bradykinin and substance P. However, these substances were rejected by most 
researchers on the grounds that they were either inactive or did not mimic the nerve-mediated 
response, or that their action was by stimulation of nerves and not by direct action on smooth 
muscle (Bumstock et al., 1970). Evidence that ATP was synthesized, stored and released 
from NANC nerves supplying the intestinal smooth muscle, together with considerable 
additional evidence available, led Bumstock to propose that ATP was a primary 
neurotransmitter in NANC nerves in the gut and bladder and thus put forward the purinergic
3
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nerve hypothesis (Bumstock, 1972). In the following years, the purinergic signaling was 
described in many other tissues and systems (see Bumstock, 1979, 1997).
1.1. b Source and mechanisms of ATP release
Considering that ATP functions as an extracellular signaling molecule, it must have a 
source of release. Both neuronal and non-neuronal cells have been shown to release ATP. 
A pilot study for neuronal ATP release has shown that ATP was released from the nerve 
endings upon antidromic stimulation of the sensory nerve (Holton, 1959). However, it was 
not until Bumstock (1972) proposed the purinergic hypothesis that ATP became a clear 
candidate for a neurotransmitter. Bumstock (1976) challenged the principle that nerve cells 
released one transmitter; his group had shown that ATP might be released from sympathetic 
nerves, together with noradrenaline in taenia coli (Su et al., 1971), and much supporting 
evidence has accumulated since then (see Bumstock, 1990, 1999a). Moreover, ATP was 
shown early on to act as a cotransmitter with acetylcholine in the bladder (Bumstock et al., 
1978) and with noradrenaline in the cat nictitating membrane (Langer and Pinto, 1976), vas 
deferens (Vizi and Bumstock, 1988; Westfall et al., 1978), the rat tail artery (Sneddon and 
Bumstock, 1984) and the aorta (Sedaa et al., 1990).
There have been an increasing number of studies describing ATP release from
4
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non-neuronal cells. The first hint of ATP release from non-neuronal cells was shown in the 
circulation of the occluded human forearm in response to effort (Forrester and Lind, 1969). 
Direct proof came from the investigation on isolated cells present in the vascular system such 
as platelets (Detwiler and Feinman, 1973), red blood cells (Bergfeld and Forrester, 1989), 
mononuclear cells (Maugeri et al., 1990), endothelial cells and smooth muscle cells (Pearson 
and Gordon, 1979; Bodin et al., 1991), which all release ATP mostly upon mechanical 
stimulation. Other cell types shown to release ATP, including distended uroepithelial cells 
(Ferguson et al., 1997), pancreatic p cells (Hazama et al., 1998), astrocytes (Contrina et al., 
1998), glial cells (Queiroz et al., 1999), Sertoli cells (Lalevee et al., 1999) and chondrocytes 
(Graff et al., 2000). ATP can be released from non-neuronal cells by a large variety of 
stimuli, including, among others, hypoxia, acidosis, osmotic shock, receptor stimulation, 
fluid shear stress and mechanical stimulation (Detwiler and Feinman, 1973; Bergfeld and 
Forrester, 1989; Bodin and Bumstock, 1996). Recent findings identify transport proteins 
belonging to the ATP-binding cassette (ABC) family that transport ATP or at least stimulate 
the activity of a separate ATP channel protein (Schwiebert, 1999). The most common ABC 
proteins are the cystic fibrosis transmembrane conductance (CFTR), P-glycoprotein and the 
sulfonylurea receptor (SUR) (see Bodin and Bumstock, 2001a).
1.2 Purinergic receptors
5
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1.2. a Classification of purinoceptors
Extracellular purines and pyrimidines mediate diverse physiological activities by acting 
on cell surface receptors termed purinergic receptors or purinoceptors (see Abbracchio and 
Bumstock, 1998). There are two main families of purine receptors, adenosine or PI 
receptors, and P2 receptors, recognizing primarily ATP, ADP, UTP and UDP (Bumstock, 
1978). Adenosine or PI receptors have been further subdivided, according to convergent 
molecular, biochemical, and pharmacological evidence into four subtypes, A;, A2a, A2 5 , and 
A3, all of which couple to G-proteins (see Ralevic and Bumstock, 1998). Similarly, P2 
receptors, based on differences in molecular structure and signal transduction mechanisms 
were divided into two families: the ligand-gated ion channels (P2X receptors) and G 
protein-coupled receptors (P2Y receptors) (Abbracchio and Bumstock, 1994). To date, 
seven P2X receptors subtypes and eight P2Y receptors have been cloned (Bumstock, 2003). 
Individual subtypes of P2X and P2Y receptors will be discussed separately, with emphasis on 
the extent of homology between members within the family, tissue distributions (in rat, 
unless specified) and pharmacological characteristics of individual receptors.
1.2. b P2X receptors
P2X receptors are ligand-gated ion channels opened by micromolar extracellular ATP. 
The receptors mediate rapid (within 10 ms) and selective permeability to cations (Na+, K+,
6
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2+Ca ). To date, seven P2X receptor subunits (P2 X 1.7) currently known are encoded by 
different genes. Each subunit has a topology that is fundamentally different from that of 
other known ligand-operated channels. P2X receptors are made of proteins, with 379-595 
amino acids, inserted in the membrane to form a pore comprising two hydrophobic 
transmembrane domains with a large extracellular hydrophilic loop. The NH2 and COOH 
termini are presumed to be cytoplasmic. The actual P2X receptors are formed from either 
homomeric or heteromultimeric association of the subunits. The putative extracellular loop 
of cloned P2 X 1-7 has 10 conserved cysteine and 14 conserved glycine residues as well as 2 to 
6  potential N-linked glycosylation sites. Most of the conserved regions are in the 
extracellular loop, with the transmembrane domains being less well-conserved. Taken 
together both the extracellular loop and the transmembrane domains, the proteins are from 40 
to 55% pairwise identical. The P2 X4  sequence is most closely related to more of the other 
forms, and the P2 X7 sequence is least like the others; these observations are true whichever 
species are considered (see North, 2002). The disulfide bridges present in the extracellular 
loop are believed to form the structural constraints needed to couple the ATP-binding site to 
the ion pore. As mentioned above, all the P2X receptor subunits have consensus sequences 
for N-linked glycosylation (Asn-X-Ser/Thr). Receptors in which any two of the three sites 
are glycosylated appear at the cell surface and are fully functional, whereas those in which 
only one site is glycosylated give barely detectable currents in response to ATP, and channels
7
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with no sites glycosylated give no current (see North, 2002).
The recombinant receptors formed from homomeric association of subunits, when 
expressed in Xenopus oocytes or in mammalian cells have been functionally characterized 
and show distinct pharmacological profiles (see Ralevic and Burnstock, 1998). Almost all 
known ionotropic receptors exist as hetero-oligomers (Barnard, 1992). More importantly, 
the functional and pharmacological characteristics of the receptors are directly determined by 
the subunit composition, with different subunit combinations yielding different phenotypes 
(Barnard et al., 1998). Functional studies of native receptors, together with patterns of 
subunit gene expression, suggest heteromultimeric assembly among members of the P2X 
receptors (Cook et al., 1997; Lewis et al., 1995). Studies by coimmunoprecipitation have 
also determined which pairs of subunits are potentially able to coassemble, as not all 
combinations are possible (Table 1) (Torres et al., 1999). Briefly, with the exception of 
P2X6, all the other P2X receptor subunits formed homo-oligomeric complexes. When 
co-assembly between pairs of subunits is examined, all are able to form hetero-oligomeric 
assemblies with the exception of P2 X7 receptor. P2 X5 receptor is tlhe only receptor subunit 
that is able to form hetero-oligomeric complexes with all the member,?s within the family.
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1.2.b.i P2Xj receptor
Using a cDNA library generated from rat vas deferens, the first cDNA encoding the 
P2Xj receptor was isolated by direct expression in Xenopus oocytes. (Valera et al., 1994). 
The recombinant receptor, having a single open reading frame encoding 399 amino acids, is 
activated by agonists with the order of potency as 2MeSATP > ATP > ap-meATP »  ADP 
and UTP, and inward currents evoked by these compounds are reversibly blocked by general 
P2 receptor antagonists like suramin and pyridoxalphosphate-6-azophenyl-2’,4,-disulfonic 
acid (PPADS) (Valera et al., 1994). Sustained application of agonist to P2Xi receptors 
results in rapid channel opening (few milliseconds), fast desensitization (300 ms) and 
receptor internalization (1-3 min). The receptors reappear at the cell surface soon after 
agonist application is terminated (see North, 2002).
P2Xi receptor mRNA is expressed in urinary bladder, smooth muscle layers of small 
arteries and arterioles, and vas deferens, with lower levels in lung and spleen (Valera et al., 
1994; Collo et al., 1996). The P2Xi receptor seems to be the most significant P2X receptor 
subtype in vascular smooth muscle, which was revealed by the similar electrophysiological 
profiles and pharmacological properties observed in smooth muscle (Bean, 1992). 
Therefore, it is believed that the vascular smooth muscle P2X receptor is a P2Xj receptor 
homomer (see Ralevic and Bumstock, 1998). In addition, the P2Xi receptor is also
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expressed in myocardium (Hou et al., 1999) and nervous tissues including dorsal root ganglia, 
trigeminal ganglia, celiac ganglia, spinal cord, and rat brain (Valera et al., 1994, Kidd et al., 
1995, Collo et al., 1996; Xiang et al, 1998, Kukley et al., 2001).
1.2. b. ii P2X2 receptor
The P2X2 receptor was first cloned from rat pheochromocytoma PC 12 cells (Brake et al.,
1994). The homology between P2 X2 receptor (472 amino acids) and other members of the 
family is shown in Table 2. ATP, ATP-yS and 2MeSATP are approximately equipotent for 
P2 X2  receptor at eliciting non-selective inward cation currents, whereas ap-meATP and 
P,y-meATP are inactive as agonists or antagonists (Brake et al., 1994). However, there are 
no agonists or antagonists currently known that are selective for P2 X2  receptors. 
Nevertheless, P2 X2 receptor has a special feature of its marked sensitivity to change in pH 
which makes it distinct from the other P2X subtypes, even from P2Y and PI receptors (King 
et al., 1996). When expressed in the oocytes, the receptor shows a maximum response to 
ATP at pH 6.5. The P2 X2  receptor undergoes little or no desensitization. It also differs
9+ * • • •from the P2Xi receptor in that it is less permeable to Ca and shows much higher sensitivity 
to inhibition by extracellular Ca2+ (Evans et al., 1996). Apart from Ca, other divalent 
cations cause a fast block of the single P2 X2 channels with the order of potency as Mn > Mg 
> Ca > Ba, which is the order of ionic radii. This suggests that the divalent ions are binding
10
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to a charged site within the channel (Ding and Sachs, 1999; 2000). The divalent ions can 
also inactivate the channel with the order of effectiveness as Ca> Mg > Ba > Mn (Ding and 
Sachs, 2000).
P2X2 receptor mRNA is distributed in bladder, brain, spinal cord, superior cervical 
ganglia, adrenal medulla, intestine and vas deferens, with highest levels found in the pituitary 
gland and vas deferens (Brake et al., 1994). Recently, expression was also reported in retina 
(Greenwood et al., 1997), cochlea (Housley et al., 1999), vascular smooth muscle (Nori et al., 
1998), thymus (Glass et al., 2000), osteoclasts (Hoebertz et al., 2000), sympathetic ganglia 
(Schadlich et al., 2001) and skeletal muscle fiber (Ryten et al., 2001). Distinct but restricted 
patterns of distribution have been described in rat brain (see Norenberg and Illes, 2000).
A splice variant of a P2 X2 receptor has been isolated from rat cerebellum (Brandle et al., 
1997; Simon et al., 1997). The receptor protein (called P2X2b) has a 69 amino acid deletion 
of the carboxyl-terminal, shows a similar distribution in the rat central and peripheral nervous 
system as the original P2 X2 receptor, and forms homomeric receptor mediating inward 
currents to ATP. Although they are equipotent to agonists, P2X2b showed significantly 
lower antagonist sensitivity and a faster rate of desensitization compared to P2 X2  receptor.
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1 .2 .b. iii P2X3 receptor
The P2 X3 receptor subunit cDNAs were cloned from rat dorsal root ganglion (Chen et 
al., 1995; Lewis et al., 1995) and was predicted to be 397 amino acids, with the amino acid 
sequence exhibiting different degree of identity with other members of the family (Table 2). 
P 2 X3 receptor shows similar profiles with P2Xi receptor upon agonist activation. It, is 
rapidly activated by agonists with a potency order of 2MeSATP »  ATP > a  p-me ATP > 
ATP-yS »  ADP »  UTP ~ p,y-meATP, and undergoes rapid desensitization with slow 
recovery in high ATP concentration (in less than 100ms). These shared characteristics 
makes the two homomeric receptors distinct from the other homomeric forms. The
a
antagonists suramin, PPADS, and TNP-ATP do not readily distinguish between P2Xi and 
P2 X3 receptors, but NF023 is approximately 20 times less effective at P2 X3 than P2Xi 
receptors. The P2 X3 receptor is remarkably insensitive to block by extracellular calcium
9+(Virginio et al., 1998). In contrast, increasing the extracellular Ca concentration can 
greatly accelerate the recovery from desensitization (Cook and McCleskey, 1997; Cook et al.,
1998).
The P2 X3 receptor has a very restricted tissue distribution in the nervous system. It is 
expressed only by a subset of sensory neurons (trigeminal, nodose, and dorsal root ganglia), 
most of them are capsaicin-sensitive neurons involved in nociception (Chen et al., 1995;
12
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Lewis et al., 1995; Vulchanova et al., 1998; Xiang et al., 1998). Accordingly, P2 X3 protein 
or its mRNA was found in cell bodies of sensory neurons, and in their central termination 
fields (dorsal horn of the spinal cord, nucleus of the solitary tract), as well as in their 
peripheral endings, e.g. in taste buds and the spiral ganglion of the inner ear. However, 
P 2 X3 was also found in other areas such as supraoptic nucleus and sympathetic ganglia (see 
Norenberg and Illes, 2000), retina (Wheeler-Schilling et al., 2001) and endothelial cells 
(Glass and Bumstock, 2001).
However, in other areas, such as certain sensory neurons in the central and peripheral 
nervous system and sympathetic ganglion cells, the action of ATP is mimicked by a (3-meATP, 
but slow desensitization. This type of response is later confirmed to be generated by 
heteromeric P2 X2 /3  receptor (Lewis et al., 1995; Radford et al., 1997; Torres et al., 1999). 
The heteromer shares some properties with homomeric P2 X2 receptor: it is potentiated by 
low pH, and shows low desensitization. On the other hand, the heteromeric P2 X2 /3  receptor is 
activated by a (3-meATP, and blocked by TNP-ATP as well as PPADS and suramin, all of 
which are the properties of P2 X3 homomer.
1.2 .b.iv P2X 4 receptor
The cDNAs for the rat P2 X4  receptor has been cloned from rat hippocampus (Bo et al.,
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1995) and subsequently from rat brain (Seguela et al., 1996; Soto et al., 1996), superior 
cervical ganglia (Buell et al., 1996) as well as pancreatic islet cells (Wang et al., 1996). The 
amino acid identity between P2 X4  receptor (388 amino acids) and other members of the 
family is shown in Table 2. The P2 X4  receptor is activated by ATP and partially by 
2-MeSATP, and ap-meATP is either weak or inactive, whereas ADP, UTP and py-meATP are 
inactive. Expression of P2 X4  receptor gives an ATP-activated cation-selective channel that
I I
has a significantly high Ca permeability, and whose agonist sensitivity is increased by Zn 
without altering maximal response (Soto et al., 1996). Desensitization at P2 X4  receptors is 
intermediate between that observed at P2X] and P2 X2 receptor (Seguela et al., 1996).
The rat P2 X4  receptor, but not its human homologue, is unusual in its low sensitivity to 
blockade by the widely used ATP antagonists, suramin, Reactive blue2 and PPADS and 
indeed, responses to ATP are even potentiated (Bo et al., 1995). A lysine residue present in 
the P2Xi and P2 X2 receptors, but absent in the P2 X4  receptor, is believed to be critical for the 
binding of antagonists but not agonists (Buell et al., 1996).
P2 X4  receptor expression is widely distributed in the brain and other tissues such as 
spinal cord, sensory ganglia, superior cervical ganglion, lung, bronchial epithelium, thymus, 
bladder, acinar cells of the salivary gland, adrenal gland, testis and vas deferens (Bo et al.,
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1995; Buell et al., 1996; Collo et al., 1996; Seguela et al., 1996). Recent studies have 
shown that P2 X4  receptor also expressed in vascular smooth muscle (Nori et al., 1998), inner 
ear tissues (Brandle et al., 1999), pancreas (Hede et al., 1999), oesteoclasts (Hoebertz et al., 
2000), endothelial cells and follicular cells in thyroid (Glass and Bumstock, 2001) and retina 
(Brandle et al., 1998; Wheeler-Schilling et al., 2000; Wheeler-Schilling et al., 2001).
1.2.b.v P2X 5 receptor
The P2 X5 receptor cDNA was first isolated from cDNA libraries constructed from rat 
celiac ganglion and heart (Collo et ah, 1996; Garcia-Guzman et al., 1996). The extent of 
amino acid identity between the 417 amino acid-P2Xs receptor protein and the members 
within the family is shown in Table 2. Rapid inward currents are activated by ATP > 
2MeSATP > ADP. The most striking feature of the current elicited by ATP in cells 
expressing the rat P2 X5 receptor is their small amplitude, compared with the currents 
observed with P2Xi, P2 X2 , P2 X3 , or P2 X4 receptors expressed under similar conditions. 
However, P2Xs receptor shared some similar features with P2 X2  receptors: they show little 
desensitization, are not activated by ap-meATP, and are blocked by suramin and PPADS at 
concentrations similar to those effective at P2 X2  receptors (Collo et al., 1996; 
Garcia-Guzman et al., 1996).
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P2 X5 receptor shows a very restricted expression pattern in the brain, where the 
expression was only found in the mesencephalic trigeminal nucleus and pineal gland (Collo 
et al., 1996). In the peripheral nervous system, expression was also detected in the ventral 
horn of the cervical spinal cord (Collo et al., 1996), sensory ganglia (Xiang et al., 1998,
1999), sympathetic neurons (Schadlich et al., 2001), retinal ganglion cells and 
(Wheeler-Schilling et al., 2001). Other tissues expressing P2Xs receptor are stratified 
squamous epithelia of the skin (Groschel-Stewart et al., 1999a), duodenal globet cells 
(Groschel-Stewart et al., 1999b), developing skeletal muscle (Ryten et al., 2001), vascular 
smooth muscle cells and the follicular cells in the thyroid (Glass and Bumstock, 2001).
Recent papers have reported the existence of heteromeric P2 Xj/5 receptors with unique 
features (Torres et al., 1998; Haines et al., 1999; Surprenant et al., 2000). The heteromeric 
receptor is more sensitive to ATP than those with homomeric receptors. Although the 
P2 Xi/5  receptor is less sensitive to ap-meATP than the homomeric P2Xi receptor, the 
heteromer shows a sustained current evoked by aP-meATP, which is not seen for either of the 
homomers when expressed separately. The currents generated by the heteromeric receptor 
are considerably larger than those seen with P2Xs subunits expressed alone, and the current is 
inhibited by either an increase or a decrease of the extracellular pH. Furthermore, P2 Xj/5
1
heteromer is much less permeable to Ca than the P2Xi homomer.
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1.2.b. vi P2X6 receptor
The cDNA for P2X6 receptor was isolated from a rat superior cervical ganglion cDNA 
library (Collo et al., 1996). The predicted receptor protein has 379 amino acids and the 
sequence shows homology with other P2X receptors (Table 2). Currents evoked by ATP in 
P2X6 receptor-expressing cells resembled those seen for the P2X2 receptor. Rapid currents 
are mediated by ATP > 2MeSATP > ADP with little desensitization, whereas ap-meATP has 
no effect. Currents are only partially inhibited by antagonist such as suramin or PPADS. 
Although the currents in cells expressing P2X6 receptor were large, they were observed in 
only a small fraction of cells examined.
The mRNA transcript of P2X6 receptor is heavily expressed in the CNS, with heaviest 
staining in cerebellar Purkinje cells and ependyma. The mRNA is also present in the spinal 
cord, trigeminal, dorsal root and celiac ganglia. In non-neuronal tissues, P2X6 receptor 
mRNA is prominent in gland cells of the uterus, granulose cells of the ovary, and bronchial 
epithelia (Collo et al., 1996). Immunoreactivity of the P2X6 receptor protein has been 
shown in superior cervical and celiac ganglia (Xiang et al., 1998), thymic epithelial cells 
(Glass et al., 2000), vascular smooth muscle (Glass and Bumstock, 2001) and developing 
skeletal muscle (Ryten et al., 2001).
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Coimmunoprecipitation studies have shown that P2X6 receptor has a very low tendency 
to form homomeric ion channel due to failure of self co-precipitation (Torres et al., 1999). 
Instead, accumulated evidence has suggested the presence of two P2X6-possessing 
heteromeric ion channels, the P2 X2 /6  and P2 X4 /6  heteromeric receptors. Cells expressing the 
P2 X2 /6  receptors have subtly different responses to ATP than those expressing P2 X2  receptors 
only (King et al., 2000), with the most convincing one being the biphasic inhibition of the 
current by suramin at pH 6.5; one component has the high sensitivity of homomeric P2 X2 
receptor whereas the other is less sensitive. For the P2 X4 /6  heteromers, the currents elicited 
by ATP are larger in cells transfected with P2 X4  and P2X6 receptor mRNA than those 
transfected with P2 X4  only (Le et al., 1998).
1.2. b. vii P2X 7 receptor
The P2 X7 receptor of 595 amino acids cloned from rat macrophages and brain 
(Surprenant et al., 1996) is the cytolytic P2Z receptor previously described in mast cells, 
macrophages, fibroblasts, lymphocytes, erythrocytes and erythroleukemia cells. The 
recombinant receptor has an agonist potency order of BzATP »  ATP »  2MeSATP > 
ATP-yS > ADP, whereas ap-meATP and py-meATP are ineffective. The P2 X7 receptor, 
though insensitive to suramin and PPADS, is inhibited by divalent cations, KN62 and
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oxidized ATP (see Ralevic and Bumstock, 1998). The unique feature of P2 X7 receptors is 
that under normal physiological conditions, the receptors are selectively permeable to small 
cations only, whereas in the continued presence of ATP and when divalent cation levels are 
low, the ion channels can convert to a pore, permeable to both molecules and ions. The 
currents evoked do not readily desensitize. Instead, longer applications of either BzATP or 
ATP result in increased permeability to larger organic cations, and the currents take longer to 
decline after each application. Prolonged stimulations may also result in cell swelling, 
vacuolization, and cell death by necrosis or apoptosis (Dubyak and el-Moatassim, 1993). 
P2 X7 receptor is structurally similar to other P2X receptors except having a significantly 
longer intracellular C-terminal (240 amino acids) than the other members of the P2X receptor 
family, of which the last 177 amino acids are crucial for non-selective pore formation 
(Surprenant, 1996, Smart et al., 2003). Another interesting feature is that after a brief 
exposure to ATP, the effectiveness of ADP and AMP is increased, suggesting that a brief 
initial exposure to ATP caused a long lasting change in the receptor, which subsequently 
alters its ability to differentiate ATP from ADP and AMP (Chakfe et al., 2002). According 
to Torres et al (1999), P2 X7 receptors do not co-immunoprecipitate with other members of 
the family.
P2 X7 mRNA and protein are distributed in immune cells (Collo et al., 1997), parotid
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acinar cells (Tenneti et al., 1998), retina (Brandle et al., 1998), rat duodenal enterocytes and 
goblet cells and stratified squamous epithelium (Groschel-Stewart et al., 1999a; 1999b), 
pancreas (Hede et al., 1999), kidney (Harada et al., 2000), vascular smooth muscle cells and 
endothelial cells (Glass and Bumstock, 2001), brain (Deuchars et al., 2002; Sperlagh et al., 
2002) and cochlea (Nikolic et al., 2003).
1.2.cP2Y receptors
P2Y receptors are purine and pyrimidine nucleotide receptors that are coupled to G 
proteins. Although the purinergic receptors were originally cloned for receptors that are 
activated by purine nucleotides such as ATP and ADP, receptors for pyrimidines that are 
activated specifically by uridine nucleotides (UTP and UDP) were first proposed by Seifert 
and Schultz (1989). For the current 8  mammalian P2Y receptors cloned, 5 of them (P2 Y]52 , 
4,6,12) have their orthologs cloned in rats. The rat P2Y receptors are 328 to 374 amino acid 
proteins. The typical P2Y receptor protein, like other G protein-coupled receptors, consists 
of 7 predicted hydrophobic transmembrane domains. However, the P2Y receptor family 
differs from other known families of G protein-coupled receptors by a high diversity in the 
amino acid sequences of its different members within the same species, despite a much 
higher homology found between a particular receptor subtype in different species (see Von 
Kugelgen and Wetter, 2000). The amino acid similarity of P2Y receptor sequences is
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summarized in Table 3. Some highly conserved amino acids residues encode for the 
transmembrane regions 3, 5, 6  and 7 have been suggested to contribute to the agonists 
binding (Van Rhee et al., 1995).
The signaling pathway of P2 Yif2 ,4 ,6  receptors is coupling to phospholipase C, leading to
• • • 9 +formation of inositol 1,4,5-triphosphate (IP3) and mobilization of Ca from intracellular 
stores (see Von Kugelgen and Wetter, 2000). Increase in IP3 and intracellular Ca2+ can 
stimulate a variety of pathways including protein kinase C (PKC), phospholipase A2 and 
nitric oxide synthase which subsequently can activate other pathways such as phospholipase 
D and mitogen-activated protein kinase (MAPK). Coupling to adenylate cyclase by 
P2 Yim 4  receptors has also been described (see Ralevic and Bumstock, 1998). The response 
time of P2Y receptors is longer than that of the P2X receptors because it involves 
second-messenger systems.
1.2.c. i P2Yj receptor
The P2Yi receptor was originally cloned from late embryonic chick brain (Webb et al.,
1993) and the orthologs were then detected in several mammalian species. The P2Yi 
receptors cloned from different mammalian species are all of 373 amino acids. In all 
species, the receptor is selective for adenine nucleotides, and especially, nucleotide
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diphosphate. However, the receptors present in different species show different agonists 
with different order of potency. In rat tissue, the recombinant receptor (in rat) is activated 
by agonists with a potency order of 2MeSADP > ADP > 2MeSATP > ATP, whereas 
ap-meATP and UTP are inactive (Tokuyama et al., 1995; Vohringer et al., 2000; see also Sak 
and Webb, 2002). The most potent antagonist for P2Yi receptor is MRS2179 (see Von 
Kugelgen and Wetter, 2000). The signal transduction pathway of recombinant P2Yi 
receptor is the activation of phospholipase C, which involves the G protein Gq/n 
characterized by its insensitivity to pertussis toxin.
P2Yi receptor is expressed in spleen, lung, liver, kidney, (Tokuyama et al., 1995), heart 
(Webb et al., 1996), lens fiber cells (Merriman-Smith et al., 1998), astrocytes (Fam et al., 
2000), brain (Moran-Jimenez and Matute, 2000), hepatocytes (Dixon et al., 2000), skeletal 
muscle (Choi et al., 2001) and osteoclasts (Hoebertz et al., 2001).
1.2.b.ii P2 Y2 receptor
The first cloned P2 Y2  receptor was isolated from mouse neuroblastoma cells (Lustig et 
al., 1993) and subsequently in rat alveolar type II cells (Rice et al., 1995). The P2 Y2 
receptor (374 amino acids) is activated by ATP and UTP with approximately equal potency 
and is insensitive or is only weakly activated by ADP, UDP and other nucleoside
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diphosphates, 2MeSATP and aPmeATP (see Sak and Webb, 2002). There are no selective 
antagonists for P2 Y2  receptors, though it is antagonized by suramin and PPADS. P2 Y2  
receptor can couple via both Gj/0 and Gq/n proteins to mediate phospholipids breakdown and 
phosphoinositides as well as Caz+ mobilization via PLCp, an effect which may accordingly 
be pertussis toxin-sensitive, -partially sensitive, or -insensitive (See Dubyak and 
el-Moatassim, 1993). For a given signaling pathway, a variety of downstream signaling 
molecules was reported and seems to be partially dependent on the cell type in which the 
P2 Y2  receptor is expressed (see Ralevic and Bumstock, 1998).
P2 Y2 receptor expression is widely distributed, and some of the physiological 
significance of P2 Y2 receptor expression has been reported. P2 Y2 receptor present on the 
endothelium stimulates the synthesis and release of prostacyclin and nitric oxide, leading to 
vasodilatation. On the other hand, P2 Y2  receptors on neutrophils stimulate degranulation 
and consequently induce aggregation. UTP stimulates mucin secretion from globet cells, 
increased surfactant released from type II alveolar cells, and increase the beat frequency of 
cilia in isolated normal and cystic fibrosis epithelial cells (Kellerman, 2002).
1.2 .c.iii P2 Y4 receptor
The P2 Y4 receptor was first cloned from human placenta (Communi et al., 1996) and
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then from rat heart (Bogdanov et al., 1998b). The cDNA cloned from rat heart gives rise to 
a predicted protein of 361 amino acids. Although the human P2 Y4  receptor is highly 
selective for uracil nucleotide over adenine nucleotide, the rat counterpart is activated 
equipotently by the full agonists ATP and UTP, whereas the partial agonists such as 
2MeSATP, ADP and ATP-yS are also equipotent. (Bogdanov et al., 1998b). The receptor 
causes rapid Ca mobilization upon agonist stimulation (Webb et al., 1998). The P2 Y4  
receptor is insensitive to UDP stimulation (see Sak and Webb, 2002). The receptor is 
reversibly antagonized by Reactive blue 2 but not by either PPADS or suramin, which helps 
differentiated it from the P2 Y2  receptor.
The rat P2 Y4  receptor shows a restricted expression pattern. The receptor transcript 
has been detected in the heart (Bogdanov et al., 1998b), neonatal brain, skeletal muscle and 
spleen, and adult vas deferens and spinal cord (Webb et al., 1998), pancreas (Hede et al., 
1999), cochlear tissues (Teixeira et al., 2000), kidney (Bailey et al., 2000) and bile duct 
epithelia (Dranoff et al., 2001).
1.2.c.iv P2 Y6 receptor
This uridine nucleotide-specific receptor has been cloned from rat aortic smooth muscle 
(Chang et al., 1995). The rat P2Y6 receptor consists of 328 amino acids, the shortest
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sequence among the family. The receptor is activated most potently by UDP, which is 
approximately 100-fold more potent than UTP, whereas ATP, ADP or 2MeSATP are almost 
inactive (Nicholas et al., 1996). The P2Y6 receptor is blocked by Reactive blue 2 and 
suramin. The response is pertussis toxin insensitive, indicating the involvement of Gq/n 
proteins in stimulation of PLC and in the formation of IP3 (Chang et al., 1995).
The P2Y6 mRNA is found abundantly in various tissues including lung, stomach, 
intestine, spleen, mesentery and aorta (Chang et al., 1995), heart (Webb et al., 1996), cochlear 
tissues (Teixeira et al., 2000) and kidney (Bailey et al., 2001). The more widespread 
distribution of the P2 Y6 receptor, compared with the P2 Y4 receptor, suggests that this 
receptor is more likely to account for endogenous uridine nucleotide-specific responses.
1.2.c.v P2Ya receptor
The P2Yn receptor was cloned from human placenta (Communi et al., 1997). The 
predicted protein possesses 371 amino acids. The receptor coupled to the stimulation of 
both the phosphinositide and the adenylyl cyclase pathways. The P2Y n receptor is the only 
P2Y receptor selective for ATP because it is stimulated by agonists with a rank order of 
potency of ATP > 2MeSATP > ATP-yS »  ADP, with UTP and UDP inactive (Communi et al.,
1997). The P2Y n receptor is antagonized by suramin and partially by Reactive blue 2, but
25
Chapter I General Introduction
not by PPADS (Communi et al., 1999). Quantitative RT-PCR study has shown that P2Yn 
receptor is strongly expressed in the brain lymphocytes and spleen (Moore et al., 2001).
1.2. c. vi P2Y)2 receptor
The human and rat P2Yn  receptors were both cloned from platelets cDNA library and 
presented in the same report (Hollopeter et al., 2001). The rat P2 Yi2 receptor is a 
343-amino acid protein which is activated by agonists in the order of potency as 2MeSATP > 
2MeSADP > ADP »  ATP (Simon et al., 2002). It has to be noted that 2MeSATP acts as a 
very potent agonist in recombinant P2 Yi2 receptor, whereas it appears weaker in cells 
expressing endogenous P2 Yi2  receptor, or even act as antagonists in platelet cells (Simon et 
al., 2002). The response is antagonized by Reactive blue 2 and suramin, but not by PPADS 
or MRS2179, which is selective for P2Yi receptor (Kulick and von Kugelgen, 2002). The 
receptor couples to pertussis toxin-sensitive G-proteins (Gj/0) and inhibits adenylyl cyclase 
upon agonist stimulation (Kulick and von Kugelgen, 2002; Simon et al., 2002). In addition, 
the receptor coupled to Gj/0 also interacts with the inward rectifier K+ channel and the voltage 
gated Ca channel, suggesting that it involves another transduction pathway independent of 
second messengers and downstream P2Y signaling (Simon et al., 2002). Expression of 
P2 Yi2  receptor is so far detected in neuronal cells (Unterberger et al., 2002), glioma cells 
(Czajkowski et al., 2002), endothelial cells (Simon et al., 2002) and platelets (Hollopeter et
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al., 2001).
1.2 . c. vii P2 Y]3 receptor
An orphan G-protein coupled receptor (SP174) was cloned from a human neutrophil 
cDNA library and, together with the preexisting mouse ortholog, designated as P2Yn 
receptors (Zhang et al., 2002). The receptor contains a 1002-base open reading frame 
encoding 333 amino acid residues, which shows highest homology with P2 Y ]2  receptor (45%) 
and the UDP-glucose receptor (later confirmed to be P2Yh receptor) (43%) (Zhang et al.,
2002). The receptor is activated by agonists with a decreasing order of potency of 
2MeSADP = 2MeSATP > ADP > ATP. The receptor couples to Gi proteins and adenylyl 
cyclase pathway.
The mRNA dot blot experiment shows that strong expression is detected in spleen, 
pancreas, brain and liver (Zhang et al., 2002).
1.2.c.viii P2Y14 receptor
An orphan G-protein coupled receptor that specifically responds to UDP-glucose and 
related sugar-nucleotides (Nomura et al., 1994; Chambers et al., 2000) was recently 
confirmed to be a human P2Ym receptor (Abbracchio et al., 2003). This receptor is
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originally cloned from human myeloid cells and designated an orphan receptor (Nomura et 
al., 1994). Sequence comparisons reveal that it is structurally related to the known members 
of the human P2Y receptor family (Chambers et al., 2000), with 18-45% overall identity 
mainly distributed in the transmembrane domains. A G-protein coupled receptor cloned 
from ventral tegmentum in rat shows 80% amino acid identity and a fully conserved amino 
acid motif in the sixth and the seventh transmembrane domains with P2 Y h receptor, 
suggesting that it is the rodent ortholog for P2Y14 receptors.
The recombinant P2Ym receptor is responsive to the agonists such as UDP glucose, 
UDP-galactose, UDP -glucuronic acid and UDP-N-acetylglucosamine, whereas ATP, ADP, 
UTP or UDP do not activate the receptor. Pertussis toxin completely abolishes agonist 
responses, indicating the receptor to be coupled to Gj/ 0  protein (Wittenberger et al., 2001). 
The rat P2Y14 receptor shows highest expression in cells of haemopoietic origin and clear 
expression in the brain (Charlton et al., 1997).
1.3 Purinergic signaling during embryonic development
1.3. a Brief introduction on mammalian embryonic development
1.3. a. i From zygote to bilaminar germ disc
Embryonic development starts from the moment when an oocyte is fertilized by a sperm.
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The chromosomes of the oocyte and sperm enclosed within the female and male pronuclei 
respectively fuse with each other to produce a single diploid zygote (see Larsen, 1998). 
Within a short period of time after fusion of the pronuclei, the zygote undergoes a series of 
mitotic cell divisions along the journey from the oviduct to the uterus to form a round shaped 
morula, consisting of around 32 cells enclosed in an acellular layer called zona pellucida. 
The centrally placed cells (embryoblasts) will form the inner cell mass that gives rise to most 
of the embryo proper, whereas the cells at the periphery (trophoblasts) are the primary source 
for the membranes of the placenta. Hydrostatic pressure develops within the morula due to 
continued fluid entry, resulting in the development of a large cavity within the morula and the 
embryo is now called blastocyst. When the morula reaches the uterus, the blastocyst 
hatches from the clear zona pellucida and eventually implants tightly to the uterine wall. 
Meanwhile, the embryoblast splits into an external columnar cell layer called epiblast and an 
internal cuboidal cell layer called hypoblast. The two layers together make up the bilaminar 
germ disc.
1.3. a. i i Gastrulation
The bilaminar germ disc is later converted into a trilaminar germ disc by a process of 
gastrulation whereby epiblast cell migrate towards and through a region, called the primitive 
streak, to form the so-called mesoderm (see Larsen, 1998). The primitive streak develops
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when a groove (primitive groove) appears along the longitudinal midline of the germ disc 
and then elongates to occupy about half the length of the embryo. A deeper depression 
called primitive node develops at the presumptive cranial end of the groove. With the 
formation of mesoderm, the hypoblast is replaced with a new cell layer derived from epiblast 
called endoderm, while the epiblast itself is transformed into the ectoderm. Thus the 
mesoderm separates the overlying ectoderm from the subjacent endoderm. The most 
important achievement of gastrulation is that it establishes the basic vertebrate body plan: the 
anteroposterior and the dorsoventral axes, for the developing embryo.
I.3.a.iii Somite formation and development o f  urogenital system and limb
The mesoderm that forms in the midline gives rise to a transient structure called 
notochord. The mesoderm adjacent to the notochord forms the paraxial mesoderm, which 
soon undergoes segmentation to form somitomeres and then to somites. These somites will 
give rise to the myotomes, sclerotomes and dermatomes that form skeletal muscle, vertebrae 
and skin, respectively. The intermediate mesoderm forms just lateral to the paraxial 
mesoderm will later give rise to the urinary system. Three sequential urinary systems 
develop from the intermediate mesoderm, i.e. i) cervical nephrotomes, which are never 
functional; ii) a thoracolumbar mesonephric system, which functions briefly during 
embryonic life; iii) a sacral metanephric system, which ascends to the lumbar region forming
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the definitive kidney (see Larsen, 1998). The metanephric system is developed by 
reciprocal interaction between the ureteric buds that branch from the mesonephric ducts and 
the metanephric blastema, both of which are derived from intermediate mesoderm (see 
Larsen, 1998; Vainio and Lin, 2002), resulting in the formation of nephrons differentiated 
within the metanephric blastema, and the collecting systems formed by bifurcation of the 
ureteric buds. The most lateral mesoderm, the lateral plate mesoderm, contributes to the 
formation of the body wall and to somatic and visceral peritoneum (see Larsen, 1998).
Migration of the primordial germ cells to the posterior body wall results in induction of 
the genital ridges just medial to the mesonephros on each side of the midline. Cells from 
the mesonephros and the coelomic epithelium invade the mesenchyme in the region of the 
presumptive gonads to form the primitive sex cords that surround the germ cells. 
Interaction between the mesonephric and paramesonephric ducts and the primitive sex cords 
results in the formation of gonads (see Larsen, 1998).
At the stage when the cranial neural tube closure is almost complete, somites induce 
proliferation of the lateral plate mesoderm in the presumptive limb region to form outgrowths 
called limb buds, which are covered by surface ectoderm. The limb buds differentiate along 
three interrelated axes: the proximodistal, the craniocaudal and the dorsoventral axes. The
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lateral plate mesoderm also gives rise to the bones, tendons, ligaments and vasculature of the 
limbs, while the somites migrate to the limb bud and contribute to the muscular component 
of the limbs. Development of the forelimb buds occurs prior to that of the hindlimb buds 
(see Larsen, 1998).
1.3. a. iv Neurulation and neural crest migration and differentiation
The axial mesoderm, including notochord, induces thickening of the overlying ectoderm 
to form a bilateral thickened epithelium, the neural plate. The neural plate appears first at 
the cranial end of the embryo and differentiates craniocaudally. The neural plate is broad 
cranially and tapered caudally. Completion of gastrulation is followed by another very 
important process called neurulation. Neurulation commences as the neural plate begins to 
fold on either side and come into contact and, eventually, fuse with each other to form a 
hollow tube along the embryo (see McLachlan, 1994). Neurulation does not take place 
simultaneously along the whole length of the forming tube: it begins in the region between 
the developing hindbrain and upper neck and then extends cranially and caudally. Closure 
of the cranial neural tube occurs prior to that of the caudal neural tube. Before neurulation, 
several expansions occur in discrete regions of the cranial neural plate. Soon after 
neurulation, the expansions undergo further enlargement and flexing to form the brain 
vesicles that give rise to the future brain, with the caudal neural tube forming the future
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spinal cord.
Neural crest cells are a special population of cells that arises along the lateral margins of 
the neural folds (see Larsen, 1998). During neurulation, these cells detach from the neural 
plate and migrate ventro-laterally to many locations in the body, where they differentiate into 
a remarkable variety of structures, e.g. in the peripheral nervous system, the neural crest cells 
differentiated into glia cells and ganglia including dorsal root, sympathetic chain, enteric, 
preaortic and some cranial ganglia (trigeminal, facio-acoustic, glossopharyngeal and vagal). 
Other neural crest derivatives include arachnoid and pia mater, dermal bones of skull, 
pharyngeal arch cartilages, connective tissue surrounding papillary and ciliary muscle in the 
eyes, odontoblasts and melanocytes, adrenal medulla, truncoconal septum, dermis and 
hypodermis of face and neck.
1.3. a. v Development o f  cardiovascular system
The heart is the first organ to function in the embryo. It is originated from a group of 
mesoderm-derived angioblasts that, subject to induction by the endoderm, differentiated into 
flattened endothelial cells that join together to form a pair of vascular elements called the 
endocardial tubes locating cranial and lateral to the neural plate early before neurulation. 
During embryonic folding, the tubes are brought into the thoracic region, where they meet
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along the midline and fuse to form a single primitive heart tube. A series of constrictions 
and expansions forms along the primitive heart tube that contributes to the various heart 
chambers (see Larsen, 1998). The heart tube formed soon undergoes looping, which helps 
bringing the primitive atria and ventricles in their adult positions. Trabeculation takes place 
in the looped heart, which is believed to be important for myocardial growth (see Sedmera et 
al., 2000). Remodeling also occurs in the looped heart to establish the proper connection 
for systemic and pulmonary circulation, followed by septation of the heart and valve 
formation.
1.3. a. vi Development o f  respiratory and gastrointestinal system
In early stages, the embryo is a flat, ovoid disc. Due to differential growth of various 
embryonic structures, the flattened disc is converted into a 3-dimensional embryo (see Larsen,
1998). The endoderm of the trilaminar embryo is destined to give rise to the lining of the 
respiratory and gastrointestinal tract. Embryo folding also converts the superior and inferior 
portions of the endoderm into blind-ended tube that gives rise to a cranial blind-ended 
foregut, a midgut that opens into the yolk sac, and a caudal blind-ended hindgut. The lungs 
emerged from the outpouching of the endodermal foregut as lung bud. The lung bud begins 
to grow ventrocaudally through the mesenchyme surrounding the foregut. Soon after, the 
lung bud bifurcates into right and left primary bronchial buds. The primary bronchial buds
34
Chapter I General Introduction
undergo continue branching morphogenesis, followed by mesenchymal thinning, epithelial 
differentiation and surfactant protein expression (see McMurtry, 2002).
Gut development involves invagination of endoderm and the subsequent growth and 
differentiation of the subjacent splanchnic mesenchyme (mesodermal). Thus, the gut is 
composed of an outer mesodermal-derived smooth muscle and an inner endodermal-derived 
luminal lining flanking the most anterior (mouth) and most posterior (anus) 
ectodermal-derived epithelium (see Roberts, 2000). The foregut itself will form the thoracic 
and abdominal esophagus, stomach, and about half the duodenum; the midgut will form half 
the duodenum, the jejunum and ileum, ascending colon, and two-thirds of the transverse 
colon. The hindgut will form one-third of the transverse colon, the descending and sigmoid 
colons, and rectum. Meanwhile, endodermal bud sprouts from the inferior end of the 
foregut and develops into liver, gallbladder and pancreas, whereas the nearby spleen is 
formed by mesodermal condensation (see Larsen, 1998).
I.3.b Purinergic signaling during embryonic development
An embryo requires different cell activities such as cell proliferation, differentiation, 
migration and degeneration that work in orchestra to ensure proper embryonic development. 
It therefore requires specific signals given by specific signaling molecules at specific time
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points. Various signal transduction pathways then cross-talk with each other to provide 
positional information and induce cell fate specification. Many signaling molecules are 
well known to regulate various developmental processes in embryos. Examples of those 
signaling molecules include Sonic hedgehog (Shh), fibroblast growth factors (FGF), bone 
morphogenic proteins (BMP), Notch and Delta, retinoic acid and Wnt family signaling 
pathway.
Accumulated evidence suggests that extracellular nucleosides and nucleotides may exert 
profound effects during embryonic development in different species (see Bumstock, 2001). 
In early zebrafish embryo, an ionotropic P2 X3 receptor is expressed in the trigeminal 
primordial and the spinal sensory Rohon-Beard cells and in the putative posterior lateral line 
ganglion (Norton et al., 2000). Studies on Xenopus cell culture have shown that 
extracellular ATP potentiates acetylcholine (ACh) responses at developing neuromuscular 
synapses during early phase of synaptogenesis (Fu and Poo, 1991; Fu, 1994; Fu and Huang,
1994). In addition, endogenously released ATP acting in concert with various protein 
kinases, is involved in the maintenance and/or development of the quantum size of synaptic 
vesicles at embryonic neuromuscular synapses (Fu et al., 1997). A novel P2Y purinoceptor 
(X1P2Y or P2Ys) was expressed in the neural plate of Xenopus embryos from stages 13 to 18 
and again at stage 28 when secondary neurulation occurs in the tail bud (Bogdanov et al.,
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1997). However, expression ceased after neural tube closure, suggesting that this receptor 
may be important during early neurogenesis.
ATP, but not pyrophosphate, AMP, ADP or GTP, has been shown to induce precocious 
evagination of the embryonic chick thyroid, an event which has been hypothesized to be 
involved in the formation of the thyroid gland from the thyroid primordium (Hilfer et al., 
1977). A transmitter-like action of ATP on patched membranes of myoblasts and myotubes 
cultured from 12-day-old chick embryos was reported (Kolb and Wakelam, 1983). ATP has 
a potent depolarizing activity on myotubes derived from pectoral muscle cultured from 
11-day-old chick embryos (Hume and Honig 1986). At embryonic day 6  of chick embryo, 
ATP elicits vigorous contractions in all the muscles tested, but by embryonic day 17 none of 
the muscles contract in responses to ATP. However, denervation of muscles in newly 
hatched chicks leads to the reappearance of sensitivity to ATP, suggesting that the expression 
of ATP receptors is regulated by motor neurons (Wells et al., 1995). Meyer et al (1999b) 
have shown that expression of two purinoceptors (P2Xs and P2X6 receptors) was detected in 
developing skeletal muscle of chick embryos. These receptors were first expressed at early 
stages of skeletal muscle development, whereas expression disappeared immediately before 
myotube formation i.e. fusion of myoblasts to form myotubes. In the embryonic chick 
neural retina, ATP or UTP induced an increase in intracellular Ca2+ and the response is
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blocked by suramin and Reactive blue 2, which suggests that the intracellular Ca2+ rise is 
mediated by P2 Y2 or P2 Y4  receptors. Interestingly, such increase is dramatically reduced 
just before synaptogenesis, indicating a very specific temporal effect of extracellular 
nucleotides (Sugioka et al., 1996). During the first 10 days of embryonic development, 
P2Yi receptor is expressed in a developmentally regulated manner in the limb buds, 
mesonephros, brain, somites and facial primordia of the chick embryos (Meyer et al., 1999a). 
It is also specifically expressed in the undifferentiated limb mesenchyme in chick embryo, 
and the expression was lost when the tissue differentiated. Application of ATP or ADP, the 
potent agonists for P2Yj receptor, inhibits cartilage formation in micromass culture (Meyer et 
al., 2001). It was therefore suggested that ATP acting on P2Yi receptor is involved in the 
differentiation of limb mesenchymal cells, more specifically in regulating cartilage formation, 
during embryonic development.
In rat embryos of embryonic day 16, expression of P2 X3 receptor is detected in the 
distinct regions of the brainstem such as mesencephalic trigeminal nucleus, superior and 
inferior olives, intermediate reticular zone, the spinal trigeminal tract and the prepositus 
hypoglossal nucleus. The expression, however, is downregulated in the postnatal brain. The 
P2 X3 receptor in the adult animal has been shown to be involved in sensory functioning. 
The expression in non-sensory related regions in the embryonic brain and subsequent
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downregulation as development progresses suggests a role to play during mammalian 
neurogenesis. Dynamic expression of different P2X receptors (P2Xs, P2X6 and P2 X2 
receptors) was reported in rat developing skeletal muscle (Ryten et al., 2001) in which P2Xs 
and P2 X6 receptors were expressed transiently in the embryonic skeletal muscle, consistent 
with the results of Meyer et al (1999b). While P2X6 and P2 X2 receptor expression was 
widespread along the myotubes, P2Xs receptor was restricted to regions of muscle close to 
the myotendinous junctions. The same authors also reported that addition of ATP into rat 
skeletal muscle satellite cell culture isolated from rat skeletal muscle inhibits cell 
proliferation, together with an upregulation of markers of muscle cell differentiation 
(myogenin, p2 1  and myosin heavy chain) and an increase in the rate of myotube formation. 
UTP, in contrast, induces an increase in satellite cell proliferation. Addition of ATP also 
enhances phosphorylation of MAPKs, particularly p38 (Ryten et al., 2002). Inhibition of 
p38 activity reverses the ATP-induced suppression of cell proliferation. All the findings 
mentioned above suggest that extracellular nucleotides, by acting via P2 receptors, are likely 
to play roles during embryonic development.
1.4 Objective of studies
Although it appears that extracellular nucleotides are candidates of signal transduction 
molecules involved in embryonic development, many of the studies were performed in
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non-mammalian species. In addition, early studies on purinergic signaling in embryos were 
performed prior to receptor cloning, and systematic analysis on expression patterns of 
purinergic receptors during embryogenesis is lacking. Thus, the present study is mainly 
focused on the expression patterns of P2 purinoceptors, both P2X and P2Y receptors, during 
mammalian (rat) embryogenesis. Studies of the expression patterns of purinoceptors in 
mammalian embryos are crucial to our understanding on the specific roles of extracellular 
nucleotides in the embryonic development. Particular interest will be given to those 
receptors that show dynamic expression patterns during embryonic development. The 
correlation between the spatio-temporal expression of both purinoceptor mRNA transcripts 
and the receptor proteins and the occurrence of different developmental process will also be 
examined. Furthermore, with the clues obtained from the expression studies, functional 
studies will also be carried out to investigate the possible functions of particular 
purinoceptors during the development of rat embryos.
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Table 1 Summary of the potential ability of co-assembly between P2X receptor subunits
P 2X i P2X 2 P2X 3 P2 X 4 P2X S P2X 6 P 2X 7
P2X i + + + - + + -
P2X 2 + + - + + -
P2X 3 + - + - -
P2 X4 + + + -
P2X S + + -
P2X 6 - -
P2X 7 +
HEK 293 cells transfected with P2X receptor subunits tagged with either FLAG 
(DYKDDDDK) or the HA (YPYDVPDYA) epitopes into the carboxyl termini were 
undergone immunoprecipitation. subunits immunoprecipitated with antibody to
one epitope could be detected with an antibody to the second epitope. (Data from 
Torres et al., 1999).
41
Chapter I General Introduction
Table 2 Amino acid identity of P2X receptor subunits
P 2X i P2X 2 P2X3 P2X4 P2X S P2X 6 P 2X 7
P2X , 100 (100) 40.5 (40.6) 46.4 (47.9) 50.6 (50.3) 45.5 (44.7) 46.8 (46.2) 44.9 (45.1)
P2X 2 100 (100) 51.5 (51.1) 50.5 (50.5) 46.9 (46.9) 42.7 (42.7) 41.0 (41.0)
P2X 3 100 (100) 49.2 (48.6) 47.0 (49.3) 41.4 (43.2) 43.1 (44.7)
P2X» 100 (100) 53.5 (55.4) 47.3 (47.6) 49.8 (48.6)
P 2X S 100 (100) 49.2 (48.5) 42.0 (42.0)
P2X6 100 (100) 39.2 (41.0)
P2X 7 100 (100)
The identities between amino acid sequences at the transmembrane regions and large 
extracellular loop of the rat P2X receptor subunits were expressed in percentage. 
The percentages in parenthesis represent the identities between human P2X receptor 
subunits.
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Table 3 Amino acid identity of P2Y receptors
P 2Y i P 2Y 2 P2Y 4 P2Y 6 P 2Y n P 2Y 12
P2Y , 100 (100) 32 (31) 33 (34) 33 (33) (26) 20 (19)
P2Y 2 100 (100) 48 (51) 39 (37) (25) 22 (20)
P2Y 4 100 (100) 41 (38) (23) 23 (21)
P2Y 6 100 (100) (23) 19 (23)
P 2Y n (100) (15)
P 2Y 12 100 (100)
The identities between amino acid sequences of the rat P2Y receptor subtypes were 
expressed in percentage. The percentages in parenthesis represent the identities 
between human P2Y receptor subtypes. Note that rat P2Yn receptor has not yet 
been cloned.
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Chapter II Localization of P2X3 receptors and 
coexpression with P2X2 receptors during rat 
embryonic neurogenesis
ABSTRACT
It is well known that extracellular ATP mediates rapid excitatory signaling by means of the 
ionotropic P2X receptors. One of its subunits, the P2 X3 receptor, is well documented to be 
associated with sensory innervation in adult animals. It is speculated that the P2 X3 receptor 
may have already been present in the early sensory system. The aim of this study was to 
investigate the distribution of the P2 X3 receptor during neurogenesis by using 
immunohistochemistry on rat embryos from embryonic day (E) 9.5-18.5. The P2 X3 receptor 
was first identified in the hindbrain neural tube and the sensory ganglia in El 1-11.5 embryos. 
At E14.5, the optic tract and retina, nucleus tractus solitarius, mesencephalic trigeminal 
nucleus, and sensory nerves in both respiratory and digestive tract showed positive staining. 
The facial nucleus, the prepositus hypoglossal nucleus, and the sympathetic ganglia also 
showed P2 X3 immunoreactivity, even though these are not sensory associated. P2 X3 
immunoreactivity was detected in the vestibular nucleus, the nerves in mesentery, bladder, and 
kidney in E16.5 and in nerves in vibrissae in E l8.5. P2 X3 immunoreactivity in the facial
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nucleus, spinal trigeminal tract, the mesencephalic trigeminal nucleus, and the vestibular 
nucleus were undetectable in postnatal day 16 rat brainstem. The P2 X3 receptor was 
coexpressed with the P2 X2  receptor in nucleus tractus solitarius, dorsal root ganglion, nodose 
ganglion, and the taste bud in E l6.5 embryo, which was 5 days later than the first appearance 
of the native P2 X3 receptor. In summary, we present a detailed expression pattern of the P2 X3 
receptor during neurogenesis and report that P2 X3 immunoreactivity is down-regulated in early 
postnatal brainstems.
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INTRODUCTION
Purine compounds such as adenosine 5'-triphosphate (ATP) play important roles in energy 
metabolism, synthesis of nucleic acids, and regulation of enzymes in living organisms. 
Nevertheless, the functions of these compounds are not restricted to intracellular actions but 
also to extracellular signaling. In recent years, the biological functions of extracellular ATP as 
a neurotransmitter and a neuromodulator have been studied intensively (Bumstock, 1997; 
Abbracchio and Bumstock, 1998). Extracellular ATP evokes responses by means of two 
families of P2 receptors, namely P2X and P2Y purinoceptors (Kennedy and Bumstock, 1985; 
Abbracchio and Bumstock, 1994). The P2X receptors consist of ligand-gated ion channels, 
which mediate rapid and selective permeability to certain types of cations (Na+, K+, Ca2+) 
(Bean, 1992; Dubyak and El Moatassim, 1993; North, 1996). To date, seven subunits of P2X 
receptors have been cloned (P2 X 1-7) from different tissues (reviewed by Ralevic and Bumstock,
1998). P2Y receptors are purine and pyrimidine nucleotide receptors that are coupled to G 
proteins, with eight established subtypes in mammals recently proposed (Abbracchio et al.,
2003).
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The distribution of the seven cloned P2X receptors in the central nervous system (CNS) has 
been well studied in adult rat (Kidd et ah, 1995; Collo et al., 1996, 1997; Soto et al., 1996; 
Kanjhan et al., 1999; Yao et al., 2001). Among the P2X receptor subunits, P2 X3 is well known 
to show strong expression in sensory neurons (Vulchanova et al., 1997; Llewellyn-Smith and 
Bumstock, 1998; Xiang et al., 1998). Xiang et al. (1998) demonstrated that the P2 X3 receptor 
is highly expressed in trigeminal, nodose, and dorsal root ganglia compared with other P2X 
receptors studied. Studies of coexpressed P2 X2 /P2 X3 receptors and native P2X receptors in 
sensory neurons indicate heteropolymerization of P2 X2 and P2 X3 receptors (Lewis et al., 1995; 
Vulchanova et al., 1997; Virginio et al., 1998). Homomeric P2 X3 receptor is expressed in the 
capsaicin-sensitive, small dorsal root ganglion neurons, whereas the heteromeric P2 X2 /3  
receptor is expressed in the capsaicin-insensitive, medium neurons (Ueno et al., 1999). These 
results all suggest the involvement of purinergic signaling in sensory function by means of the 
action of the P2 X3 receptor. This has been reinforced in knockout experiments in which 
P2X3-deficient mice exhibited a marked urinary bladder hyporeflexia and showed a reduction 
in pain sensation (Cockayne et al., 2000). However, Xiang et al. (1998) have demonstrated the 
expression of P2 X3 receptor protein in scattered neurons in superior cervical and coeliac 
ganglia. In addition, Glass and Bumstock (2001) have also reported P2 X3 receptor expression 
in thyroid follicular and endothelial cells, suggesting that the P2 X3 receptor may have other 
roles in addition to sensory functioning.
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There is growing evidence to suggest that purinergic signaling is involved in early 
embryonic development. Purinoceptors were shown to be one of the first functionally active 
membrane receptors in chick embryo cells during gastrulation, in which, by means of
9 +purinoceptors, ATP induced rapid accumulation of inositol phosphate and Ca mobilization in 
a similar way and to the same extent as acetylcholine (Laasberg, 1990). Recent reports also 
implicate ATP as a key regulator of the development of various organs and systems in frog and 
chick as well as in mammalian embryos (reviewed by Bumstock, 1996, Bumstock, 2001). 
Responses to ATP have been described in chick ciliary neurons acutely dissociated from day 
14 embryonic ciliary ganglia (Abe et al., 1995). In many cases, responses to extracellular ATP 
have been shown to vary, depending upon the stage of embryonic development. For example, 
ATP elicits vigorous muscle contraction at embryonic day 6 (E6), but by El 7, no effect of ATP 
on muscle contraction is observed (Wells et al., 1995). Meyer et al. (1999) demonstrated that 
two P2X receptor subunits, P2Xs and P2X6, were first expressed at early stages of chick 
skeletal muscle development and expression disappeared immediately before fusion of 
myoblasts to form myotubes. These data strongly suggest that P2X receptors play a role in 
embryonic development. However, although the involvement of P2X receptors has been shown 
in early development of chick embryo (Meyer et al., 1999a,b), there is little information 
regarding the expression and function of the P2X receptors in mammalian embryos. One study
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by Ryten et al. (2001) demonstrated the sequential expression of P2X5, P2X6, and P2 X2 
receptor subtypes in developing rat skeletal muscles, whereas Kidd et al. (1998) reported P2 X3 
receptor expression in various nuclei such as spinal trigeminal tract, mesencephalic trigeminal 
nucleus, and solitary nucleus in late embryonic rat brain; this expression was down-regulated 
in young adult brain. This finding clearly demonstrates the presence of the P2 X3 receptor in the 
sensory system of the prenatal central nervous system. For the peripheral nervous system, the 
sensory ganglia such as the trigeminal ganglia and dorsal root ganglia have their primordial 
tissues present as early as in E10 and in E ll  in the rat embryo, respectively (Kaufman and 
Bard, 1999; Kaufman, 1992). However, it is not currently known whether P2 X3 receptors are 
already expressed during early neurogenesis of the sensory system and, if present, whether 
P2 X3 receptor subtypes are expressed as homomeric receptors or coexpress with other P2X 
receptor subtypes (especially P2 X2  receptors).
It is not currently known whether P2 X3 receptors (either homomeric or heteromeric forms) 
are expressed during early neurogenesis. Thus, in the present study, we investigated the 
distribution of P2 X3 receptors during the development of the nervous system in the rat embryo. 
Expression of P2 X3 receptor protein in the neonatal rat brain was examined to show whether 
there is a down-regulation of P2 X3 receptor protein expression after birth. Coexpression of
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P2 X2 and P2 X3 by double labeling was also examined to investigate whether P2 X2 and P2 X3 
receptor coexpression is a common phenomenon during early neurogenesis.
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MATERIALS AND METHODS
Tissue preparation
The embryonic expression of P2 X3 receptor protein was studied in Sprague-Dawley rat 
embryos of E9.5-18.5 by using immunohistochemical techniques. Postnatal rat brain on 
postnatal day (P) 1 and P I 6  were chosen for examination. The day of identification of the 
presence of a vaginal plug was designated as day zero (EO). Pregnant Sprague-Dawley rats 
were killed by asphyxiation with a rising concentration of CO2  (between 0 % and 1 0 0 %), and 
death was confirmed by cervical dislocation according to Home Office (UK) regulations 
covering schedule 1 procedures. Embryos from prenatal day 9.5-18.5 were collected and fixed 
in 4% paraformaldehyde in 0.1 M phosphate buffer (PB; pH 7.2) at 4°C overnight. Embryos 
were then washed in 0.1 M phosphate buffered saline (PBS, pH 7.2) and dehydrated by using 
10% sucrose, 20% sucrose, and finally 30% sucrose. Thereafter, the embryos were immersed 
in OCT-embedding medium and frozen in precooled isopropanol (-70°C) for cryosectioning. 
Whole embryos were serially cryosectioned (12pm) and mounted on gelatin-coated slides and 
dried at room temperature. Every section cut was analyzed for immunoreactivity. Neonatal rat 
brains were dissected after cervical dislocation, and the brains were fixed and processed as
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described above. Frozen sections (15pm) sections were cut and mounted. One in every ten 
sections was analyzed for immunoreactivity.
Immunohistochemistry
Immunohistochemistry for P2X receptors was performed by using rabbit polyclonal 
antibodies against a unique peptide sequence of P2 X2 and P2 X3 receptor subtypes provided by 
Roche Bioscience, Palo Alto, CA (Oglesby et al., 1999). The immunogens used for production 
of polyclonal P2 X3 antibody were synthetic peptides corresponding to the carboxyl terminal of 
the cloned rat P2 X2  and P2 X3 receptors, covalently linked to keyhole limpet hemocyanin. The 
peptide sequences of the P2 X2 and P2 X3 receptors are of amino acid sequence 458-472 
(QQDSTSTDPKGLAQL) and 383-397 (VEKQSTDSGAYSIGH), respectively. The 
polyclonal antibodies were raised by multiple, monthly injections of New Zealand rabbits with 
the corresponding peptides (prepared by Research Genetics, Huntsville, AL). The specificity of 
the antisera was verified by immunoblotting with membrane preparation from CHO K1 cells 
expressing the cloned P2 X2 and P2 X3 receptors (Oglesby et al., 1999). As previously reported 
by Oglesby et al. (1999), the antisera recognized only one protein of the expected size in the 
heterologous expression systems and were shown to be receptor-subtype-specific.
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For immunostaining of cryosections, the standard avidin-biotin complex (ABC) technique 
was used. Sections were post-fixed with 4% paraformaldehyde for 2 minutes at room 
temperature. Endogenous peroxidase was blocked by 0.5% H2 O2  and 50% methanol 
(methanokPBS, 1:1) for 20 minutes. The P2 X3 primary antibody was used at a concentration of 
1:200 prepared in 10% normal horse serum (NHS) containing 0.2% Triton X-100. For P2 X2  
immunohistochemistry, the primary antibody was used at a dilution of 1 : 2 0 0  prepared in 1 0 % 
NHS only. Subsequently, the sections were incubated with biotinylated donkey anti-rabbit IgG 
(Jackson ImmunoResearch Lab, West Grove, PA) at a dilution of 1:500 in PBS containing 1% 
NHS for 1 hour. The sections were then incubated in ExtrAvidin peroxidase diluted 1:1000 in 
PBS for 30 minutes at room temperature. For color reactivity, a solution containing 0.05% 3,3' 
-diaminobenzidine (DAB), 0.04% nickel ammonium sulfate, 0.2% p-D-glucose, 0.004% 
ammonium nitrate, and 1.2 U/ml glucose oxidase in 0.1 M PB (pH 7.2) was applied. Sections 
were washed three times with 0.1 M PBS after each of the above steps (except for serum 
preincubation). Slides were mounted with Eukitt (BDH Laboratory, UK) and examined with 
light microscopy. The control experiments were carried out with the primary antibodies 
preadsorbed with the peptides for immunizing the rabbits or the primary antibody replaced 
with the normal horse serum.
Immunofluorescence double labeling
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In colocalization studies investigating the coexpression of P2 X2 and P2 X3 receptors, P2 X2  
receptor immunoreactivity was enhanced with tyramide amplification, which allows high 
sensitivity and low background specificity (Renaissance, TSA indirect, NEN, USA). Tyramide 
amplification was performed after the primary antibody, specific for the P2 X2  receptor (1:800), 
was coupled to biotinylated donkey anti-rabbit IgG and ExtrAvidin peroxidase as described 
above. The immunoreactivity was detected with Streptavidin-fluorescein isothiocyanate (FITC) 
(Amersham, UK). Polyclonal rabbit antibody against P2 X3 receptor subtype (1:150) was 
applied as a second primary antibody and detected with Cy3-conjugated donkey anti-rabbit 
IgG (Jackson ImmunoResearch Lab, West Grove, PA). To prevent the generation of artifacts 
due to nonspecific labeling after tyramide amplification, double labeling was also performed 
by using anti-P2X3 receptor antibody as the first primary antibody and the anti-P2X2 receptor 
antibody as the second primary antibody, to confirm the expression pattern.
To demonstrate the colocalization of the P2 X2 receptor with embryonic heart muscle, the 
P2 X2  receptor antibody (1:800) was used as the first primary antibody, enhanced with tyramide 
amplification and detected with Streptavidin-FITC as described above. Mouse monoclonal 
antibody against a-smooth muscle actin (1:400; Sigma, UK) was applied as the second primary
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antibody and the immunoreactivity was then detected with rhodamine (TRITC)-conjugated 
goat anti-mouse IgG (Jackson ImmunoResearch Lab, West Grove, PA).
Photom icroscopy
Images of DAB immunohistochemical staining and immunofluorescence labeling were 
taken with the Leica DC 200 digital camera (Leica, Switzerland) attached to a Zeiss Axioplan 
microscope (Zeiss, Germany). Images were imported into a graphics package (Adobe 
Photoshop 5.0, USA). The two-channel readings for green and red fluorescence were merged 
by using Adobe-Photoshop 5.0.
Data analysis
Analysis was performed and scored and was confirmed by an independent observer in a 
blind manner. Scores for P2 X3 immunohistochemical staining were made by using a 
subjective, graded scale varying from -, undetectable staining; +, weak staining but 
distinguishable from background, or scattered cells with moderate intensity staining; ++, 
moderate intensity staining in over 50% of cells; +++, very intense immunoreactivity in over 
50% of cells.
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RESULTS
P2X 3 immunoreactivity in the rat embryonic nervous system
Immunohistochemistry was performed to investigate the pattern of P2 X3 receptor protein 
expression during rat embryonic development. By using the standard ABC method with nickel 
and DAB as chromogens, black staining indicated positive immunoreactivity. In this study, rat 
embryos of E9.5-18.5 were chosen to investigate P2 X3 immunoreactivity and the results are 
summarized in Table 1.
No detectable P2 X3 immunoreactivity was observed in E9.5-E10.5 embryos. Weak P2 X3 
immunolabeling was first identified in the trigeminal preganglia, facioacoustic ganglion 
complex, glossopharyngeal-vagal ganglion complex, and the ventrolateral region of the 
hindbrain neural tube in El 1-11.5 rat embryos (data not shown). At E l2.5, stronger P2 X3 
staining intensity was found in the same embryonic tissues as El 1.5 rat embryos (Fig. 1). For 
the trigeminal preganglion in El 1-11.5 rat embryos, P2 X3 was found in the neurons and fibers 
only, which were separated from the neural tube. In E l2.5 rat embryos, when the spinal 
trigeminal tract has begun to appear between the trigeminal ganglion and the neural tube, the 
spinal trigeminal tract was stained with P2 X3 antibody (Fig. 1). In addition, the dorsal root
56
Chapter II P2X? receptor in neurogenesis
ganglia and the vagal trunk also started expressing P2 X3 receptors in E l2.5 rat embryos (Fig.
1). Unlike the El 1.5 embryo, where P2 X3 receptors were expressed in only a few neurons and 
fibers in the neural tube, extensive neurons and fibers in the ventrolateral region of the neural 
tube showed stronger P2 X3 immunoreactivity in E l2.5 embryos (Fig. 1). Although the 
expression was strong in the hindbrain neural tube, weak expression was also found in the 
spinal neural tube. However, expression of P2 X3 protein was not found in the forebrain neural 
tube.
For E14.5 rat embryos, more embryonic organs showed P2 X3 neural immunoreactivity (Fig.
2). The central nervous system (CNS), which differentiates from neural tube, was shown to 
have P2 X3 immunoreactivity at this stage. The P2 X3 receptor was expressed in the 
mesencephalic trigeminal nucleus, spinal trigeminal tract, nucleus tractus solitarius, and the 
spinal cord. In the pontine region, P2 X3 receptor expression was strong in the facial nerves, 
and both the settled and migrating facial neurons of the facial nucleus. The prepositus 
hypoglossal nucleus, however, showed very weak P2 X3 receptor staining. In the spinal cord, 
the P2 X3 receptor was expressed in the ventral region of the spinal cord (Fig. 2). The optic 
nerve and retina (neural layer) showed very weak P2 X3 immunoreactivity (data not shown). In 
the peripheral nervous system, trigeminal and dorsal root ganglia (which were more
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differentiated than in previous stages) showed strong P2 X3 receptor expression. 
Vestibulocochlear ganglia, which are derived from the facioacoustic ganglion complex, also 
expressed P2 X3 receptor protein. In addition to the cell bodies of the ganglia showing P2 X3 
expression, nerve fibers in the ganglion (e.g., trigeminal nerve, facial nerve, vestibular nerve, 
glossopharyngeal nerve, spinal nerve, vagal trunk, and sympathetic trunk) also expressed P2 X3 
protein (data not shown). The innervation of visceral organs such as lung, esophagus and 
stomach (Fig. 2), and the nerves in tongue and pharynx were P2 X3 receptor-positive.
In E l6.5 rat embryos, vestibular nucleus in the medulla started to show weak P2 X3 receptor 
staining (data not shown). Peripheral nerves such as the mesenteric nerves (especially those 
surrounding blood vessels), nerves in the bladder and intestine did not show P2 X3 receptor 
expression until E l6.5. However, P2 X3 immunoreactivity was not detected in the ventral spinal 
cord in E l6.5 embryos. Unlike the sensory ganglia (e.g., trigeminal ganglion, dorsal root 
ganglia, and nodose ganglia) that showed strong P2 X3 immunoreactivity, only scattered 
ganglionic cells in superior cervical ganglion and the sympathetic ganglion were stained 
weakly with P2 X3 receptor antibody in El 8.5 embryos (Fig. 3). The sympathetic trunk, 
however, showed relatively stronger P2 X3 receptor expression (Fig. 3). In the CNS, P2 X3 
immunoreactivity was strong in the dorsal spinal cord (Fig. 4) and the mesencephalic
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trigeminal nucleus (Fig. 5). P2 X3 receptor expression was also found along the whole optic 
tract running from the neural layer of the retina through the optic chiasm to the lateral 
geniculate of the diencephalon. However, the lateral geniculate nucleus in the diencephalon 
appeared to have no P2 X3 immunoreactivity. In the retina, high magnification revealed that 
P2 X3 expression was restricted to the retinal ganglion cells in the inner neural layer of the 
retina and was not seen in the outer pigmental layer (Fig. 4). The prepositus hypoglossal 
nucleus in the medulla still expressed weak P2 X3 receptor protein. Strong P2 X3 
immunoreactivity was observed in the peripheral nerves supplying the tongue, mesentery, and 
vibrissae (Fig. 4). There was no immunostaining observed in any of the following regions: 
forebrain (olfactory bulb, cerebral cortex, caudate putamen, amygdala, internal capsule), 
diencephalon (thalamus, hypothalamus), cerebellum and brainstem (superior and inferior 
colliculus, superior and inferior olive, vagal motor nucleus, dorsal motor nucleus of vagus, 
trigeminal motor nucleus, cuneate nucleus, gracile nucleus). There was no visible staining in 
control experiments where the P2 X3 antibody was replaced with NHS (data not shown) or 
preadsorbed with peptide (Fig. 4).
P2X3 receptor immunoreactivity in neonatal rat brain
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In PI rat brain, P2 X3 receptor expression was localized to a subpopulation of the 
mesencephalic trigeminal nucleus. At this developmental stage, weaker P2 X3 receptor 
expression was seen in spinal trigeminal tract, spinal trigeminal nucleus, facial nucleus and 
facial nerve, vestibular nucleus, nucleus tractus solitarius, and in the prepositus hypoglossal 
nucleus when compared with expression in embryonic brain (Fig. 5). In P I 6  rat brain, no P2 X3 
receptor immunoreactivity was detected in the mesencephalic trigeminal nucleus, spinal 
trigeminal tract, facial nerves, and facial nucleus or the vestibular nucleus. Only the nucleus 
tractus solitarius and the hypoglossal nucleus remained P2 X3 immunopositive at this time point 
(data not shown).
Expression o f  P2X2 and P2X2/3 receptor protein
P2 X2  receptor expression was first identified in the El 1-11.5 rat embryo. Immunostaining 
was observed in the notochord at the level of the spinal neural tube and the myocytes of the 
heart. The expression of the P2 X2 receptor in notochord persisted in E l2.5 embryo (Fig. 6). 
However, P2 X3 receptor protein was not detected in the notochord or the heart at this stage 
(Fig. 6). In the heart, cardiomyocytes stained strongly with P2 X2  receptor antibody, a-smooth 
muscle actin, which is known to be strongly expressed during early development of cardiac 
muscle (Woodcock-Mitchell et al., 1988; Sawtell and Lessard, 1989), was used as a marker for
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early stage cardiac muscle. Double-labeling experiments showed that P2 X2 was coexpressed 
with a-smooth muscle actin in both El 1.5 and E l2.5 heart, including the truncus arteriosus, 
right and left atria, ventricle, and bulbus cordis (Fig. 7). The smooth muscle layer of the dorsal 
aorta was continuous with the embryonic heart. Together with the heart muscles, the smooth 
muscle layer at these stages also expressed g l -smooth muscle actin. However, the aortic 
muscle layer did not show any P2 X2 immunoreactivity (Fig. 7). In El 1.5 and 12.5 rat embryos, 
no detectable P2 X2 immunoreactivity was seen in the neural tubes. In the central nervous 
system, very weak P2 X2 immunoreactivity was first identified in the nucleus tractus solitarius 
and the spinal nerves emerging from the dorsal root ganglia of E l4.5 embryo. However, the 
dorsal root ganglia did not show any P2 X2 immunoreactivity. At E l6.5, the smooth muscle of 
the dorsal aorta, trachea and bronchi, esophagus, stomach, intestine, and bladder clearly stained 
positive with the P2 X2 receptor antibody. In addition, the nodose ganglia and the vagal trunk 
showed weak and moderate P2 X2  immunoreactivity (Fig. 6), respectively. The peripheral 
nerves supplying the tongue also showed P2 X2  immunoreactivity. The nucleus tractus 
solitarius and the nodose ganglia in El 8.5 embryos showed obvious P2 X2 receptor expression 
(Fig. 6). Most of the skeletal muscles in El 8.5 embryos were found to be P2 X2  receptor 
positive (data not shown). In all the P2X3-immunopositive neural tissue examined, the P2 X2 
receptor was expressed in the nucleus tractus solitarius and spinal nerves from E l4.5 and the 
nodose ganglion, the vagal trunk, and the peripheral nerves supplying the tongue from E l6.5.
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However, at E14.5, the staining was very weak even after tyramide amplification. Thus, 
coexpression of P2 X2  and P2 X3 receptors could only be detected clearly at E l6.5. Double 
labeling experiments (Fig. 7) showed that in the nodose ganglia, only a subpopulation of 
neurons showed P2 X2 /3  colocalization. After tyramide amplification, the dorsal root ganglia 
showed P2 X2  immunoreactivity; however, high magnification revealed the staining to be 
localized in the spinal nerves. Only few neurons in the dorsal root ganglia showed P2 X2  
receptor staining, and this was coexpressed with P2 X3 receptor protein. A high degree of P2 X2 
and P2 X3 coexpression was detected in the peripheral nerves ending in tongue. The strongest 
staining of both P2 X2 and P2 X3 immunoreactivity was found in the median circumvallate 
papilla. Quantitatively, however, P2 X2 -positive nerves in the tongue were more frequently 
identified than P2 X3 -positive nerves. Apart from taste buds in tongue, the nucleus tractus 
solitarius in E l6.5 showed a high degree of P2 X2 and P2 X3 colocalization (Fig. 7).
Preliminary studies in our laboratory have shown that, except for P2 X3 , all the other P2X 
receptors, including P2 X2 , were absent in neural tubes and the sensory ganglia from E ll  to 
E l2.5 embryos. They were first detected in the embryonic brain and spinal cord in E l4 
embryos (unpublished data). In addition, of all the P2X receptors examined, only P2 X2  
receptor subtypes were found in the heart and the notochord at this stage.
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DISCUSSION
P2X receptors are ligand-gated ion channels activated by extracellular ATP that mediate 
rapid cation permeability and fast excitatory neurotransmission in both the central and 
peripheral nervous systems (reviewed by Ralevic and Bumstock, 1998). One of the P2X 
receptor subunits, P2 X3 , was cloned from rat dorsal root ganglia (Chen et al., 1995; Lewis et al., 
1995) and is known to be largely restricted to a subset of sensory neurons (trigeminal, nodose, 
and dorsal root ganglia). In early reports, P2 X3 was not detected in sympathetic, enteric, and 
CNS neurons (Chen et al., 1995; Collo et al., 1996), although the presence of the P2 X3 
receptors has been demonstrated in superior cervical and celiac ganglia (Xiang et al., 1998; 
Zhong et al., 2000) and nucleus tractus solitarius (Vulchanova et al., 1997; Llewellyn-Smith 
and Bumstock, 1998; Yao et al., 2000). In this study, we present the detailed expression pattern 
of the P2 X3 receptor at different stages of rat embryonic development. In addition, the 
coexpression of P2 X2  and P2 X3 receptors was also examined to investigate whether P2 X2 /3  
receptor heteromerization is an early event during embryo development. The results obtained 
have shown that the P2 X3 receptor is the dominant receptor subtype among the P2X receptor 
family in the early embryonic nervous system and that P2 X3 receptor expression is
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down-regulated in the neonatal rat brain. P2 X2 /3  expression appeared late in development 
compared with the individual receptor subtypes.
During Ell-11.5, when gastrulation is complete and the neural tube has closed, 
gangliogenesis occurs (Kaufman and Bard, 1999). At this stage, the trigeminal ganglion and 
facioacoustic ganglion complex is formed and the glossopharyngeal-vagal preganglion is 
developing. At this time, P2 X3 protein first appears during rat embryonic development and is 
localized in the developing trigeminal preganglia, facioacoustic ganglion complex, and 
glossopharyngeal-vagal ganglion complex. At E12.5, the spinal trigeminal tract, which acts as 
a connection between the peripheral nervous system and CNS in the trigeminal system, showed 
strong P2 X3 immunoreactivity. P2 X3 receptors were also found in the vagal trunk and dorsal 
root ganglia at this stage.
The ganglia mentioned above are either wholly or partially derived from neural crest cells
(Le Douarin and Kalcheim, 1999). These ganglia are also involved in sensory function. It is not
known whether expression of the P2 X3 receptor has any association with neural crest
development or whether it is only associated with sensory function. From E l4.5 onward, the
mesencephalic trigeminal nucleus, the nucleus tractus solitarius and the prepositus hypoglossal
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nucleus in the CNS showed P2 X3 immunoreactivity. Although the mesencephalic trigeminal 
nucleus belongs to the CNS, it is not derived from the neural tube. Instead, studies on the 
heterospecific grafting between quail and chick embryos have shown that the mesencephalic 
trigeminal nucleus is actually derived from neural crest cells in which the precursor cells of the 
nucleus migrate from the crest toward the ventricular surface of the neuroepithelium 
(Narayanan and Narayanan, 1978). This finding further increases the association between the 
neural crest cells and P2 X3 receptor expression. P2 X3 receptors are constantly expressed in the 
above ganglia throughout prenatal development (from El 1.5 to El 8.5), and most of the ganglia 
still express P2 X3 receptor even in adulthood (Xiang et al., 1998, 1999), so they would 
appear to be involved in development, maturation, and normal sensory functioning of the 
ganglia. P2 X3 receptors were expressed not only in sensory ganglia but also in the superior 
cervical ganglia and sympathetic ganglia, although the immunostaining appeared scattered and 
weak. Xiang et al. (1998) showed scattered ganglionic cells expressing P2 X3 receptor protein 
in the superior cervical ganglia, which is consistent with the present study and suggests that the 
pattern of P2 X3 immunoreactivity in the superior cervical ganglion persists from the embryonic 
stage to adulthood.
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P2 X3 receptor expression was not only detected in the sensory and sympathetic ganglia but 
also in the neural tube, which gives rise to the CNS. The results from this study showed that, in 
early stage embryos, intense P2 X3 receptor expression was observed in the anterior part of the 
hindbrain neural tube (ventral neural tube) and that the intensity of P2 X3 immunoreactivity 
decreased with increasing distance along the spinal cord. The anterior hindbrain neural tube 
gives rise to the metencephalon, which consists of a dorsal region that develops into the 
cerebellum and a ventral region that will form the pons. The posterior hindbrain neural tube 
forms the myelencephalon which gives rise to the medulla oblongata. Our results show that 
P2 X3 receptors are expressed in the ventral part of the prospective metencephalon and 
myelencephalon, thus, defining the P2 X3 immunopositivity in the pons and medulla in the late 
stage embryos. Later during development, P2 X3 receptor protein was expressed in brainstem 
nuclei such as mesencephalic trigeminal nucleus, nucleus tractus solitarius, and prepositus 
hypoglossal nucleus. These results are in agreement with a study demonstrating P2 X3 
immunoreactivity in E l6 rat embryos reported by Kidd et al. (1998), except that we did not 
identify P2 X3 receptor expression in the superior and inferior olives. P2 X3 receptors were also 
expressed in the neural layer of the retina and the optic tract that extends all the way to the 
lateral geniculate in the diencephalon. The P2 X3 receptor expression in the retina appeared to 
be present even in the adult (Brandle et al., 1998). Our results show that P2 X3 
immunoreactivity was present in the ventral spinal cord at El 2.5-El 4.5. However, P2 X3
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receptor expression was not observed in the ventral spinal cord at E l6.5. Instead, strong P2 X3 
immunoreactivity was localized in the dorsal spinal cord. Surprisingly, P2 X3 receptors were 
present in the facial motor nucleus, which is known to be involved in motor function. Our 
results show that both the ventral spinal cord and facial motor nucleus are down-regulated 
during prenatal and postnatal development, respectively. Such changes in expression pattern 
together with the P2 X3 receptor expression in the sympathetic nervous system suggests that the 
P2 X3 receptor has a role other than a sensory function during early development of the nervous 
system. Although intense P2 X3 receptor protein expression was detected in the rat embryonic 
brain and spinal cord, previous studies have shown reduced expression of the P2 X3 receptor in 
the adult rat brain (Kidd et al., 1998). The nucleus tractus solitarius and the spinal cord have 
been described in the adult rat CNS (Vulchanova et al., 1997; Kidd et al., 1998; 
Llewellyn-Smith and Bumstock, 1998). In addition, a recent report also described strong P2 X3 
receptor immunoreactivity in nucleus tractus solitarius, and medial and lateral parabrachial 
nucleus by using antibodies recognizing the extracellular domain of the P2 X3 receptor protein 
(Yao et al., 2000). In the present study, we show that P2 X3 immunoreactivity in the spinal 
trigeminal tract, facial nucleus, mesencephalic trigeminal nucleus, and vestibular nucleus is 
absent in PI 6 rat brain. Together, the results suggest that the expression of the P2 X3 receptor is 
developmentally regulated and the transient expression of P2 X3 in these tissues may indicate a 
role in neurogenesis.
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In addition to the CNS, P2 X3 immunoreactivity is also found in nerve fibers innervating the 
developing visceral organs, including tongue, vibrissae, lung, bladder, stomach, and intestine. 
Chen et al. (1995) claimed that the P2 X3 receptor was absent from the lung, bladder, stomach, 
intestine by using Northern analysis, a technique that is not sensitive for detecting low levels of 
mRNA expression. Cockayne et al. (2000) have shown recently that P2 X3 knockout mice 
suffered from urinary bladder hyporeflexia, demonstrating the importance of P2 X3 receptors in 
somatic and visceral sensory function.
In the present study, we show that during organogenesis (i.e., E11-E12.5), P2 X3 and P2 X2 
receptors are differentially expressed in embryonic tissues, whereas the P2 X3 receptor is 
expressed in both the central and peripheral nervous system, the P2 X2  receptor is mainly 
expressed in the cardiac muscle and notochord at the level of the spinal neural tube. The 
notochord, a mesodermally derived structure, is well known for its inductive effect on neural 
tube patterning (Roelink et al., 1994) in both invertebrates and vertebrates. It is not yet known 
whether ATP has any effect on spinal cord patterning by means of the P2 X2  receptor. 
Therefore, it would be of interest to investigate in future studies whether there is any 
interaction between the ATP effects on the neural tube by means of P2 X3 and that on the
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notochord by means of P2X2. The findings from the present study indicate that P2 X3 and P2 X2 
are expressed as homomeric receptors. During embryonic development, P2 X3 receptor protein 
expression is restricted to the nervous system, whereas P2 X2  receptor protein is also expressed 
in developing muscle tissues. The P2 X2  receptor is expressed in cardiac muscle, visceral 
smooth muscle, and in skeletal muscle. A recent study from our laboratory has shown the 
expression of P2 X2 in rat skeletal muscle in the late embryonic stages (Ryten et al., 2001). In 
this study, although P2 X3 and P2 X2  homomeric receptors were individually expressed as early 
as in El 1.5, the coexpression of the two receptor subtypes could only be detected clearly at 
E l6.5, which was 5 days later than the first appearance of individual receptor expression. 
Despite the strong expression of P2 X3 receptor found in dorsal root ganglion, only scattered 
neurons showed P2 X2 immunoreactivity in the dorsal root ganglion, which previously has been 
shown to express heteromeric P2 X2 /3  receptor expression (Lewis et al., 1995; Ueno et al., 
1999). The nodose ganglion, which is also known to express P2 X2 /3  receptors, also showed 
P2 X2 and P2 X3 coexpression in a subpopulation of neurons at E l6.5. These data are in 
agreement with previous functional studies from our laboratory that showed P2 X2 /3  heteromers 
are expressed in a subpopulation of nodose ganglia (Lewis et al., 1995; Dunn et al., 2000). 
Functional studies in the P2 X3 knockout animal have shown that it is mainly the P2 X3 receptor 
that responds to ATP in the dorsal root ganglion, whereas the P2 X2  and P2 X2 /3 receptors 
appear more important in the nodose ganglion (Cockayne et al., 2000). In the present study, the
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distribution in the P2 X2  and P2 X3 receptors in the dorsal root ganglion and the nodose 
ganglion seem to be consistent with the functional studies mentioned above. Previous reports 
have shown that the P2 X2  receptor is expressed in the retinal ganglion cells in rat (Greenwood 
et al., 1997). In contrast, our study shows that P2 X3 receptor protein is only detected in the 
retinal ganglion cells from E14.5 onward; furthermore, P2 X2 receptor expression was not 
detected in the retina at any of the prenatal stages examined (data not shown).
The results obtained may indicate that the role of the P2 X3 receptor as a sensory-involving 
molecule in the retina may be replaced, at least in part, by P2 X2 receptor expression during 
postnatal development. Both the taste buds in the tongue in the peripheral nervous system and 
the nucleus tractus solitarius in the central nervous system showed a high degree of P2 X2 and 
P2 X3 coexpression. In tongue, the median circumvallate papilla showed strong P2 X3 and P2 X2  
immunoreactivity which is in agreement with the results demonstrated by Bo et al. (1999). 
Therefore, it is not surprising that the nucleus tractus solitarius also showed a high degree of 
P2 X2 and P2 X3 coexpression, as the sensory fibers that receive input from the taste cells run in 
cranial nerves VII, IX, and IX and enter the solitary tract in the medulla. Despite the fact that 
dorsal root ganglion, nodose ganglion, taste buds, and nucleus tractus solitarius have sensory 
functions in the peripheral and central nervous systems, different degrees of P2 X3 and P2 X2
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receptor expression in different sensory neurons and nerves account for the different responses 
reported in functional studies (reviewed by Norenberg and Illes, 2000). Preliminary 
immunohistochemical studies in our laboratory have shown that the P2 X3 receptor protein is 
the only receptor subtype among the P2X receptor family present in the early central and 
peripheral nervous system before E l4.5. These data suggest that the homomeric P2 X3 is the 
dominant P2X receptor during early neurogenesis, despite the fact that P2 X2 and P2 X4  are the 
dominant receptor subtypes in the adult central nervous system (reviewed by Norenberg and 
Illes). In addition, our data also indicate that the P2 X3 receptor is expressed as a homomeric 
receptor rather than the heteromeric P2 X2 /3 form in early stage embryos.
In summary, we have shown a detailed expression pattern of P2 X3 in both central and 
peripheral nervous systems at different stages of rat embryonic development. Strong 
association was observed between P2 X3 expression and neural crest derivatives. The P2 X3 
receptors appear to have a major role in sensory function in the early stage embryos but these 
receptors may also be involved in somatic and autonomic motor systems. P2 X3 and P2 X2  
receptors are expressed separately during organogenesis and the P2 X2  and P2 X3 receptor 
coexpression appeared later in development than the individual native P2X receptors. Absence 
of other P2X receptor expression in the nervous system of the early stage embryos indicates
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that P2 X3 may be the only receptor subtype involved in fast excitatory signaling mediated by 
ATP during embryonic neurogenesis. The precise function of purinergic signaling by means of 
the P2 X3 receptor in the embryo still remains to be elucidated. However, the transient 
expression of P2 X3 receptor protein reported here clearly suggests a role in the development of 
the nervous system in the mammalian embryo. The involvement of other P2X and P2Y 
receptor subtypes in early mammalian embryogenesis remains to be explored.
The work of this chapter has been published in:
Cheung KK and Bumstock G. (2001). Localization of P2 X3 receptors and coexpression with 
P2 X2  receptors during rat embryonic neurogenesis. JComp Neurol 443:368-382.
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FIGURES & LEGENDS
TABLE 1. Localization of P2 X3 receptor immunoreactivity at different stages during rat 
embryonic development
Embryonic PNS E9.5-10.5 Ell-11.5 E12.5 E14.5 E16.5 E18.5
Trigeminal (V) ganglia and its -
+ ++ +++ +++ +++
nerve
Facial (VII) ganglia and its - + ++ +++ +++ +++
nerve
Vestibulocochlear (VIII) ganglia 
and its nerve
- + ++ +++ +++ +++
Glossopharyngeal (IX) ganglia 
and its nerve
- + +++ +++ +++ +++
Dorsal root ganglia and its nerve - - + +++ +++ +++
Vagal (X) ganglia and vagal 
trunk
— — +++ +++ +++ +++
Sympathetic trunk - - - + ++ ++
Sympathetic ganglia 
Nerves supplying the internal
— — — + + +
organs
Stomach and intestine - - - ++ ++ +++
Lung and trachea na - - ++ ++ +++
Tongue and pharynx na na na ++ +++ +++
Mesentery na na na - +++ +++
Kidney na na na - + +
Bladder na na na - ++ ++
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Nerves in mesentery - - - — ++ +++
Nerves around vibrissae na na na - - ++
Embryonic CNS
Forebrain neural tube - - na na na
Olfactory bulb na na na - - -
Cerebral cortex na na na - - -
Caudate putamen na na na - - -
Amygdala na na na - - -
Internal capsule na na na - - -
Hippocampus na na na - - -
Thalamus na na na - - -
Hypothalamus na na na - - -
Optic (II) tract na na na + ++ +++
Retina na na - + ++ +++
Superior and inferior colliculus na na na - - -
Mesencephalic trigeminal 
nucleus of the fifth nerve
na na na ++ ++ +++
Locus coeruleus na na na - - -
Hindbrain neural tube — + ++ na na na
Spinal cord _ - + ++ +++ +++
Spinal trigeminal tract na na ++ +++ +++ +++
Trigeminal motor nucleus na na na - - -
Superior and Inferior olive na na na - - -
Nucleus tractus solitarius na na na +++ +++ +++
Facial nucleus na na na +++ +++ +++
Cerebellum na
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Vagal motor nucleus na na na
Prepositus hypoglossal nucleus na na na + + ++
Vestibular spinal nucleus na na na - + ++
Dorsal motor nucleus of vagus na na na - - -
Cuneate nucleus na na na - - —
Gracile nucleus na na na - - -
The degree of P2 X3 immunoreactivity: +, just detectable; ++, moderate; +++, strong; 
undetectable; na, not applicable
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Figure 1 P2 X3 immunoreactivity in embryonic day (E) 12.5 rat embryos. A-C: Transverse 
sections at the first (A), second (B), and third (C) branchial arch levels showing P2X3 
immunoreactivity (arrow) in the trigeminal ganglion, facioacoustic ganglion complex, md 
glossopharyngeal ganglion, respectively. Note the expression of P2 X3 in the primitive spinal 
trigeminal tract between the trigeminal ganglion and the neural tube (Nt). D: Transverse 
section at the caudal part of the embryo showing P2 X3 expression (arrow) in the dorsal root 
ganglia on both sides of the neural tube. Insert figures show enlargements of the aieas 
indicated by arrows in the corresponding figures. E: Transverse section at the hindbrain neural 
tube showing P2X3-positive neurons (arrows in the insert) and nerve fibers in the ventrolateral 
region of the neural tube. F: Transverse section at the pericardio-peritoneal canal (Pc) showing 
P2 X3 expression in the vagal trunk (arrows) on both sides of the esophagus (Opg). Note dso 
that P2 X3 receptor expression in the hindbrain neural tube shown in both B and E was rmch 
stronger than the spinal neural tube shown in C and D. Scale bar = 200pm in D (appliej to 
A-D), 50pm in inset of D (applies to insets in A-D), 50pm in inset of E, 200pm in E,F.
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Figure 2 P2 X3 immunoreactivity in embryonic day (E) 14.5 rat embryo. A: coronal section 
at the midbrain level showing P2 X3 expression in the mesencephalic trigeminal nucleus. B: 
Coronal section at the pontine level showing strong P2 X3 expression in the spinal trigeminal 
tract (Sp5t) and the longitudinal running trigeminal nerve (5n). C,D: Coronal section at the 
pontine level showing the genu of the facial nerve (g7n) and the facial nucleus (7N) stained 
strongly with P2 X3 receptor antibody. E: Coronal section at the medulla level showing the 
P2 X3 stained nucleus tractus solitarius. F: Transverse section showing P2 X3 receptor 
expression in the ventral spinal cord. G,H: Spinal nerves (Spn), and nerves found in lung (L) 
(G) and stomach (Sm) (H) at this stage showing P2 X3 immunoreactivity. Scale bar in H = 
25pm in A, 50pm in B,E,F, 100pm in C,D,G,H.
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Figure 3 P2 X3 immunoreactivity in neural crest-derived ganglia of the embryonic day (E) 
18.5 rat embryo. A-D: The P2 X3 receptor is strongly expressed in trigeminal ganglion (A), 
dorsal root ganglion (C), vestibulocochlear ganglion (E) and nodose ganglion (F). Note the 
peripheral staining of P2 X3 immunoreactivity in the ganglionic neurons. (B) and (D) H&E 
staining showing the cellular structures of the trigeminal (B) and dorsal root ganglia (D) (2-3 
sections from the corresponding P2 X3 immunostained sections). G: Scattered ganglionic cells 
(arrows) in superior cervical sympathetic ganglion also express P2 X3 protein. H: Strong P2 X3 
receptor expression was detected in the nerve fibres of the sympathetic trunk (syk). Only 
scattered neurons in the sympathetic ganglion showed weak P2 X3 immunoreactivity. Note also 
the uneven localization of the P2 X3 immunoreactivity on the surface of the neuronal membrane. 
Scale bar = 100pm in H (applies to A-H).
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Figure 4 P2 X3 immunoreactivity in embryonic day (E) 18.5 rat embryo. A: Transveise 
section showing P2 X3 immunoreactivity in the dorsal spinal cord in the lumbar region. B: 
High-magnification image showing the retinal ganglion cells in the neural retina (Ret) 
expressing P2 X3 receptor protein. No P2 X3 immunoreactivity was found in the pigmental layer 
of the retina. C: Coronal section showing very weak P2 X3 receptor expression (arrows) in the 
prepositus hypoglossal nucleus ventrolateral to the fourth ventricle. D: Transverse section 
showing strong P2 X3 expressing in the taste bud of the tongue (Tog). E: Transverse section 
showing the mesentery (Mes) of the gut. P2 X3 immunoreactivity was found in the nerves 
surrounding the blood vessels (Bv) in the mesentery. F: Transverse section showing the 
vibrissae (Vb). P2 X3 -positive nerve fibers (arrows) are found innervating the hair follicle of the 
vibrissae. G: Transverse section showing P2 X3 receptor expression in the nerves surrounding 
the esophagus (Opg); the nearby vagal trunk (Vk) also showed strong P2 X3 immunoreactivity. 
H: Adjacent section of G incubated with P2 X3 receptor preadsorbed with the preimmune 
peptide did not show any P2 X3 receptor staining. Scale bar in A = 200pm, scale bar in H = 
200pm in C,D,F, 100pm in E,QH, 50pm in B.
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Figure 5 P2X3 immunoreactivity in late embryonic and neonatal rat brainstem. A,C,E: 
P2 X3 receptor expression in the mesencephalic trigeminal nucleus in embryonic day (E) 18.5, 
postnatal day (P) 1, and PI 6  rat brainstem, respectively. Note that only a subpopulation of the 
neurons in the mesencephalic trigeminal nucleus showed positive immunostaining in PI 
brainstem (C). No P2 X3 immunoreactivity was detected in P I 6  brainstem (E). The spinal 
trigeminal tract, the nucleus tractus solitarius, the vestibular nucleus, and the prepositus 
hypoglossal nucleus in PI brainstem clearly expressed P2 X3 receptor (B,D). F: In P16 medulla, 
P2 X3 receptor in the spinal trigeminal tract was not detected. Scale bars = 100pm in E (applies 
to A,C,E), 500pm in D (applies to B,D), 200pm in F.
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Figure 6 P2 X2 immunoreactivity at different stages of rat embryo development. A: 
Transverse section in the spinal neural tube (Nt) in embryonic day (E) 12.5 embryos showing 
P2 X2  receptor expression in the notochord. B: Adjacent section of A stained with P2 X3 
receptor antibody. P2 X3 receptor protein was absent in the notochord. C: Transverse section at 
the heart level showing P2 X2  receptor expression in the E l2.5 heart, including the left and right 
atria (LA and RA), bulbus cordis (B), and the primitive ventricle (V). D: Transverse section 
showing the esophagus in El 6.5 rat embryo. The P2 X2 receptor was localized in the smooth 
muscle of the esophagus. E: Sagittal section showing the trunk region of the E l6.5 embryo. 
The P2 X2  immunoreactivity was found in the vagal trunk (Vk) at the periphery of the 
esophagus (Opg). F,G: The nucleus tractus solitarius in E l6.5 showed P2 X2 immunoreactivity 
(F) and the preadsorption control in the adjacent section did not show any P2 X2 receptor 
staining (G). 4V, fourth ventricle. H,I: P2 X2 immunoreactivity was found in the nodose 
ganglion (H) and the nucleus tractus solitarius (I) in El 8.5 rat embryo. Scale bar = 500pm in C. 
Scale bar in I = 200pm in E, 100pm in H, 50pm in A,B,D,F,G.
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Figure 7 Immunofluorescence double labeling for the P2 X2  receptor and a-smooth 
muscle actin (A-C), and for P2 X2  and P2 X3 receptors (D-O) in rat embryos. A: In embryonic 
day (E) 12.5 heart, the cardiac muscles in the heart and the smooth muscle in the dorsal aorta 
(arrows) showed a-smooth muscle actin expression (red). B: On the same section 
immunostained with P2 X2 , the heart also showed P2 X2 receptor expression (green). However, 
no P2 X2  immunoreactivity was found in the dorsal aorta, indicated by arrows. C: 
Double-labeling images showed the colocalization of the P2 X2 receptor and a-smooth muscle 
actin in the cardiac muscle but not the dorsal aorta (arrows). D-F: P2 X3 (D) and P2 X2 (E) 
immunoreactivities in nucleus tractus solitarius in E l6.5 embryos. Most of the cells in the 
nucleus tractus solitarius showed P2 X3 and P2 X2  coexpression (F), although the staining 
intensity of P2 X3 is much stronger than P2 X2 (even after tyramide amplification). G-I: P2 X3 
and P2 X2  immunoreactivities in nodose ganglion in E l6.5 embryos. Most of the neurons in 
nodose ganglion showed P2 X3 receptor expression (G), whereas only scattered P2 X2 receptor 
expression was detected (H). I: Double-labeling revealed a subpopulation of nodose ganglion 
showing P2 X2 and P2 X3 receptor coexpression (arrows). Although P2 X2  immunoreactivity was 
not as strong as that of P2 X3 , scattered neurons did show P2 X2  receptor protein only, instead of 
P2 X2  and P2 X3 heteromers. J-L: P2 X3 and P2 X2 immunoreactivities in the E l6.5 dorsal root 
ganglion. Neurons in the dorsal root ganglion showed strong P2 X3 receptor expression (J). 
Only very few neurons in the dorsal root ganglion showed P2 X2 immunoreactivity (K), and
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they coexpressed with P2 X3 receptors indicated by arrows (L). K: The P2 X2 receptor, appeared 
to be mainly expressed in spinal nerves instead of the neurons. Note that the stronger P2 X2
receptor expression in the spinal nerves compared with P2 X3 receptor was due to tyramide
amplification. For 3,3 * -diaminobenzidine immunostaining, P2 X3 receptor protein showed 
stronger expression than that of the P2 X2  receptor (data not shown). M-O: P2 X3 and P2 X2
immunoreactivities in the taste bud in E l6.5 embryo. P2 X3 and P2 X2 receptors were
coexpressed in the taste bud in the tongue (O). The nearby peripheral nerves showed P2 X2 and 
P2 X3 coexpression, although some of the nerves also showed P2 X2  receptor expression only. 
Scale bar = 100pm C (applies to A-C). Scale bar in O = 100pm in G-I,M-0, 50pm in D-F,J-L.
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Chapter III Abundant and dynamic expression of G 
protein-coupled P2Y receptors in 
mammalian development
ABSTRACT
Extracellular ATP mediates diverse biological effects by activating two families of receptors,
the P2X and P2Y receptors. There is growing evidence to show that activation of G
protein-coupled P2Y receptors can produce trophic effects in many cell types. Yet the expression
and function of the P2Y receptors in development has rarely been studied, and has never been
investigated in mammalian development. This study used the reverse transcriptase-polymerase
chain reaction and immunohistochemistry to demonstrate the abundant and dynamic expression
of P2Y receptors in rat development. These receptors were expressed in a wide range of
embryonic structures, notably somites, skeletal muscle, the central and peripheral nervous
system, the heart, lung and liver. All the P2Y receptors studied were expressed as early as E ll,
when most embryonic organs were far from being functional and still in the process of being
formed. P2Y receptor proteins were strongly expressed in temporary, developmental structures
that do not have a correlate in the adult animal, including the somites (P2Yi, P2 Y2  and P2 Y4 )
and the floor plate of the neural tube (P2Yj). P2Y receptors were also dynamically expressed,
91
Chapter III P2Y receptor in embryogenesis
with receptor mRNA and protein being both up- and down-regulated at different developmental 
stages. The down-regulation of the P2Yi, 2 and 4 receptor proteins in skeletal muscle and heart, 
and the disappearance of the P2 Y4  receptor from the brainstem and ventral white matter of the 
spinal cord postnatally, demonstrated that many P2Y receptors were likely to be involved in 
functions specific to embryonic life. Thus, these findings strongly suggest that P2Y receptors 
play an important role in the development of many tissues, and pioneer further studies into the 
role of purinergic signaling in development.
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INTRODUCTION
Extracellular nucleotides evoke responses by activation of two families of purinoceptors, 
namely the P2X and P2Y receptors (Abbracchio and Bumstock, 1994). Whereas P2X receptors 
are ligand-gated ion channels, P2Y receptors are G protein-coupled receptors. Eight P2Y 
receptor subtypes have been cloned to date in mammals (P2Yij2,4, 6, n, 12, 13, 14) (Abbracchio et al., 
2003). These receptors couple predominantly to phospholipase C activation, leading to the
• • • • *74*formation of inositol phosphate and mobilization of intracellular Ca (Ralevic and Bumstock, 
1998; Vassort, 2001). In addition to increased intracellular Ca , a variety of signal transduction 
pathways, involving protein kinase C, phospholipase A2 and the mitogen-activated protein 
kinases, mediate the effects of P2Y receptors. Thus, activation of the P2Y receptors can cause 
long-term, trophic effects on cell activity (Neary et al., 1996; Abbracchio and Bumstock, 1998, 
Bumstock, 2002a).
P2Y receptors have been implicated in the regulation of cell proliferation and differentiation.
Activation of P2 Y receptors on a variety of cell types, including astrocytes and vascular smooth
muscle cells, results in cell proliferation (Bumstock, 2002b; Neary et al., 1998; 1999; Neary,
2000). In contrast, activation of the P2Yh receptor has been strongly implicated in neutrophil
differentiation (Jiang et al., 1997; Conigrave et al, 1998; Communi et al., 2000). Although these
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findings strongly suggest a role for purinergic signaling in development, there have been few 
studies focusing on the expression and function of P2Y receptors in embryonic and postnatal 
development.
The Xenopus P2Y receptor, the XIP2Y (also called P2Yg), was shown in the neural plate 
during neurulation, but not detected after neural tube closure (Bogdanov et a l, 1997), suggesting 
a role for this receptor in the process of neurulation. More recently, expression of P2 Yi receptor 
(cP2Yi) mRNA and protein has been demonstrated during chick embryonic development (Meyer 
et al., 1999a; Choi et al., 2001). Meyer et al. (1999a) reported strong expression of cP2Yi 
receptor mRNA in undifferentiated limb mesenchyme cells, but expression was lost as the cells 
differentiated. The same group also demonstrated that ATP acting by means of cP2Yi, 
significantly inhibited cartilage formation in micromass cultures (Meyer et al., 2001).
These studies are limited to the P2Yi and P2Ys receptors. Other P2Y receptor subtypes have
rarely been studied in development, and none have ever been studied in mammalian in vivo
development. In this chapter we used the reverse transcriptase-polymerase chain reaction
(RT-PCR) and immunohistochemistry to investigate the expression of four P2Y receptors, P2Yi,
P2 Y2 , P2 Y4  and P2Y6, in rat embryonic and postnatal development. Expression of all the P2Y
receptors cloned in rat to date was studied by RT-PCR. In addition, by using specific antibodies
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that have only recently become commercially available, the localization of P2Yi, P2 Y2  and P2 Y4  
receptor proteins was investigated. Thus, it has been possible to demonstrate for the first time, 
the abundant and dynamic expression of P2Y receptors in mammalian development.
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MATERIALS AND METHODS
RT-PCR analysis
Total RNA was extracted from fresh embryonic tissues at E ll , E l2, E14 and E l8 by using 
SV Total RNA Isolation system (Promega, Madison, WI). Reverse transcription and cDNA 
amplification for all the P2Y receptors was carried out with a thermal cycler (Hybaid, UK) in a 
two-step protocol using Ready-To-Go RT-PCR Beads (Amersham Pharmacia Biotech, 
Buckinghamshire, UK). Every sample was further treated with Amplification Grade DNase I 
(Sigma, UK) to remove any residual DNA present that could generate false positive results. 
Briefly, lpg  of total RNA was reverse transcribed using the pd(T)i2 -i8 as the first-strand primer 
at 42°C for 30 min and the enzyme was denatured at 95°C for 5 min. The sequence specific 
primers (Life Technologies, Bethesda, MD) for P2Y receptors (Bailey et al., 2000; 2001; see 
Appendix) were then added to the reaction mixtures and the PCR cycling parameters were 95°C 
for 30 s, 58°C for 1 min (58°C for P2Yh 60°C for P2Y2 and P2Y6, 64°C for P2Y4), 72°C for 1.5 
min for 35 cycles (40 cycles for P2Y4), followed by a further stage of 10-min extension at 72°C. 
The resulting PCR products were resolved in a 2% agarose gel containing ethidium bromide and 
observed under ultraviolet illumination.
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RT-PCR results for all tissues were confirmed by repetition with at least three separate RNA 
samples, prepared from embryonic tissues obtained from separate rat litters. Furthermore, a 
minimum of three RT-PCR experiments were performed for each P2Y receptor on each 
individual embryonic tissue. Control experiments were conducted by denaturing the reverse 
transcriptase (95°C for 15 min) before the RT-PCR reaction. These experiments demonstrated 
that, on denaturation of the reverse transcriptase, no P2 receptor mRNA could be detected. Thus, 
we were able to verify that the results obtained were due to the presence of P2 receptor mRNA 
in a sample and not as a result of genomic DNA contamination.
Tissue preparation
Please refer to the section of Materials and Methods on Chapter II. Tibialis anterior 
muscles from both 3 -week- and 2-month-old animals were collected and freshly embedded in 
Tissue-Tek. Frozen sections (12pm) were cut in a cryostat and mounted.
DAB Immunohistochemistry and Immunofluorescence double labeling
Please refer to the section of Materials and Methods on Chapter II for 
immunohistochemistry (using DAB as chromogen). For double labeling using antibodies 
raised from different species, the primary antibodies were applied to the tissue sections at the
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same time for overnight incubation at room temperature. After washing with PBS, secondary 
antibodies were applied to the tissue sections at the same time for 1 hour incubation at room 
temperature. The sections were washed and mounted with glycerolrPBS (9:1). For double 
labeling using antibodies raised from same species (e.g. rabbit), the first primary antibody was 
applied to the tissue sections for overnight incubation at room temperature. After washing and 
secondary antibody incubation, sections were washed and the second primary antibody was then 
applied to the same tissue sections for overnight incubation at room temperature. After 
washing with PBS, second secondary antibodies were applied to the tissue sections for 1 hour 
incubation at room temperature. The sections were washed and mounted with glycerohPBS 
(9:1). The primary antibodies used were rabbit anti-P2Yi)2,4 (diluted 1:200 for P2Yi and P2 Y2 ; 
1:100 for P2 Y4 ; Alomone, Israel; see Appendix), rabbit anti-PGP9.5 (UltraClone Ltd., UK), 
mouse anti-a-smooth muscle actin (1:400, Sigma) and mouse anti-MF20 (1:100, Developmental 
Studies Hybridoma Bank). For labeling of acetylcholine receptors, sections were incubated with 
Texas Red-conjugated a-bungarotoxin (1:800, Sigma). The secondary antibodies used were 
either fluorescein Isothiocyanate-conjugated or Cy3-conjugated (Jackson Immunoresearch 
Laboratories, Inc., WestGrove, PA).
Photomicroscopy
Please refer to the section of Materials and Methods on Chapter II.
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RESULTS
RT-PCR for P2Y receptors
By using RT-PCR, the developmental expression profiles for P2Yi, P2 Y2 , P2 Y4  and P2Y6 
were studied in rat embryos (Fig. 1, Table 1, 2). All the P2Y receptor subtypes examined were 
detected as early as embryonic day 11 (E ll), and mRNA transcripts were present throughout 
development (E12-E18). From E ll onward, clear bands were observed for P2Yi and P2 Y4  
mRNA transcripts (Fig 1). P2 Y2  receptor expression was very weak at E ll but became 
progressively stronger with development. Although P2Y6 receptor expression was present as 
early as E ll, expression was only barely detectable and strong expression was observed only at 
E18.
To determine more precisely the location of P2Y receptor expression, brain, heart, liver, 
lung and muscle were taken from both E14 and El 8 embryos for RT-PCR analysis (Fig. 1, Table 
2). All embryonic tissues examined expressed at least one P2Y receptor subtype. However, 
different embryonic organs demonstrated different P2Y receptor profiles. For example, at E l4 
only P2 Y4  receptor mRNA was detected in the brain, whereas P2Yi, P2 Y2 and P2 Y4  were 
expressed in lung, and all the P2Y receptors tested (P2Yi, 2 , 4 , 6) were expressed in heart.
99
__________________________________________________________________ Chapter III P2Y receptor in embryogenesis
Furthermore, the expression of P2Y receptor mRNA was up- and down-regulated during the 
course of embryonic development. In the brain, no P2Yi was detected at E l4, but at E l 8 , 
RT-PCR demonstrated strong expression. Similarly in muscle, P2Y6 expression only began at 
E l 8 . In contrast, whereas P2 Y4  was expressed in the lung at E l4, no P2 Y4  transcripts were 
detected at E l 8 .
Immunohistochemistry demonstrated expression o f P2Yj, P2 Y2 and P2 Y4 receptor protein in 
somites
P2Yreceptor immunoreactivity was first detected in embryos at E ll. At this stage P2Yi and 
P2 Y4  receptor proteins were detected in the somites. Whereas the P2 Y4  receptor was detected 
in the dermomyotome, P2Y 1 receptor expression appeared to be restricted to the myotome (Fig. 
2 A, C and D). The P2 Y2  receptor was also expressed in the somites at E12 (Fig. 3 A), a day 
later than the expression of P2Y1 and P2Y4 . By using MF20 as a marker for the myogenic cells 
of the myotome (Fig. 3 B), the expression of all the P2Y receptors was demonstrated specifically 
in this area of the somite. As in the case of P2Yi and P2 Y4 , double-labeling for P2 Y2 and MF20 
showed co-localization of these proteins in the myotome as opposed to the sclerotome (Fig. 3 
C).
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Immunohistochemistry demonstrated expression of P2Yi, P2 Y2  and P2 Y4  receptor protein in 
skeletal muscle
Consistent with the expression of P2Yi, P2 Y2  and P2 Y4  in the myotome, the primary 
skeletal muscle fibers were also immunopositive for these P2Y receptors (Fig. 2 B, E and F). 
However, in the case of the P2Yi and P2 Y2 receptors, expression was not maintained. By El 8, 
no P2Yi or P2 Y2  immunoreactivity was detected in skeletal muscle fibers (Fig. 2 G). In contrast, 
at this stage strong P2 Y4 receptor expression was found in all skeletal muscle masses (Fig. 2 H).
Examination of postnatal skeletal muscles (3-week and 2-month old rats) demonstrated the 
down-regulation of P2 Y4  receptor expression. Immunoreactivity for P2 Y4  was detected only in 
the peripheral muscle fibers. P2Yi and P2 Y2 receptor expression was detected in cells in 
between muscle fibers. The smooth muscle layer of blood vessels showed strong P2Y1 receptor 
staining (Fig 3 D), as identified by double labeling with smooth muscle actin (data not shown). 
The P2 Y2 receptor was expressed in scattered cells adjacent to the skeletal muscle fibers (Fig 3 
E). Although the identity of the cells was not confirmed, this expression pattern would suggest 
that these cells were skeletal muscle satellite cells. None of the P2Y receptors showed any 
immunoreactivity at the neuromuscular junction (identified by staining with Texas Red-labeled 
a-bungarotoxin) in either the prenatal or postnatal skeletal muscle examined (Fig 3 D-F).
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Immunohistochemistry demonstrated expression o f only P2Yi and P2Y4 receptor protein in the 
brain
Consistent with RT-PCR results, which demonstrated the expression of P2 Y4  receptor 
mRNA alone at E l4, only P2 Y4  receptor protein was detected in embryonic brain at this age (Fig. 
4 A- F). Receptor expression was demonstrated in the olfactory system, diencephalons, 
amygdala and brainstem. In the olfactory system, P2 Y4  receptor staining was detected in the 
olfactory nerve and lateral olfactory tract (Fig. 4 A and B). In the diencephalons, expression was 
restricted to the anterior hypothalamus, dorsal geniculate nucleus and lateral hypothalamic area 
(Fig. 4 C and D). In the amygdala, only the cortical amygdaloid nucleus showed P2 Y4  receptor 
expression (Fig. 4 D). P2 Y4  receptor expression in the brainstem was widespread. The midbrain, 
pons and medulla all showed P2 Y4  receptor immunoreactivity (Fig. 4 E and F). The cerebral 
cortex, the basal ganglia, the hippocampus and the cerebellum did not show any P2 Y4  receptor 
staining at E l4.
Expression of P2 Y4  receptor protein was not maintained in all parts of the brain postnatally.
In the neonatal brain (postnatal day 1, PI), P2 Y4  receptor expression disappeared from the
midbrain, isthmus and medulla. However, receptor protein was still detected in the olfactory
system, the amygdala, the diencephalons and the pons. In addition, areas such as the septum and
the neuroepithelium (adjacent to the ventricles), which had previously not showed any staining
102
Chapter III P2Y receptor in embryogenesis
for P2 Y4  became immunopositive for this receptor (Fig. 4 G and H). Consistent with the 
up-regulation of P2Y1 receptor mRNA in late embryonic development, P2Y1 receptor protein 
was also detected in the PI brain. Receptor expression was restricted to the cerebral peduncle 
(Fig. 4 I). As would be predicted from RT-PCR no P2 Y2  receptor protein was expressed at any 
stage examined.
Immunohistochemistry demonstrated expression o f P2Y receptor protein in the spinal cord and 
peripheral nervous
P2Yi, P2 Y2  and P2 Y4  receptor proteins were all expressed in the neural tube and peripheral
nervous system from E l2. At this stage, P2Yi receptor protein was detected in the floor plate of
the spinal neural tube (Fig. 5 A). Subsequently, expression was detected in the ventral
commissure of both El 4 and El 8  spinal cord (Fig. 5 B). P2Yi receptor protein was also detected
weakly in the gray matter, but not the white matter at E l 8  (Fig. 5 B). The P2 Y2 receptor was
first detected in the spinal motor nerves in E l2 embryos (Fig. 5 C). At E l4, P2 Y2  receptor
protein was expressed heavily in the white matter of the intermediate and ventral homs, and the
dorsal column of the spinal cord (Fig. 5 D). The gray matter showed clear but relatively weaker
P2 Y2  immunoreactivity. This pattern of expression was maintained in late embryonic
development (Fig. 5 E). At E l8, the presence of P2 Y2 receptor expression in the dorsal root
ganglia was also clearly apparent (Fig. 5 E). P2 Y4  immunoreactivity was first weakly detected
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in the ventral horn of the spinal neural tube at E l2. Staining for P2 Y4  in the ventral horns 
increased in strength at E l4. Both the spinal motor neurons and the white matter showed 
immunoreactivity for this receptor (Fig. 3 G). However, double labeling with the neural marker 
PGP9.5 showed that P2 Y4  was not expressed in any of the peripheral nerves (Fig. 3 J-LV In the 
El 8  spinal cord, P2 Y4  expression disappeared from the ventral white matter and was only 
weakly expressed in the gray matter and dorsal root ganglia (Fig. 5 F).
Immunohistochemistry demonstrated expression o f P2Y receptor proteins in the embryonic 
cardiovascular system, liver, lung and lens
P2Yi, P2 Y2  and P2 Y4 receptor proteins were strongly expressed in the cardiovascular
system, liver, lungs and lens. The P2Yi, P2 Y2  and P2 Y4  receptors were first weakly expressed in
the heart at E ll  and expression became stronger at E l2 (Fig. 6  A and B). Immunostaining was
localized to both the primitive atria and ventricles at this stage. By E l4, the P2Y receptors (P2Yi,
P2 Y2  and P2 Y4 ) were detected only in the atria and the inner trabecular layer of the ventricles
(Fig. 6  C). The outer myocardial layer and the interventricular septum showed either weak or no
expression. At E l 8 , P2Yi, P2 Y2  and P2 Y4 receptor expression was restricted to the atria and the
inner trabecular layer of the ventricles. No P2Y receptor proteins were detected in the
myocardium and interventricular septum (Fig. 6  D). In the case of all three P2Y receptors
detected, P2Yi, P2 Y2  and P2 Y4 , expression appeared to be restricted to the myocardium, with no
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immunostaining present in the endocardium. This was confirmed by double-labeling 
experiments, performed for P2Y 1,2 ,4  and muscle myosin/ von Willebrand factor (a marker for 
endothelial cells), which showed that expression of the P2Y receptors was localized to the 
myocardial and not the endocardial cells (data not shown).
In the case of P2Yi, receptor protein was also detected in the blood vessels from E12 
onwards (Fig. 6  E and F). Colocalization experiments, performed for P2Y1 and smooth muscle 
actin/ von Willebrand factor (a marker for endothelial cells), confirmed that expression of the 
P2Yi receptor was localized to the smooth muscle cells of the dorsal aorta and not the 
endothelial cells (data not shown).
P2Y receptor expression in the liver began at E l4 (Fig. 7 A). At this stage only the P2Yi 
receptor was expressed. By El 8 , P2 Y2 receptor expression could also be detected. Whereas the 
P2Yi receptor showed distinct staining in scattered cells (Fig. 7 B), very weak P2 Y2  receptor 
expression was detected in the general embryonic liver parenchyma (data not shown). The P2 Y4  
receptor was not detected in the liver in any of the stages examined.
In the lung, the smooth muscle layer beneath the bronchial epithelium showed P2Yi
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receptor immunoreactivity weakly in E14 and clearly in E l 8  embryos (Fig. 7 C). The P2 Y2  
receptor was not expressed in the lung until El 8 . Some, but not all, of the epithelial cells of the 
bronchus within the fetal lung showed P2 Y2  immunoreactivity (Fig. 7 D). P2 Y4  receptor 
expression was absent from the lung (Fig 7 E).
The P2Yj receptor was strongly expressed in the primary lens fibers at E14 (Fig. 7 F). 
Although these fibers differentiate from the epithelial cells in the anterior part of the lens 
(between the lens capsule and the elongating primary lens fibers), the epithelial cells showed no 
P2Y1 receptor immunostaining. Immunoreactivity for the P2Y1 receptor was maintained in the 
lens fibers postnatally (Fig. 7 G). At this stage, the P2 Y4  receptor was also expressed in the lens 
fibers but was absent from lens epithelial cells (Fig. 7 H). No P2 Y2  receptor expression was 
detected in the lens at any stage examined.
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DISCUSSION
Despite that P2Y receptors have been shown to regulate cell proliferation and differentiation, 
key processes in tissue formation, few studies have investigated the expression and function of 
P2Y receptors in embryonic development. Before this study, the expression of the P2 Y2 , P2 Y4  
and P2Y6 receptors had never been investigated in development and none of the P2Y receptors 
had ever been studied in mammalian development. Using RT-PCR and immunohistochemistry, it 
was possible to demonstrate the abundant and dynamic expression of the P2Yi, P2 Y2 , P2 Y4 and 
P2 Y6  receptors in many tissues and organs, including skeletal muscle, heart, brain, spinal cord, 
liver, lung and lens, in rat embryonic and postnatal development. The pattern and timing of 
receptor expression strongly suggested a role for these receptors in development.
All the P2Y receptors studied were expressed as early as E ll,  when most embryonic organs
far from being functional, were still in the process of being formed. Furthermore, P2 Y receptor
proteins were strongly expressed in transient, developmental structures, including the somites
(P2Yi, P2 Y2 and P2 Y4 ) and the floor plate of the neural tube (P2Y]). While both these structures
play an essential role in embryonic development, the floor plate in patterning the ventral neural
tube and the somites in the formation of mesodermal tissues, neither are retained. P2Y receptors
were also dynamically expressed, with receptor mRNA and protein being both up- and
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down-regulated. The down-regulation of the P2Yj, 2 and 4 receptor proteins in skeletal muscle 
and heart, and the disappearance of the P2 Y4  receptor from the brainstem and ventral white 
matter of the spinal cord postnatally demonstrated that many P2Y receptors were 
developmentally regulated and were involved in functions specific to embryonic life. Thus these 
findings strongly suggest that whereas there are many well-recognized functions for P2Y 
receptors in mature, adult tissues, P2Y receptors may also play a role in tissue formation and 
development.
Skeletal muscle
The transient expression of the P2Yi, P2Y2 and P2 Y4 receptors in skeletal muscle strongly 
suggests a role for these receptors in the formation and differentiation of skeletal muscle. The 
onset of P2Yi and P2 Y4  receptor expression (E ll) was similar to that of MyoD and Myf5, the 
two myogenic transcription factors responsible for defining the muscle precursor cells 
(myoblasts) (Buckingham, 2001). The expression of both receptors was ultimately confined to 
the myotome, as opposed the dermatome that will form the dermis of the skin. It is still 
difficult to determine whether the expression of P2Yi and P2 Y4 receptors was required for 
myogenic specification, or the expression follow the specification, unless the P2Y receptor 
expression has been positioned in the signaling pathway of myogenesis. The P2Y2  receptor 
was expressed a day later (E l2) in the myotome. P2Y receptor expression in muscle was not 
maintained. Staining for the P2Yi and P2Y2 receptors disappeared by E l 8  and P2 Y4  receptor
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expression was down-regulated postnatally. These findings suggested that while the P2Y 
receptors were unlikely to be involved in myogenic specification, these receptors could regulate 
subsequent processes in muscle formation including the proliferation of myoblasts, migration or 
fusion to form primary and secondary myotubes (Buckingham, 2001). In fact, a recent study by 
Ryten et al. (2002) demonstrates that myoblast proliferation in vitro can be potentiated by 
application of UTP, an agonist at both P2 Y2 and P2 Y4  receptors. P2Y receptors have also been 
implicated in the migration of several cell types, including vascular smooth muscle cells and 
human dendritic cells (Idzko et al., 2002; Pillois et al., 2002).
The pattern of P2Y receptor expression in skeletal muscle also suggested a role specifically 
for the P2 Y4 receptor in myotube maturation and differentiation. P2 Y4  receptor expression was 
maintained during postnatal development of muscle fibers, which included muscle fiber 
hypertrophy and maturation of the neuromuscular junction. Since these processes are largely 
dependent on changes in intracellular Ca2+ concentration and P2Y receptor activation will result 
in the mobilization of intracellular calcium, this receptor has the potential to be involved in any 
of these processes (Olson and Williams, 2000a; 2000b; Sanes and Lichtman, 2001). However, 
because neither the P2 Y4  receptor, nor for that matter the P2Yi and P2 Y2  receptors, were found 
to be expressed specifically at the neuromuscular junction, it is more likely that P2 Y4  receptor 
activation plays a role in muscle fiber hypertrophy or fiber-type determination. Although these
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findings do not entirely agree with a recent study by Choi et al. (2001), they are consistent with 
the work of Meyer et al. (1999a). Choi et al. (2001) have demonstrated the up-regulation of the 
P2 Yi receptor during the course of embryonic muscle development in chick and expression of 
P2Yi receptor protein at the adult neuromuscular junctions in chick and rat, whilst our findings 
and those of Meyer et al. (1999a) suggest that this receptor is down-regulated in development 
and is not expressed at the neuromuscular junction.
Heart
The dynamic expression of the P2Y receptors in embryonic heart also suggested a role for 
these receptors in the development of cardiac muscle. Immunoreactivity for the P2Yi, P2 Y2 and 
P2 Y4  receptors was detected in both the primitive atria and ventricles of the embryonic heart 
from E ll ,  just before trabeculations first become evident along the inner myocardial layers 
(El 1.5) (Sedmera et al., 2000). At E14, when trabeculations develop and become compressed 
within the ventricular wall, P2Y receptor expression was restricted to the trabeculated layers of 
the atria and ventricles, no immunoreactivity being found in the compact layer of the ventricular 
myocardium. Consistent with previous reports, P2Y receptors were down-regulated with further 
development (Webb et al., 1996).
Because formation of the trabeculated layer of the heart and its fusion with the compact
layer is vital to heart development, the expression of the P2Y receptors in the trabeculated layer
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specifically, is likely to be of functional significance. In fact, trabeculations are so vital to 
cardiac morphogenesis that the absence of these structures in neuregulin null mice results in 
embryonic death at E ll (the tubular heart stage) (Gassmann et al., 1995; Lee et al., 1995). Thus, 
the pattern and timing of P2Y receptor expression in the heart might suggest a role for these 
receptors in the differentiation of the trabeculated layer and the formation of the ventricular 
myocardium.
Nervous system
Expression of the P2Y receptor proteins, and particularly the P2 Y4 receptor, was prominent
in the embryonic nervous system. Among all the P2Y receptors examined, the P2 Y4  receptor was
the first to be expressed in the embryonic brain at E l4 on the basis of both RT-PCR and
immunohistochemistry. Instead of a general or weak expression throughout the whole brain, the
receptor expression was intense and localized. At E l4, P2 Y4  immunoreactivity was detected in
the telencephalon (olfactory system, pallidum and amygdala), diencephalons (lateral
hypothalamic area and dorsal geniculate nucleus) and brainstem (midbrain, pons and medulla).
After birth, additional regions of the brain, such as the septum and the neuroepithelium adjacent
to the ventricles showed P2 Y4  receptor expression, and P2Y1 receptor staining was detected in
the cerebral peduncle. However, of greatest developmental significance was the disappearance of
P2 Y4  immunoreactivity from the brainstem after birth. Thus, the P2 Y4  receptor appeared to be
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the dominant P2Y receptor present early in the brain. The early expression of P2 Y4  receptor in 
specific brain regions and its subsequent down-regulation in some areas, suggested that this 
receptor has role to play in prenatal brain development, particularly within the brainstem.
The spinal cord showed immunoreactivity for the P2Yi, P2 Y2 and P2 Y4 receptors. 
Expression of all these receptors was related either directly or indirectly to motor neuron 
development. The P2 Y2  and P2 Y4  receptors were expressed in the ventral horns of the 
embryonic spinal cord, in the case of the P2 Y4  receptor only transiently (El4-El 8 ). Both P2 Y2  
and P2 Y4  receptor expression was mainly localized to the white matter of the ventral horns, 
although the spinal motor neurons also showed weak expression. P2Y1 expression was localized 
to the floor plate of the spinal neural tube and subsequently the ventral commissure of the spinal 
cord, the former an important structure in the differentiation of the ventral neural tube. The floor 
plate expresses a powerful signaling molecule, Sonic hedgehog (Shh), which specifies the 
identities of motor neurons and intemeurons in a concentration-dependent manner (Dodd et al., 
1998). Thus the expression of the P2Yi receptor in floor plate, and the P2 Y2 and P2 Y4  receptors 
in the ventral horns, suggests that purinergic signaling could regulate motor neuron development 
at multiple sites.
It seems likely that not all P2Y receptor expression had a role in embryonic development,
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but rather some receptor expression was related to adult function. The lack of dynamic or 
transient P2Y receptor expression in the embryonic and fetal liver suggested that P2Y receptors 
were not involved in liver formation. As in adult hepatocytes (Dixon et al., 2000), experiments 
conducted on embryonic liver demonstrated the expression of P2Yi, P2 Y2 , P2 Y4  and P2Y6 
receptor mRNA transcripts and immunoreactivity for P2Yi and, to a lesser extent, the P2 Y2  
receptor. Expression of the P2Yi and P2 Y4  receptors in the lens fibers is also unlikely to be 
involved in lens development. The P2Yi receptor is strongly expressed in both the adult 
(Merriman-Smith et al., 1998) and embryonic lens, but the P2 Y4  receptor was only expressed 
postnatally. Nonetheless this study does demonstrate for the first time the expression of the P2 Y4  
receptor in lens fibers, and expression of this receptor could account for the reports of responses 
of adult lens cells to ATP (Churchill and Louis, 1997; Collison and Duncan, 2001). Similarly, 
expression of the P2Yi and P2 Y2  receptors in the fetal lung is unlikely to be related to lung 
development. In the fetal (E l8 ) lung, the P2 Y2 receptor was expressed in the epithelial cells of 
the bronchi. Adult lung epithelial cells also express this receptor and can respond to the P2 Y2  
receptor agonist UTP, with an increase in transepithelial chloride secretion and mucus secretion 
(Rice and Singleton, 1987; Rice et al., 1995; Bumstock, 2002b). The P2Yi receptor, which is 
known to be expressed on many types of smooth muscle cells, was also expressed in the smooth 
muscle layer of the bronchi. Thus, although P2Y receptors are undoubtedly essential for proper 
lung function, it is very unlikely that embryonic P2Y receptor expression is related to
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The question of the source(s) of ATP involved in activating these P2 receptors should next 
be raised. Many cell types are known to release ATP in response to mechanical disturbance 
(Bumstock, 1999b; Bodin and Bumstock, 2001 a,b) and because there is much cellular 
movement during embryogenesis, several cell types might be releasing ATP. In addition, the 
presence of apoptotic cells in several developing tissues might represent another source of ATP.
In summary, we have demonstrated for the first time the early and dynamic expression of 
the P2Yi, P2 Y2 , P2 Y4  and P2Y6 receptors during rat embryonic development. Although not all 
P2Y receptor expression is likely to be related to embryonic development, these findings suggest 
the involvement of purinergic signaling in skeletal muscle, heart and central nervous system 
development. Thus, purinergic signaling is likely to be an important signaling system in 
embryonic development and in particular organogenesis.
The work of this chapter has been published in:
Cheung KK, Ryten M and Bumstock G. (2003). Abundant and dynamic expression of G 
protein-coupled P2Y receptors in mammalian development. Dev Dyn. (in press)
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FIGURES & LEGENDS
Figure 1 RT-PCR analysis to investigate the expression of P2Yj, P2 Y2 , P2 Y4  and P2Y6 receptor 
transcripts during rat development from embryonic day 11 (E ll) to E l 8 . Total RNA from whole 
embryos (E ll, E l2, E14 and E l 8 ) or isolated embryonic organs (brain, heart, liver, lung and 
muscle) was extracted and subsequently used for RT-PCR experiments.
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Table 1 Summary of the expression of P2Yi, P2 Y2 , P2 Y4  and P2Y6 receptor mRNA at 
different developmental ages (E ll, E l2, E14 and E l 8 ). Key: (+) indicates clear positive bands, 
(-) indicated absence of expression and (+/-) indicates barely detectable bands.
Table 2 Summary of the expression of P2Yi, P2 Y2 , P2 Y4 and P2Y6 receptor mRNA in brain, 
heart, liver, lung and skeletal muscle taken from E l4 and E l 8  embryos. Key: (+) indicates clear 
positive bands, (-) indicated absence of expression and (+/-) indicates barely detectable bands.
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Table 1
E ll E12 E14 E18
P2Yi + + + +
P2Y2 +/- + + +
P2Y4 + + + +
P2Y6 +/- +/- +/- +
Table 2
Brain
E14 E18
Heart
E14 E18
Liver
E14 E18
Lung
E14 E18
Muscle
E14E18
P2Y i - + + + + + + + + +
P2Y 2 - - + + + + + + + +
P2Y 4 + + + + + +/- + - + +
P 2Y 6 - - + + + + +/- +
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Figure 2: Immunoreactivity for P2Y receptors in somites and developing skeletal muscle. A, 
Transverse section with haematoxylin and eosin staining showing the morphology of E ll 
somites (sm). B, Transverse section showing haematoxylin and eosin staining of an E l4 embryo 
at the mid-liver level. The rectangular insert shows an area of developing skeletal muscle. C, 
Transverse section taken at the level of the embryonic heart at high magnification showing 
limited P2Yi receptor expression in E ll somites (sm). In order to aid orientation the ventral (v) 
and dorsal (d) aspects are marked. P2Yi receptor expression was detected in the myotome. D, 
Transverse section taken at the caudal region at high magnification showing widespread P2 Y4  
receptor expression in E ll somites (sm). P2 Y4 receptor expression was detected in the 
dermomyotome. E, Higher magnification (of the rectangular insert shown in B) demonstrating 
P2Yi receptor expression in the developing skeletal muscle (skm). F, Higher magnification (of 
the rectangular insert shown in B) demonstrating P2 Y4  receptor expression in the developing 
skeletal muscle (skm). G, H, Transverse sections of El 8  embryo showing the intercostal muscle 
between ribs (rb). The P2Y1 receptor was not detected in the skeletal muscle fibers (G), whereas 
strong P2 Y4  receptor immunoreactivity (H) was detected in the intercostal muscle. Scale bar = 
50pm (C, D), 200pm (A, E-H) and 750pm (B).
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Figure 3: Immunofluorescence of P2Y receptors during skeletal muscle development and in the 
embryonic spinal cord. A, Transverse section showing P2 Y2 receptor immunoreactivity (green) 
in E12 myotomes (my). B, The same section also showed immunoreactivity for MF20 (red), a 
marker of the differentiated myogenic cells. C, Double labeling showing that the P2 Y2  receptor 
and MF20 were co-expressed in the myotome (yellow). D-F, Double labeling experiments for 
P2Y receptors (green) and acetylcholine receptors (red) on the tibialis anterior muscle of 3-week 
old animal. D, P2 Y 1 receptor immunoreactivity was localized at the smooth muscle layer of the 
blood vessel (bv) between the skeletal muscle fibers. E, P2 Y2  receptor immunoreactivity was 
detected in scattered cells (arrowhead) located between skeletal muscle fibers. F, P2 Y4 receptor 
protein was detected on the membranes of the peripheral, but not the central muscle fibers. None 
of the P2Y receptors were detected at the neuromuscular junctions, as demonstrated by 
acetylcholine receptor expression (red). G, Transverse section showing P2 Y4 receptor 
immunoreactivity (green) in the spinal cord of an E l4 embryo. Arrows showing the spinal 
nerves emerging from dorsal (dh) and ventral homs (vh). H, PGP9.5 immunoreactivity (red) on 
the same section (G). I, Double labeling showing the co-localization (yellow) of the P2 Y4  
receptor and the PGP9.5 in the ventral spinal hom but not the dorsal spinal cord. J, Transverse 
section showing expression of the P2 Y4 receptor (green) in embryonic skeletal muscle (skm). K, 
PGP9.5 stains nerves (red) innervating the muscles in the same section. L, Double labeling 
experiment showing that P2 Y4  receptor protein was expressed in the muscles only but not in the
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peripheral nerves innervating the muscles. Scale bar = 105pm (A-C), 50pm (D-F), 200pm 
(G-L).
Figure 4: P2Y receptor immunoreactivity in embryonic and neonatal rat brain. Coronal sections 
of an E14 embryonic brain are shown in an antero-posterior direction (A to F). A, B, P2 Y4  
immunoreactivity was detected in the olfactory tubercle (A, ot) and the lateral olfactory tract (B, 
lot). C,D, In the diencephalon, P2 Y4  receptor protein was expressed in the anterior 
hypothalamus (C, ah), the dorsolateral geniculate nucleus (D, dgn) and the lateral hypothalamic 
area (D, Ih). The cortical amygdaloid nucleus also stained for P2 Y4 (D, ca). E, F, In the 
brainstem, the P2 Y4  receptor expression was detected in the midbrain (E, mb), the pons (E, pn), 
the isthmus (F, is) and the medulla (F, md). G, H, Coronal sections of a neonatal rat brain 
showing P2 Y4  receptor immunoreactivity in the septum (G) and the neuroepithelium adjacent to 
the ventricles (H). I, Coronal section showing P2Yj receptor immunoreactivity in the cerebral 
peduncle. Scale bar = 500pm (A-F), 100pm (G) and 200pm (H-I).
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Figure 5: Immunohistochemical expression of P2Y receptors in the embryonic nervous system. 
A, Transverse section of E12 embryos (at the level just caudal to the hindbrain neural tube) 
showing P2Yi receptor immunoreactivity specifically located in the floor plate region (fp, 
arrow). B, Transverse section showing P2Yi receptor expression in the ventral commissure 
(arrowhead) of the El 8  spinal cord. Note the very weak P2Yi immunoreactivity in the gray 
matter (gm). C, Transverse section of E l2 embryos demonstrating P2 Y2  receptor expression in 
spinal nerves (arrows). D, In E14 spinal cord P2 Y2  receptor protein was heavily expressed in the 
white matter of the ventral horns (vh) and in the peripheral nerves. The gray matter and dorsal 
root ganglia (drg) also stained weakly for the P2 Y2 receptor. E, At E l 8 , widespread P2 Y2  
receptor expression was detected in the spinal cord, with very strong immunoreactivity in the 
white matter of the intermediate and ventral horns (arrows). Immunostaining for P2 Y2 was also 
detected in the dorsal root ganglia. F, The P2 Y4 receptor was expressed in the gray matter of the 
spinal cord at El 8 . Weak staining was also observed in the white matter and dorsal root ganglia 
at this stage. Scale bar = 50pm (A), 200pm (C), 450pm (B, E-F) and 750pm (D).
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Figure 6 : Immunoreactivity for the P2Y receptors in the embryonic cardiovascular system. A, 
Transverse section showing the expression of the P2 Y2 receptor in the developing heart at E l2. 
B, Transverse section showing the expression of the P2 Y4  receptor in the developing heart at 
E12. C, D, Transverse sections showing P2 Y4  receptor immunoreactivity in the hearts of E14 (C) 
and E l 8  (D) embryos demonstrate that this receptor was specifically expressed in the 
trabeculated layer of the ventricles and atria of the developing hearts, but was absent from the 
interventricular septum (ivs). E, F, Transverse sections showing P2Y1 receptor immunoreactivity 
in the smooth muscle layers of dorsal aorta at E12 (E) and E l 8  (F). Scale bar = 200pm (A, B), 
450pm (C), 750pm (D), 50pm (E) and 200pm (F).
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Figure 7: Immunoreactivity of P2Y receptors on embryonic liver, lung and lens. A, B, 
Transverse sections showing P2Yi receptor expression in E l4 (A) and E l 8  (B) liver. The P2Yi 
receptor was expressed weakly in E14 (A) and clearly in E l 8  (B) liver. Scattered cells showed 
clear P2Yi receptor immunoreactivity in E l 8  liver. C, D, E, Transverse sections showing P2Yj 
(C), P2 Y2  (D) and P2 Y4  (E) receptor-stained E l 8  lung tissues. Note that the P2Yi receptor was 
expressed in the smooth muscle layer of the bronchi (arrows, C) and the P2 Y2  receptor 
expressed in the epithelial cells (arrows, D). The P2 Y4  receptor was not expressed in the lung 
(E). F, G, Transverse sections of the lens at E14 (F) and PI (G) show that the P2Yi receptor was
expressed in the elongating lens fiber cells (If), but not the epithelial cells (ep) inside the anterior 
capsule of the developing lens. H, The P2 Y4  receptor was also expressed in the elongating lens 
fiber cells at PI (If). Scale bar = 200pm (A-E), 50pm (F), 100pm (G) and 50pm (H).
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Chapter IV Expression of P2X purinoceptors during rat 
brain development and their inhibitory role 
on motor axon outgrowth in neural tube 
explant cultures
ABSTRACT
Extracellular ATP is well known as a neurotransmitter and neuromodulator in adult central 
and peripheral nervous systems. ATP mediates rapid synaptic responses via ligand-gated P2X 
receptors. However, little is known about the involvement of ATP during the development of 
mammalian embryos. We studied the expression pattern of P2X receptor subtype mRNA and 
protein during prenatal rat brain development (from E10 to PI brain) using RT-PCR and 
immunohistochemical methods. It was shown that the P2 X3 receptor was the first to be 
expressed in the neural tube at E ll ,  followed by the P2 X2  and P2 X7 in the embryonic brain at 
E l4, and later the P2 X4 , P2Xs and P2X6 receptors at PI. P2 X7 receptor was expressed in the 
lateral hypothalamus and isthmus in the E l4 brain, and subsequently expressed throughout the 
brain as development proceeded. Expression of P2 X4  receptor was observed in the striatal 
subventricular zone, mesencephalic trigeminal nucleus, parabrachial nucleus, lateral deep 
cerebellar nucleus and cuneate nucleus, whereas P2 X5 receptor was detected in the striatal
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subventricular zone, supraoptic nucleus and cuneate nucleus. P2 X5 immunoreactivity was 
also observed in cells scattered over the cortex and the diencephalon. P2 X6 receptor 
expression was detected weakly but widespread in the lateral hypothalamus. P2Xi receptor 
expression was not observed in the brain at any of the stages examined. The sensory-related 
P2 X3 receptor was also expressed in a subpopulation of motor neurons and the outgrowing 
motor axons in the ventral neural tube of rat embryos at El 1-12 and the expression was 
downregulated as development progressed, whereas the outgrowing axons emerged from 
somatomotor neurons did not express P2 X3 receptor. It was therefore speculated that ATP 
might be involved in motor axon outgrowth. Thus we then investigated the effect of ATP on 
motor axon outgrowth in collagen-embedded neural tube explant cultures. Motor 
neurons-containing neural tube explants at E l2 were cultured for 4 days in a 3-dimensional 
collagen gel bathed with lOOpM ATP or aP-meATP (selective agonist for P2Xi, P2 X2 /3  and 
P2 X3 receptors). Both ATP- and ap-meATP-treated neural tubes showed a significant 
reduction in neurite outgrowth compared with the control explants. The inhibitory effect 
could not be induced by UTP. In conclusion, all P2X receptor subtypes, except for P2Xi, are 
strongly represented in the developing rat embryonic brain. The possibilities will be 
discussed that: ATP is involved in inhibition of motor axon outgrowth during early embryonic 
neurogenesis, most likely via the P2 X3 receptor; that P2 X7 receptors may be involved in 
programmed cell death during embryogenesis and; that P2 X4 , P2 X5 and P2X6 receptors might
132
be involved in postnatal neurogenesis.
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INTRODUCTION
Extracellular ATP was first shown to be released from sensory nerves during antidromic 
stimulation in 1959 (Holton, 1959). However, it was not until Bumstock et al (1970) found 
evidence for the role of ATP as a neurotransmitter in nonadrenergic, noncholinergic (NANC) 
nerves supplying the gut and bladder that purinergic signaling was hypothesized (Bumstock, 
1972). It is now well known that ATP mediates wide ranges of physiological activities by 
activating two types of receptors: ligand-gated P2X receptors and G protein-coupled P2Y 
receptors (Ralevic and Bumstock, 1998). To date, seven P2X receptor subunits (P2 X 1-7) 
(North, 2 0 0 2 ) and eight P2Y receptors (P2Yi>2,4)6,ii,i2,i3,i4) have been cloned from mammals 
(Bumstock, 2003a; Abbracchio et al., 2003).
ATP is released from the peripheral and central neurons, where it can act on P2X receptors 
to elicit fast excitatory neurotransmission (Bumstock, 2003b). Of the seven cloned P2X 
receptor subunits, P2 X2 , P2 X4 , and P2X6 receptor transcripts and proteins are widely 
distributed in adult rat brains (Norenberg and files, 2000). P2Xi receptor is localized in the 
adult cerebral cortex, striatum, hippocampus and cerebellum. P2X5 shows restricted 
localization, where the mRNA transcript was only found in the mesencephalic trigeminal 
nucleus. P2 X3 is present in the sensory-related area such as nucleus tractus solitarius
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(Norenberg and Illes, 2000). P2 X7 has been reported recently in the hippocampus and 
medulla oblongata (Deuchars, 2001; Sperlagh et al., 2002). Functional analysis showed that 
ATP acts both as a fast neurotransmitter and as a neuromodulator regulating the release of 
classical neurotransmitters like glutamate and GAB A (Labrakakis et al., 2000; D’Ambrosi et 
al., 2001; Sperlagh et al., 2002; see Bumstock, 2003b).
We have previously identified the P2 X2  and P2 X3 receptor expression in rat embryonic 
brain (Cheung and Bumstock, 2002). P2 X2 receptor is first expressed weakly in the nucleus 
tractus solitarius at embryonic day 14 (E l4), whereas P2 X3 receptor is expressed even earlier 
in a subpopulation of the neurons and its extended axons in the ventral hindbrain neural tube as 
early as El 1. At E l2 the axons expressing P2 X3 receptor grew dorsally to leave the hindbrain 
via the large dorsal exit point to trigeminal ganglia, suggesting that the P2 X3 immunoreactive 
cells were branchiomotor (BM) or visceromotor (VM) neurons (Jacob et al., 2001). However, 
expression of P2 X3 receptor was downregulated during further development. According to 
the spatial and temporal information of P2 X3 receptor expression in the ventral neural tube, we 
proposed that the receptor has a role to play in axon outgrowth during hindbrain development.
In the present study, we use RT-PCR and immunohistochemistry to examine the expression 
pattern of all the seven P2X receptor subunits during embryonic rat brain development from
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E l4 to postnatal day 16 (PI6 ). In addition, we have explored the role of ATP on axon 
outgrowth during embryonic neurogenesis by culturing hindbrain neural tube explants 
containing motor neurons in collagen gels in the presence of ATP and its derivative a  p-me ATP, 
which is a stable and selective agonist for P2 X3 receptors (and P2Xi receptors).
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MATERIALS AND METHODS
RT-PCR analysis
Embryonic and neonatal Sprague-Dawley rat brain tissues of different ages were dissected 
and the meninges were removed. Total RNA was extracted from the whole brain tissues of 
four developmental ages (E14, E18, PI and P16) according to the sections of Materials and 
Methods in Chapter III. The sequence specific primers (Life Technologies, NY, USA) for 
P2X receptors (Shibuya et al., 1999; see Appendix) were then added to the reaction mixtures 
and the PCR cycling parameters were 95°C for 30 s, 58°C for 1 min (58°C for P2Xi, P2 X3 , 
P2 X4 , P2 X5 , P2 X7 ; 61°C for P2 X2 and 64°C for P2X6), 72°C for 1.5 min for 35 cycles, 
followed by a further cycle of 10-min extension at 72°C. The resulting PCR products were 
resolved in a 2% agarose gel and observed under ultraviolet illumination. At least 3 separate 
RT-PCR experiments were performed for each P2X receptor on each individual embryonic 
tissue.
Tissue processing and immunohistochemistry
Please refer to the sections of Materials and Methods on Chapter II. The primary 
antibodies used were rabbit polyclonal antibodies against P2Xj_6 receptors (gifts from Roche 
Bioscience, USA, 1:200; see Appendix) and P2 X7 receptor (Alomone, Israel, 1:500 see
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Appendix). For control experiments, the sections were incubated with the primary antibodies 
pre-adsorbed with the control peptide antigens that used in raising the antibodies or with 
normal horse serum only. Double labeling experiment of P2 X3 and Islet-1 antibody (1:700, 
Developmental Studies Hybridoma Bank, DSHB) was performed as previously described in 
the section of Materials and Methods in Chapter III.
Photomicroscopy
Images of DAB immunohistochemical staining were taken with a Leica DC 200 digital 
camera (Leica, Switzerland) attached to a Zeiss Axioplan microscope (Zeiss, Germany). 
Images were imported into a graphics package (Adobe Photoshop 5.0, USA).
Neural tube explant culture
Rat embryos were obtained at E l2. The hindbrain neural tube explants used were taken 
between rhombomere 1 (rl) to r4 axial levels (Caton et al., 2000). Motor neuron-containing 
explants were dissected using Dispase (Roche Bioscience) and tungsten needles. The 
bilateral explants were cut open at the dorsal midline and flattened. Only the medial one-third 
of each side of the neural tube was used for culture to avoid contamination of the roof plate and 
dorsal neural tube. Tissues were washed in Hank’s Balanced Salt Solution (HBSS, Gibco, 
UK) and kept on ice until needed. Collagen gel was freshly made by mixing the rat tail
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collagen (Roche Bioscience, USA) with 7.5% sodium bicarbonate solution and 10X Minimum 
Essential Medium (MEM) in a ratio of 8:1:1 (collagen: sodium bicarbonate: 10X MEM). A 
thin layer of collagen gel was laid and allowed to set in the culture well of 4-well pates (Nunc). 
The neural tube explant was transferred onto the thin collagen layer and a large drop of 
collagen gel was added to embed the explants. The collgen gel with embedded neural tube 
explant was covered with high glucose-Dulbecco’s modified Eagle medium (DMEM) with 
Glutamax I (Gibco) supplemented with IX antibiotic/antimycotic solution and 
insulin-transferrin-selenium supplements (Gibco). To examine the effects of extracellular 
purines on the axon outgrowth, lOOpM of ATP, ap-meATP or UTP (Sigma, USA) was added 
to the medium at the beginning of the culture period. The collagen-embedded explants were 
cultured for 4 days in a humidified atmosphere of 5% CO2 at 37°C. The culture medium was 
replaced with fresh medium containing same concentration of the nucleotides every 2  days.
Immunostaining o f  collagen gels and quantitation o f  axon outgrowth
Collagen gels were fixed for immunostaining according to Guthrie and Lumsden (1994) 
using monoclonal antibody 2H3 (Developmental Studies Hybridoma Bank), which recognizes 
the 165 kDa neurofilament protein. Gels were mounted under propped coverslips in 90% 
glycerol/10% PBS and photographed. Images were imported into both Neurolucida 
(MicroBrightField, Inc, USA) for analysis of neurite length and an analytical package
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(Metamorphs, Universal Imaging Corporation, USA) for comparison of the number of neurites 
projecting from the explants between treatment groups. A total of 50 longest neurites from 
each explant were taken for comparison of neurite length. The pixels occupied by 
immunostained neurites were taken as a representative of the number of neurites projecting 
from the explants for comparison. The pixels occupied by total neurites were then divided by 
the pixel occupied by the explants to determine the neurite/explant ratio. Neural tube 
explants together with the collagen gel were cryoembedded, sectioned and stained for neural 
cell adhesion molecule (NCAM) expression using monoclonal NCAM antibody (1:4000; 
Sigma).
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RESULTS
Expression pattern of P2X receptors during rat brain development
Previously, we have shown that P2 X3 was the first purinoceptor to express during 
neurogenesis. It was detected in the cranial motor neurons early at E ll ,  whereas P2 X2  
receptor protein was found in the nucleus tractus solitarius at E14 (Cheung and Bumstock, 
2002). Here we examined the expression pattern of all the known P2X receptor subtypes 
during rat brain development using RT-PCR and immunohistochemistry. The mRNA 
transcripts of receptor subtypes P2 X2 , P2 X3 , P2 X4  and P2 X7 were detected as early as E l4 
brain (Fig. 1) and they continued to express, though to different extents, from this stage 
onward into the postnatal period (E l4 to PI 6 ). The abundance of the P2 X2 and P2 X7 receptor 
transcripts appeared approximately the same throughout the stages examined. A gradual 
decrease in expression of P2 X3 receptor was observed, where the expression was high at E14 
and E l 8  but appeared to be lower at PI and P I 6 . In contrast, the intensity of P2 X4  receptor 
transcripts amplified was gradually increased from E14 to P I 6 . P2Xs and P2X6 receptor 
transcripts started to express weakly at E l 8  and PI, respectively. P2Xi receptor transcript 
was not detected in the brain at all the stages examined although in the positive control using 
uterine tissues, the primers for P2Xi receptor showed strong positive signals (data not shown).
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P2 X3 receptor was expressed in the neurons and the outgrowing axons in the hindbrain neural 
tubes as early as in E ll confirming our earlier report (Cheung and Bumstock, 2002). 
Immunoreactivities of other P2X receptor subtypes were not observed at this early stage. 
P2 X2  receptor was expressed in the nucleus tractus solitarius at E l4. To obtain the spatial 
information of expression of the P2X receptors, we used immunohistochemistry to examine the 
distribution of the P2Xi, P2 X4 , P2 X5 , P2X6 and P2 X7 receptor protein during rat brain 
development. Consistent with the RT-PCR results, P2 X7 immunoreactivity was observed at 
E14. Expression was localized in the lateral hypothalamus (Fig. 2) and the isthmus. At E l 8 , 
P2 X7 receptor was detected in the lateral olfactory tract and the optic tract, and widespread 
throughout the diencephalon (thalamus and lateral hypothalamus), cerebellum and brainstem 
(midbrain, pons and medulla) and the expression persisted after birth (data not shown). The 
P2 X4  immunoreactivity was not observed until PI, although its mRNA transcript was 
expressed early at E l4. P2 X4  receptor was expressed in distinct populations of cells instead 
of a widespread expression in adult (see review Norenberg and Illes, 2000) (Fig. 3). P2 X4  
immunopositive cells showed cytoplasmic staining and were located in the striatal 
subventricular zone, mesencephalic trigeminal nucleus, parabrachial nucleus, lateral deep 
cerebellar nucleus and cuneate nucleus (Fig. 3). Likewise, both the receptor proteins of P2 X5 
and P2X6 receptors were also detected in PI brain. P2Xs receptor was expressed in the 
supraoptic nucleus, striatal subventricular zone and cuneate nucleus and in cells scattered over
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the cortex and diencephalons (Fig. 3). Similar to P2 X4  receptor staining, the 
P2 X5 -immunopositive cells in the supraoptic nucleus showed cytoplasmic staining and round 
in shape, whereas the scattered P2 X5-immunoreactive cells in the cortex and those in the 
striatal subventricular zone appeared pyramidal in shape (Fig. 3). P2X6 receptor was, 
however, expressed weakly in the lateral hypothalamus (Fig. 3). Specific immunoreactivity 
for P2Xi receptor was not detected at all the stages examined.
Based on the timing of the initial appearance of the receptors, the sequential expression for 
P2X receptors during brain development was summarized as in Fig 4.
Neural tube explant culture and axon outgrowth
P2 X3 immunoreactivity was also localized in the motor neurons and its outgrowing nerves 
in the ventral neural tube at E ll-E l 2 (Fig 5C). In order to investigate if ATP, the receptor 
ligand, also participated in motor axon outgrowth, the collagen-embedded cranial neural tubes 
containing motor neurons were treated with ATP and related compounds. In a control 
experiment where the collagen gel was bathed with medium only, motor axon outgrowth 
extended from the lateral sides as well as the rostral and caudal borders of the explants. The 
outgrowing motor axons were visualized with immunostaining using monoclonal 2H3 antibody. 
After staining, the axons appeared dark brown in color. In the ATP-treated group, the extent
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of the axon outgrowth was significantly reduced compared to the control group (Fig 5, 6). 
There was a 46% reduction of neurite length in the ATP-treated group (Fig 6). Similarly, 
ap-meATP, a stable analog of ATP and also the agonist for P2 X3 receptor, caused a 41% 
decreased in axon length (Fig 6). Application of UTP did not show significant inhibitory 
effect on neurite outgrowth from neural tube explants compared to control explants, 
eliminating the possibility of P2 Y2 and P2 Y4  receptor involvement (Fig 6). We subsequently 
compared the area occupied by all the outgrowing neurites (excluding the neural tube explants) 
between treatment groups. Both ATP and ap-meATP caused a reduction of 61% and 62%, 
respectively, of the total area occupied by the neurites (Fig 6). To minimize the variation in 
neurite outgrowth due to the difference in the sizes of the neural tube explants, the 
neurites-occupied areas were then divided by the area occupied by the explants. Reduction of 
47% of total neurite area was observed in both ATP-treated group and 46% in 
ap-meATP-treated groups (Fig 6). ATP and ap-meATP appeared to reduce the length and 
probably the number of extending neurites, too.
The neural tube explants were stained with P2 X3 receptor and NCAM, a marker for neural 
cell adhesion and neurite outgrowth. Results of immunofluorescence showed that both P2 X3 
and NCAM were expressed in the neurons as well as the outgrowing neurites (Fig 5). Double 
labeling experiment showed that co-localization of P2 X3 receptor and NCAM was frequently
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seen in the outgrowing neurites, although neurites showing NCAM but not P2 X3 receptor 
expression were also observed (Fig 5).
145
Chapter IV P2X? receptor in neurite outgrowth
DISCUSSION
The idea of extracellular ATP acting as a neurotransmitter or neuromodulator has been 
examined extensively in both the central and peripheral nervous system in adult animals, and a 
large body of evidence shows that the ATP-induced fast synaptic response is mediated by 
activation of ATP-gated ion channels, the P2X receptors (Bumstock, 1972; Bumstock and 
Kennedy, 1985; Norenberg and Illes, 2000; North, 2002; Bumstock, 2003b). We have 
previously found that ATP-gated P2 X3 purinoceptor was expressed in the early embryonic 
nervous system (Cheung and Bumstock, 2002). The present study shows for the first time the 
developmental expression of six of the seven P2X receptor subtypes during prenatal brain 
development, and the possible role of ATP and the P2 X3 receptor during embryonic 
neurogenesis.
We demonstrated that the neuronal P2 X3 and P2 X2  receptors start to express in the 
embryonic rat central nervous system (CNS) at E ll and E l4, respectively, in confirmation of 
our earlier findings (Cheung and Bumstock, 2002). Here we showed that in addition to the 
P2 X2  receptor, the P2 X7 receptor in the brain was also expressed from E14 onwards. P2 X7 
receptors have been shown to be involved in programmed cell death or to induce cytotoxicity 
at a high concentration of ATP released during inflammation or upon tissue trauma (reviewed
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by Le Feuvre et al., 2002). Sperlagh et al. (2002) demonstrated that ATP regulates glutamate
•y j
release via activation of P2 X7 receptor, and excessive glutamate release altered the Ca 
homeostasis, resulted in activation of apoptosis-related gene (e.g caspase) (see review by Le 
Feuvre et al., 2002). Since apoptosis is a common event in developing brain, it is therefore 
likely that the activation of P2 X7 receptor is also involved in cell death during neurogenesis, 
but this possibility awaits further investigation.
Although the expression of P2 X4 , P2Xs and P2X6 receptors appeared late during 
development, P2 X4  and P2 X5 receptors were both expressed in the subventricular zone, the site 
of postnatal neurogenesis (see review Conover and Allen, 2002). It has been claimed that 
astrocytes in the subventricular zone served as neural stem cells (Doetsch et al., 1999) that give 
rise to both neurons and glia. An opposing report by Johansson et al (1999), however, 
suggests that it is the ependymal cells adjacent to subventricular zone that generate multipotent 
neurospheres. It is as yet unknown whether the P2X receptor-positive cells present in the 
subventricular zone are neural stem cells or migrating neuroblasts. P2 X4  and P2Xs may 
constitute two different types of cells in terms of the morphology and area of expression. 
P2 X4  receptor-expressing cells appeared round and resided in the subventricular zone, while 
cells positive for P2 X5 receptor looked pyramidal in shape and were scattered throughout 
different layers of the cortex as well as being located in the subventricular zone. An
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investigation of the identity of the P2 X4  and P2 X5 receptor-expressing cells in the 
subventricular zone is in progress. Little is known about the role of P2X6 receptors in the 
neonatal hypothalamus, but the P2 X6 receptor has been implicated in hormone release from 
axon terminals as well as membrane recycling of the granular vesicles and microvesicles in the 
adult hypothalamo-neurohypophysial system (Loesch and Bumstock, 2001). It is therefore 
believed that such expression may not relate to development. The P2Xi receptor, according 
to the present results, did not express throughout the perinatal stages examined. However, 
previous studies have shown P2Xj receptor expression in the cerebellum (Loesch and 
Bumstock, 1998) and P2Xi receptor up-regulation in the CNS after injury (Florenzano et al., 
2002; Franke et al., 2001).
The presence of molecules that are involved in both embryonic neurogenesis and 
regeneration after injury is not unusual (Waschek, 2002). However, the possibility that ATP is 
involved in both processes is yet to be established. Among all the P2X receptors examined, 
homomeric P2 X3 receptor was the first to express during neurogenesis in both central and 
peripheral nervous system. P2 X3 immunoreactivity is detected in the cranial motor neurons 
as early as E ll ,  by the time when the neurons finish their final mitosis, exit the cell cycle, and 
start axon outgrowth (Ericson et al., 1992; Yamada et al., 1993). Based on the locations of 
immunoreactivities which are overlapping with dorsal axon trajectories and the dorsal
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migratory pathway of motor neurons from the ventral neural tube, it was suggested that the 
P2 X3 receptors expressing cells are the BM and/or VM neurons, instead of somatomotor (SM) 
neurons (see review Jacob et al., 2001). Although the P2 X3 immunoreactivity in the spinal 
neural tube suggests that the VM neurons express the receptor, the intense staining in the 
hindbrain neural tube compared to the weak staining in the spinal neural tube suggests that the 
BM neurons also expresses the receptor.
We have shown that both ATP and ap-meATP significantly reduced neurite extension from 
motor neuron-containing neural tube explants at E l2. ATP is a non-selective agonist for most 
of the P2X and P2Y receptor subtypes. Although it is possible that PI adenosine receptors 
may also be involved after adenosine is produced following ectoenzymatic breakdown of ATP, 
adenosine receptors were not included in our present study. Instead, the ap-meATP was used 
in the present study as a stable analog of ATP to exclude any possible PI receptor involvement. 
In addition, since aP-meATP is a selective agonist only for P2Xi, P2 X2 /3  and P2 X3 receptors. 
Since neither RT-PCR and immunohistochemical data showed any P2Xi receptor expression in 
embryonic and postnatal brains and P2 X2 receptor expression was not observed in the brain 
until E l4, it is most likely that the effect of ap-meATP was mediated via P2 X3 receptor. In 
addition to the P2 X3 receptor, P2 Y2 and P2 Y4  receptors, which are UTP-activated receptors, 
have also been demonstrated previously in motor neurons in the ventral neural tube (Cheung et
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al., 2003). However, the P2Y receptors reside mainly in the spinal instead of cranial neural 
tube. Furthermore, the present result also showed that the inhibitory effect was not observed 
when UTP was used instead of ATP, thus excluding the involvement of P2 Y2 and P2 Y4  
receptors.
ATP has previously been shown to inhibit neurite outgrowth in hippocampal neurons 
transfected with NCAM, a marker for neural cell adhesion and neurite outgrowth, and the 
inhibitory effect of ATP was lost when the hippocampal neurons did not express NCAM, 
suggesting that ATP regulates neurite extension via NCAM (Skladchikova et al., 1999). 
Immunohistochemical studies showed that axons growing out from the neural tube at E12 
expressed NCAM. Some but not all of the outgrowing axons showed NCAM and P2 X3 
receptor coexpression, implicating that ATP-mediated inhibition in neurite outgrowth might act, 
at least partly, through the NCAM signaling system.
In summary, we present the first report to show the developmental expression profile of 
P2X receptors subtypes during prenatal brain development in the rat. Results from the 
present study indicated that different P2 receptor subtypes may participate in different 
developmental processes such as neurite outgrowth (involving P2 X3 receptor), postnatal 
neurogenesis (relating to P2 X4  and P2Xs expression) and cell death (possibly involving P2 X7
150
_______________________________________________________________ Chapter IV P2X? receptor in neurite outgrowth
receptor), whereas others might not be involved in development (P2Xi and P2X6 receptors). 
Furthermore, extracellular ATP may function as a signaling molecule to inhibit motor axon 
outgrowth in the embryonic neural tube, most likely via the interaction between P2 X3 receptor 
and NCAM.
151
Chapter IV P2X? receptor in neurite outgrowth
FIGURES & LEGENDS:
Figure 1 RT-PCR analysis on P2X receptor mRNA expression during prenatal rat brain 
development. Total RNA from brain samples of four developmental ages (E l4, E l8, PI and 
P I6) was reverse-transcribed, and the resulting cDNA was PCR-amplified using gene-specific 
P2X receptor primers (see Experimental Procedure). Lane L represents lOObp-DNA ladder. 
The amplified products are arranged in 4 lanes corresponding to RT-PCR products of E l4, El 8, 
PI and P I6 rat brains (from left to right) for each P2X receptor examined, i.e. P2X] (lane 1-4); 
P2X2 (lane 5-8); P2X3 (lane 9-12); P2 X4  (lane 13-16); P2X5 (lane 17-20); P2X6 (lane 21-24) 
and P2 X7 (lane 25-28). The P2Xi receptor primers that detects no expression in brain 
samples shows strong positive signals using rat uterus as positive control (data not shown). 
Note the gradual decline in P2X3 mRNA expression from E l4 to P I 6 . The expression pattern 
shown here represents results from at least three independent experiments.
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Figure 2 Immunoreactivity of P2 X7 receptor protein in the developing brain. P2 X7 
immunoreactivity is detected in: (A), the lateral hypothalamus (lh) at E l4 (B), the lateral 
olfactory tract (lot) and optic tract (opt). Diagram inserted in B outlines the region 
represented (arrows). (C) cerebellum and midbrain (cb and mb) and (D) medulla (md) at E l8. 
3v, third ventricle; 4v, fourth ventricle; aq, aqueduct. Insert in B outline the structure shown 
in B. Scale bar = 250pm (A, C, D) and 500pm (B).
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Figure 3 Immunoreactivity of P2X receptors in neonatal (PI) brain. Rectangular boxes 
in the inserts outline the regions shown in the corresponding pictures and the black dots in 
some of the inserts represent P2X immunoreactivity. (A) P2 X4  receptor-positive cells (arrows) 
are detected in regions along the striatal subventricular zone. (B) A high magnification of the 
rectangular box is shown in (A). (C) P2 X4  receptor immunoreactivity is also detected in
mesencephalic trigeminal nucleus and (D) lateral deep nucleus of the cerebellum. (E) P2Xs 
receptor expression is located in the supraoptic nucleus and (F) the cells along the striatal 
subventricular zone. (G) Scattered P2Xs immunoreactive cells are also observed throughout 
the cortex (G). Note that the whole cell bodies of the P2Xs receptor-positive cells shown in F 
and G are labeled. (H) P2X6 receptor expression is detected in the lateral hypothalamus. 
Scale bar = 750pm (A), 100pm (B, E, H) and 200pm (C, D, F, G).
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Figure 4 Summary of the sequential expression of P2X receptors during rat neurogenesis. 
P2X receptors are arranged from top to bottom according to the chronological order of 
expression during rat brain development from E ll to Adult. While P2 X3 receptors appear 
early, they decline in the stages that follow. P2 X2  and P2 X7 receptors are expressed from the 
same day (E l4) onwards, while P2 X4 , P2 X5 and P2X6 are also expressed from PI onwards. 
Dotted line for P2Xi receptor represents unknown starting point, since expression of P2Xi 
receptor was not observed in any of the developmental ages examined in this study.
158
Fig 4
E ll  E14 E18 PI P16 Adult
P 2 X 3  -------------------------------------------------------------------------------------------------------------------- ►
P2X2 ----------------------------------------------------------------------------
P2X? ----------------------------------------------------------------------
P 2 X 4 -----------------------------------------------------------------------------------------------------------------------------
P2Xs----------------------------------------------------------- -------------------------------------
P 2 X 6  ------------------------------------------------
P2Xi ..............
Chapter IV P2Xi receptor in neurite outgrowth
Figure 5 Neural tube explants in collagen gel after treatment with lOOpM of (A) ATP and 
(B) control. (C) Cross section from E l2 hindbrain neural tube showing P2 X3 receptor 
immunoreactivities (red) in the motor neurons and the motor fibers in the ventral neural tube. 
(D and E) Neural tube explants are cryosectioned and immunostained with the P2 X3 receptor 
(red) and NCAM (green). (F) Image merged from D and E showing co-localization 
(yellow/orange) of P2 X3 and NCAM (arrows). Scale bar = 500pm (A-B) and 100pm (C-F).
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Figure 6 Quantitation of neurite outgrowth from collagen embedded neural tube explant 
culture. Neural tube explants were bathed with lOOpM of extracellular nucleotides (ATP, 
aP-meATP and UTP). Control explants were treated with medium only. Images of treated 
neural tube explants were imported into Neurolucida and neurite outgrowth was analyzed by 
measuring the 50 longest neurites from each explant. (A) Results expressed as the average 
length of neurites counted with error bar represents standard error. (B) Images of treated 
neurite tube explants were imported into Metamorph and the total pixel area (arbitrary units) of 
the neurites (excluding the explants) were computed (B). (C) To minimize the variations of
the neurite outgrowth due to the differences in individual explant size, the total pixel area 
occupied by the neurites (excluding the explants) were divided by the total pixel area occupied 
by the corresponding explants and the ratios were compared between groups. Significant 
difference is represented by ** (p< 0.001) or * (p< 0.05) analyzed by unpaired t-test.
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Chapter V Pharmacological and molecular 
characterization of functional P2 
receptors in rat embryonic 
cardiomyocytes
ABSTRACT
Purinergic receptors activated by extracellular nucleotides (ATP, ADP, UTP and UDP) 
are well known to exert physiological effects on the cardiovascular system, including 
cardiomyocytes. However, the possibility that nucleotides participate in embryonic heart 
development is not clear. We have investigated the responsiveness of embryonic 
cardiomyocytes to P2 agonists by means of the fluorometric imaging plate reader (FLIPR), 
which measures Ca influx. Cardiomyocytes taken from embryonic day (E) 12 did not 
respond to P2 agonists, but responses were detected in cardiomyocytes taken from E l4 and 
E l 8  rats. ATP, 2MeSADP, UTP, UDP and BzATP, but not ap-meATP, were able to induce
n  I
Ca mobilization. PPADS blocked the ATP-induced responses of E14 embryonic 
cardiomyocytes but not those produced in El 8  hearts. RT-PCR showed a dominant 
presence of P2 X2  and P2 X4  mRNA transcripts on E l4 cardiomyocytes with a lower 
expression of P2 X3 and P2 X7 . P2Xi and a low level of P2 X5 receptor mRNA were also
Chapter V P2 receptor in embryonic cardiomvocvte
expressed at E l8. Immunocytochemical data indicated that only P2X2 and P2 X4  receptor 
protein was expressed in E l4 cardiomyocytes. All the P2X receptor subtype protein was 
expressed in E l8 cardiomyocytes except for P2 X3 and P2X6. Responses mediated by 
agonists specific for P2Y receptors subtypes (2MeSADP, UTP and UDP) showed that P2Y 
receptors (P2Yi, P2 Y2 , P2 Y4  and P2Y6) were also present in both E14 and E l8 
cardiomyocytes. Our results provide evidence that specific P2 receptor subtypes are 
present in embryonic cardiomyocytes, including P2 X7 and P2 Y4  receptors which have not 
been identified in adult rat cardiomyocytes. Some of the receptors have shown 
responsiveness to the ATP stimulation even before birth, suggesting that ATP may be an 
important messenger in embryonic as well as adult hearts.
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INTRODUCTION
Extracellular purines and pyrimidines (ATP, ADP and UTP) are well known to act as 
agonists in regulating a variety of physiological functions in many different cell types 
(Bumstock, 1997). In 1978, Bumstock proposed that there were specific receptors for 
adenine nucleosides (PI) and nucleotides (P2 receptors). Based on cloning and second 
messenger systems P2 receptors were divided into two receptor families, ionotropic P2X 
receptors and metabotropic P2Y receptors (Abbracchio and Bumstock, 1994). P2X receptors 
are ligand-gated ion channels formed from either homomeric or heteromeric association of 7 
receptor subunits (P2 X 1-7) (North, 2002). P2Y receptors are G protein-coupled receptors, 
with 8  mammalian subtypes (P2 Yi>2 ,4 ,6 ,n,i2 ,i3 ,i4 ) being cloned (Bumstock, 2003a).
ATP is known to mediate various physiological activities in the adult heart of different 
species (Olsson and Pearson, 1990; Ralevic and Bumstock, 1991, Vassort, 2001). However, 
only a few studies focused specifically on P2 receptor expression in cardiomyocytes 
(Vulchanova et al., 1996; Webb et al., 1996; Nori et al., 1998; Hansen et al., 1999). The 
mRNA transcripts of P2Yi, P2 Y2 , P2 Y4  and P2Y6 receptors are all expressed in the neonatal 
cardiomyocytes, whereas P2 Y4  receptor transcript is no longer detected in the adult myocytes
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(Webb et al., 1996), suggesting that dynamic changes in expression of P2Y receptors were 
occurring during heart development. While it was demonstrated that the P2Xi receptor 
protein was specifically expressed in the intercalated disks of cardiac muscle (Vulchanova et al., 
1996), Nori et al (1998) also detected the mRNA transcripts for P2X], P2 X2 and P2 X4  
receptors from the micro-dissected tissues in various areas of the heart, with strong signals in 
the atria and only the typical band for P2 X4  receptor transcripts in ventricles. In addition, 
Hansen et al (1999) showed an abundance of colocalized P2 X2  and P2 X5 receptor clusters on 
the sarcolemma of neonatal heart.
The heart is the first organ to function in developing embryos (Fishman and Chien, 1997).
The tubular heart undergoes sequential morphological changes such as looping, segmentation,
trabeculation, septation etc (Franco et al., 1998). As with skeletal or smooth muscle, the
arrangement of the myocardial cells is not random, but shows certain patterns which change
during ontogenetic development. Such arrangement is of great importance to ensure the
efficiency of the myocardial pump. It is therefore considered that dynamic changes in
spatiotemporal patterns of gene expression resulting in complex structural changes during heart
ontogeny are involved in the developing embryo (Olson and Srivastava, 1996; Zhao and
Rivkees, 2000); thus the gene expression may be different between different developmental
stages and from that of the adult (Franco et al., 1998). Nevertheless, identifying the presence
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of gene expression may not provide the information of whether the gene products are in 
functional status or not. There have been some studies of P2 receptors gene expression in 
embryonic heart. Previously, the expression of some of the purinergic receptors subtypes 
(P2 X2  and P2Yi ,2 ,4 ,6) in the embryonic rat heart have been identified (Cheung and Bumstock, 
2002; Cheung et al., 2003), yet the functional status of the receptors remained unclear. There 
have also been reports of the expression of P2X receptor subtypes in the chick embryonic heart 
where P2 X4  and P2Xs mRNA has identified (Ruppelt et al., 1999, 2001; Hu et al., 2002) and in 
the human embryonic heart, where mRNA for P2Xi, P2 X3 , P2 Y2 , P2 Y4  and P2Y6 receptors 
were expressed (Bogdanov et al., 1998a). However, information on the developmental 
expression profile together with the functional status of other P2X receptor subunits in rat 
embryo is lacking. To fill this gap, we have used the fluorometric imaging plate reader 
(FLIPR) together with RT-PCR analysis and immunocytochemistry to study the expression 
profile of the purinergic receptors during the development of rat cardiomyocytes. Such 
combinatorial information on the gene expression and pharmacological analysis may clarify 
the specific receptors responsible for ATP-mediated activities during cardiac embryogenesis.
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MATERIALS AND METHODS
Cell Culture and Ca2+ mobilization analysis
Cardiomyocytes were prepared from embryonic Sprague-Dawley rats according to 
Burton et al (1999). Briefly, female time-mated rats were sacrificed using carbon dioxide 
inhalation and cervical dislocation. The day of identification of the presence of a vaginal plug 
was designated as day zero (EO). Embryos were removed and placed into ice-cold
* iphosphate-buffered saline (PBS, pH 7.4). The hearts were dissected out, placed in Ca -free 
PBS at 4°C, washed, and the heart tissues were digested in type II collagenase (Worthington; 1 
mg/ml in the same medium) at 37°C. The hearts were then gently triturated until all tissue 
fragments disappeared. The cell suspension was then mixed with Dulbecco’s modified 
Eagle’s medium (DMEM) with GLUTAMAX I containing 10% (v/v) fetal calf serum (FCS) 
and centrifuged at 700g for 6  min. The cell pellet was resuspended in DMEM-FCS 
containing penicillin (lOOU/ml), streptomycin (0.1 mg/ml), and amphotericin B (0.25 pg/ml) 
and passed sequentially through a 21- and 25-gauge needle. Cells were allowed to preplate 
(twice, 1 hr each) and the nonadherent cells were then plated at 1 x 1 0 4  cells per well into 
96-well black-wall, clear bottom microtitre plates (BD Biosciences, Franklin Lakes, NJ), which 
had been previously coated with a solution of 1% (w/v) gelatin in water. These 
cardiomyocyte preparations were >98% pure as judged by immunocytochemical staining with
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monoclonal antibodies against sacromeric actin (Sigma; diluted 1/500). The myocytes were 
cultured in the same medium plus insulin-transferrin-selenium supplement at 37°C in 5% CO2 
for one day. The growth medium was then aspirated and replaced with 100 pi of loading 
medium (PBS containing ImM Fluo-4-AM, 10 % pluronic acid and 2.5 mM probenicid) and 
incubated for one hour at room temperature. The cells were subsequently washed three times 
with PBS, and 100 pi of PBS supplemented with 1 mM CaCb were added to each well. The 
cells were then placed in a Fluorometric Imaging Plate Reader (FLIPR; Molecular Devices 
Corp., Sunnyvale, CA), and changes in cellular fluorescence were recorded after the addition 
of 50 pi control buffer or 50 pi of the ATP diluted in PBS. Maximum change in fluorescence 
over baseline was used to determine the response towards ATP. In addition, P2 agonists such 
as 2’,3’-0-(4-benzoylbenzoyl)-ATP (BzATP), ap-methylene ATP (aP-meATP), 
2-Methylthio-ATP (2MeSADP), uridine 5’-triphosphate (UTP) and uridine 5’-diphosphate
9 -1-(UDP) were also used for examining the Ca mobilizing response on the cardiomyocytes. To 
investigate if pyridoxalphosphate-6-azophenyl-2’,4’-disulphonic acid (PPADS), a P2 receptor 
selective antagonist, blocked the ATP-induced response, cells were treated with PPADS (30pM) 
for 30 min before addition of ATP. ATP and related nucleotides were obtained from Sigma 
Chemical Co. (UK) except for PPADS, which was from Tocris Cookson, UK.
Double labeling immunocytochemistry
170
Chapter V P2 receptor in embryonic cardiomyocyte
Cardiomyocytes were grown on gelatin-coated 8 -well chambered slides (Nunc). The 
cells were fixed in 4% paraformaldehyde in phosphate buffer (PB, pH 7.4) for 2 hr at room 
temperature. Cells were washed with PBS, blocked with 10% normal horse serum in 0.1% 
Triton, and the cells were stained with the monoclonal antibody against sacromeric actin (1:500; 
Sigma), together with the polyclonal antibodies against P2Xi_6 (1:200; Roche Bioscience) and 
P2 X7 receptors (1:500; Alomone) followed by an FITC-conjugated donkey anti-mouse IgG 
antibody and cy3-coupled donkey anti-rabbit IgG antibody (1:200; Jackson ImmunoResearch 
Lab) for 1 hr. Please refer to the sections of Materials and Methods on Chapter II for the 
details for Photomicroscopy
RT-PCR analysis
Embryonic hearts at E l4 and E l 8  were dissected and total RNA was extracted from the 
dissected hearts according to the sections of Materials and Methods on Chapter III. The 
sequence specific primers (Life Technologies, NY, USA) for P2X receptors (Shibuya et al., 
1999) were then added to the reaction mixtures and the PCR cycling parameters were 95°C for 
30 s, 58°C for 1 min (58°C for P2Xh P2X3, P2 X4 , P2X5, P2X7; 61°C for P2X2 and 64°C for 
P2X6), 72°C for 1.5 min for 35 cycles, followed by a further stage of 10-min extension at 72°C.
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RESULTS
Effects o f  agonists on Ca2+ mobilization o f  cardiomyocytes
We used FLIPR to study the responses of purinergic receptors that are present in cultured 
embryonic cardiomyocytes upon exposure to ATP and its derivatives. Positive responses were
•  • * • • • 9 -1-  • • •represented by an increase in fluorescence units, indicating Ca mobilization in response to 
receptor activation. Cardiomyocytes from three embryonic ages (E l2, E14 and E l 8 ) were 
taken for analysis. All the agonists were in a concentration of lOOpM. No apparent change
9+was observed in control group when Ca -containing PBS was added into the cells (Fig IB, D,
9 .
G). Cardiomyocytes taken from E l2 did not show any significant response in Ca 
mobilization against ATP (Fig 1A) or any of the ligands tested. In contrast, significant 
responses were detected with cardiomyocytes taken from E l4 and E l 8  embryonic hearts when 
the cells were treated with rapid application of ATP (Fig 1C, IF). Rapid increase in 
fluorescence occurred in a second. We then investigated if the P2 antagonist PPADS blocked 
the ATP-triggered response. The ATP-induced response on E l4 cardiomyocytes was 
antagonized by PPADS at a concentration of 30pM (Fig ID), whereas the antagonizing effects 
of PPADS on El 8  cardiomyocytes was not significant (Fig 1H). On the other hand, the P2Y 
receptor agonists such as 2MeSADP, UTP and UDP all induced significant response in Ca2+ 
mobilization on cardiomyocytes taken at both embryonic ages (Fig 2A-F). BzATP induced a
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weak response on E14 cardiomyocytes, and the response was increased in E l 8  cardiomyocytes 
(Fig 3A, 3B). ap-meATP did not induce a significant response on E l4 cardiomyocytes (Fig 
3C). The response by ap-meATP, though very weak, was observed in El 8  cardiomoyocytes 
(Fig 3D).
RT-PCR analysis
Two developmental ages of embryonic heart at E l4 and E l 8  were studied for mRNA 
expression of all the seven P2X receptors (P2X1.7). Results of the mRNA expression were 
summarized in Fig 4. For all the P2X receptors examined, P2X2, P2X3, P2X4 and P2X7 
receptors showed mRNA expression in the heart at both E14 and E l8. P2Xi and P2X5 
receptor was expressed at E l 8  but not at E l4, though the expression of P2Xs in the heart was 
barely detectable at E l 8 . The P2X6 receptor, however, was not expressed in either E l4 or 
E l 8  hearts.
Double-labeling immunocytochemistry
Fluorescence immunocytochemical staining has shown that among all the P2X receptors 
examined, only P2 X2 and P2 X4  receptors were expressed in the cardiomyocytes at E14 (Fig 
5A-F), as were shown in the double-labeled immunocytochemical staining with a-sarcomeric 
actin. None of the other P2X receptor subunits was coexpressed with a-sarcomeric actin (Fig
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5G-K). Similar to E14, P2 X2  and P2 X4  receptors were detectable in E l 8  cardiomyocytes 
labeled with a-sarcomeric actin shown by double-labeling (Fig 6 A-F). P2Xi, P2 X5 and P2 X7 
receptors were also expressed in E l 8  cultured cardiomyocytes (Fig 6 G-O). However, 
immunoreactivity of P2 X3 and P2 X6 was not detected in any of the stages examined.
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DISCUSSION
It is well known that extracellular ATP exerts a wide range of activities on the adult 
myocardium (for reviews, see Olsson and Pearson, 1990; Ralevic and Bumstock, 1991; Pelleg 
and Belardinelli, 1998; Vassort, 2001). However, combined functional, molecular and 
immunocytochemical information about P2 receptor expression in the embryonic heart is 
lacking, which is needed for our understanding of purinergic signaling during embryonic 
development. The present study focused on the expression pattern of P2 receptors in the rat 
heart during embryonic development.
With the use of FLIPR, the responsiveness of cardiomyocytes taken at different 
embryonic ages towards ATP was analyzed. Indeed, cells at different embryonic ages 
responded differently to ATP. In addition to the previous reports demonstrating the presence 
of functional PI adenosine receptors in mammalian embryonic cardiomyocytes (Hofman et al., 
1997; Zhao and Rivkees, 2001; Zhao et al., 2002), the results of the present study clearly 
indicated the presence of functional P2X and P2Y receptors in rat cardiomyocytes from E14 
onwards. Taken together the results of RT-PCR and immunocytochemical staining showed 
that P2 X2  and P2 X4  receptors were the most likely P2X receptor subtypes responding to ATP at 
E l4. The discriminating feature between the P2 X2 - and the P2 X4 -receptor is the blockade of
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the latter but not the former by PPADS (Ralevic and Bumstock, 1998). However, the 
ATP-induced response at E l4 was almost completely blocked by PPADS, which suggested that 
it was mostly the P2 X2 receptor that accounted for the ATP-mediated response at E l4 
cardiomyocytes. RT-PCR studies were consistent with this conclusion, with the P2 X2  mRNA 
band dominant. In addition, the P2 X2  receptor was also expressed in the embryonic rat heart 
as early as at E l2 (Cheung and Bumstock, 2002), the stage at which none of the other P2X 
receptors were detected (unpublished data). In contrast, the ATP-induced response at El 8  
cardiomyocytes was sustained after treating with PPADS, suggesting the involvement of P2 X4 , 
P2X6 and P2 X7 receptors (see Ralevic and Bumstock, 1998). However, absence of P2X6 
mRNA transcript in the present study ruled out the possibility of P2X6 receptor involvement. 
RT-PCR and immunocytochemistry indicated the presence of P2Xi, P2 X3 , P2 X4  and P2 X7 
receptors at E l 8  hearts. In addition, BzATP, a P2Xi and P2 X7 receptor-sensitive agonist, 
triggered Ca mobilization in El 8  cardiomyocytes. Although P2Xi receptor is also 
sensitive to BzATP, a (3-meATP, a P2Xi-specific agonist, did not induce significant responses in 
both E l4 and E l 8  cardiomyocytes. It is therefore suggested that the BzATP-induced response 
is mostly contributed by activation of functional P2 X7 rather than P2Xi receptors; this has not 
been reported previously. In contrast, P2 X4  receptor expression has been reported in human 
fetal and chick embryonic heart (Bogdanov et al., 1998a; Ruppelt et al., 1999; Hu et al., 2002). 
ATP is known to stimulate a large increase in cytosolic calcium transient and myocyte
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contractile amplitude (see review by Vassort, 2001). Transgenic mouse overexpressing 
human P2 X4  receptors demonstrated an increase in contractility in cardiomyocytes subject to 
ATP stimulation (Hu et al., 2001). In contrast to P2 X4  receptor, little is known about the 
function of P2 X2  and P2 X7 receptor in the myocardium, although it has been shown previously 
that activation of P2 X7 receptors induced contraction of human saphenous vein smooth muscle 
(Cario-Toumaniantz et al., 1998). It is still not clear what factors underlie early embryonic 
changes in contractility in rat, as both changes in Ca sensitivity and troponin isoforms occur 
after 7 days postnatal (Reiser et al., 1994; Jin, 1996). However, the possibility of increase in 
contractility in embryonic rat as a result of P2Xt and P2 X7 receptor activation (and probably 
P2 X2  receptor as well) mediated by ATP is worth investigating.
The presence of receptor transcripts of P2Y], P2 Y2 , P2 Y4  and P2Y6 receptors in 
embryonic rat heart has been demonstrated previously (Cheung et al., 2003), as well as in 
human fetal heart for P2 Y2 , P2 Y4  and P2Y6 receptors (Bogdanov et al., 1998a). The present 
study helps to uncover the functional status of the receptors on cardiomyocytes during heart
1
development. The P2Y receptor agonists all induced Ca mobilization on cardiomyocytes at 
E14. 2MeSADP, which is a stable analog to ADP, induced a P2Yi-specific response on Ca 
mobilization on cardiomyocytes. The uracil nucleotides that preferentially activate P2 Y2  and 
P2 Y4  receptors (by UTP) and P2Y6 receptor (by UDP) also induced Ca2+ mobilization on
177
Chapter V P2 receptor in embryonic cardiomyocyte
cardiomyocytes. Although the receptor proteins were expressed as early as in E12 (Cheung et 
al., 2003), the receptors were shown to be responsive to the agonists in the cardiomyocytes 
from E14 onwards. We have previous shown that the P2Y receptor proteins expressed 
initially all over the heart but soon restricted to the trabeculated layers; the expression was 
absence in compact myocardium after E14 (Cheung et al., 2003). Trabeculation differs from 
compact myocardium in terms of extent of differentiation, rate of contractions and impulse 
conduction (Franco et al., 1998). P2Y receptor expression in the trabeculated layer, and the 
responsiveness towards agonists from E14 onwards suggested that the receptor may have 
something to do with either the differentiation or contraction. Small spontaneous responses 
were occasionally observed in E14 and E l8 cardiomyocytes. Such responses appeared to be 
artifacts, as the spontaneous responses retained in the presence of PPADS. It is probably due 
to the contractile property of the cardiomyocytes that generate the responses.
Bogdanov et al (1998a) have shown the presence of P2Xi and P2 X3 mRNA transcripts in 
human fetal heart. Here we were also able to amplify the mRNA transcripts of P2Xi and 
P2 X3 receptors in El 8 hearts. However, compared to ATP, BzATP and the P2Y receptor 
agonists, ap-meATP only triggered a very small response in E l8 cardiomyocytes. It is 
therefore unlikely that P2Xi and P2 X3 receptors are highly involved in the development of 
cardiomyocytes in rats.
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Ruppelt et al. (2001) demonstrated the mRNA expression of the chick P2 X5 receptor 
subtypes in the embryonic chick heart. Although the results of RT-PCR from the present 
study showed very weak P2Xs mRNA transcript expression in E l 8  rat heart, double labeling 
experiments confirmed the presence of P2Xs receptor protein in the cardiomyocytes.
Although expression profile of P2 receptors on heart development has been examined 
previously, expression pattern together with functional analysis on embryonic cardiomyocytes 
have not been studied previously. Our observations support the hypothesis that ATP acts on 
particular P2 receptor subtypes during different stages of development, suggesting that 
complex mechanisms are involved in governing sequential P2 receptor subtype expression. 
In summary, we have identified P2X receptor subtypes (P2Xj, P2 X2 , P2 X3 , P2 X5 and P2 X7) 
and P2Y receptor subtypes (P2Yi, P2 Y2 , P2 Y4  and P2Y6) in rat embryonic cardiomyocytes. 
All these receptor subtypes, except for P2 X7 and P2 Y4  have been described in adult rat 
cardiomyocytes. Therefore it appears that P2 X7 and P2 Y4  play additional roles in the embryo. 
Complex remodeling occurs during embryonic development of the heart, but further 
investigations are needed to uncover the precise roles played by the various P2 receptor 
subtypes.
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FIGURES & LEGENDS
^ i 1
Figure 1 Ca mobilization of embryonic cardiomyocytes. The response of Ca mobilization 
is represented by an increase in the mean of fluorescent units (n = 3; error bars represent standard 
error of the mean). ATP-induced response in cultured cardiomyocytes taken from El 2 (A), E14 
(C), El 8 (F) and the corresponding controls (B, D, G, respectively). E and H show the 
ATP-induced response after the preincubation with PPADS.
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Figure 2 Ca2+ mobilization of embryonic cardiomyocytes. The response of Ca2+ mobilization 
is represented by an increase in the mean of fluorescent units (n = 3; error bars represent standard 
error of the mean). A, C, E show responses of E14 cardiomyocytes induced by 2MeSADP, 
UTP and UDP, respectively; whereas B, D, F show responses of El 8 cardiomyocytes induced by 
corresponding agonists.
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Figure 3 Ca mobilization of embryonic cardiomyocytes. The response of Ca mobilization 
is represented by an increase in the mean of fluorescent units (n = 3; error bars represent standard 
error of the mean). A, B show responses induced by BzATP on E14 and El 8 cardiomyocytes, 
respectively. C, D show responses induced by ap-meATP on E14 and E l8 cardiomyocytes, 
respectively.
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Figure 4 RT-PCR analysis for P2X 1 .7 receptors on E14 and El 8 heart tissues. Primers for P2X6 
receptors that gave negative results at both stages showed positive signals using rat brain tissue 
extract (data not shown).
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Figure 5 P2X receptor subtype expression in cultured E l4 cardiomyocytes. Cardiomyocytes 
were identified by monoclonal antibody against a-sacromeric actin (a-SMA, green) (A and D). 
P2X receptor-immunoexpressing cells were shown in red (B and E). Cardiomyocytes showing 
coexpression (yellow) of P2X receptors (P2 X2 and P2 X4 ) with the a-SMA (C and F). 
Cardiomyocytes at this stage did not express P2Xi, P2 X3 , P2 X5 , P2X6 and P2 X7 receptors (G-K, 
respectively). Scale bar = 25 pm.
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Figure 6 P2X receptor expression in cultured El 8 cardiomyocytes. Cardiomyocytes were 
identified by monoclonal antibody against a-sacromeric actin (a-SMA, green) (A, D, G, J  and 
M). P2X receptor-expressing cells are shown in red (P2 X2 (B), P2 X4 (E), P2Xi (H), P2Xs (K) 
and P2 X7 (N)). P2X receptor subtypes coexpressing with a-SMA on cardiomyocytes were 
shown in yellow (C, F, I, L and O). P2 X3 and P2X6 receptors were not expressed in El 8 
cardiomyocytes (data not shown). Scale bar = 50pm.
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Chapter VI Early expression of ATP-gated P2X7 receptor 
in the developing rat pancreas
ABSTRACT
Extracellular ATP modulates the functions of the adult pancreas via two nucleotide 
receptor families, the P2X and P2Y receptors. Recently, expression of the P2 X7 receptor was 
demonstrated in islet cells of the pancreas, particularly the mature a  cells that secrete glucagon. 
In streptozotocin-induced diabetic model, loss of insulin-secreting cells was accompanied by 
an increase in a  cells that expressed the P2 X7 receptor. In the present study we have 
examined the expression of P2 X7 receptor in the developing pancreas from embryonic days (E) 
11-18. We detected P2X7-immunoreactive cells in pancreatic islets cells as early as at E ll ,  
prior to glucagon expression. Subsequently P2 X7 receptor was expressed in 
glucagon-secreting cells at E12 and complete colocalization was observed at E l4. Occasional 
colocalization of P2 X7 receptor and insulin was observed in scattered cells at E l2 and E14 but 
not at E l8, when the glucagon-secreting and insulin-secreting cells were almost completely 
segregated. In summary, it was found that P2 X7 receptor was expressed early in a 
subpopulation of glucagon- and insulin-immunopositive cells in developing islets and 
subsequently became restricted to glucagon-expressing cells as development proceeded.
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INTRODUCTION
The functional units of the endocrine pancreas are the islets of Langerhans composed of 
four cell types: a , p, 5 and PP cells. The insulin-secreting P cells constitute the majority of 
the endocrine cell population and form the core of the islet, whereas a , 5 and PP cells secreting 
glucagon, somatostatin and a pancreatic polypeptide respectively make up the rest of the islet 
cell population. In mammals the embryonic pancreas develops from the primitive foregut as 
two outpocketings (the dorsal and ventral buds), each of which consists of an inner endodermal 
epithelium surrounded by the mesenchyme (Pictet and Rutter, 1972). Both buds subsequently 
proliferate to form multiple branches and fuse together to make a functional organ. Among 
the hormones secreted from the endocrine portion of the pancreas, glucagon is the first peptide 
expressed in the developing pancreatic epithelium at embryonic day (E) 9.5 in the mouse (Rail 
et al., 1973; Guz et al., 1995). The functional significance of this early appearance of 
glucagon in the pancreas has not been resolved, although a recent study suggests that glucagon 
regulates the differentiation of insulin-secreting cells (Prasadan et al., 2002). However, the 
relationship of these endocrine cells in embryos and how the differentiation of these various 
types of pancreatic cells is regulated is still far from clear. The histogenesis of pancreatic 
endocrine cells requires complex and dynamic gene expression (Larsson, 1998; St-Onge et al., 
1999).
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Receptors responsible for ATP-mediated activities are subdivided into ionotropic P2X 
and metabotropic P2Y receptor families (Ralevic and Burnstock, 1998). P2X receptors 
mediate rapid non-selective passage of small cations across the cell membrane resulting in an
• • • Oj. 9 tincrease in intracellular Ca and depolarization (see Ralevic and Burnstock, 1998). Among 
all the P2X receptors cloned, the P2 X7 receptor is structurally and functionally unique in that 
the cation channel of the P2 X7 receptor, under the continuous presence of ATP and a low level 
of divalent cations, converts to a pore permeable to small molecules as well as ions (North, 
2002). The significantly longer intracellular C-terminus than other P2X receptors is 
associated with the induction of the non-selective pore (Surprenant et al., 1996). In addition, 
the P2 X7 receptor is the only P2X receptor subunit that is unable to form heteromeric 
assemblies with other P2X receptor subunits (Torres et al., 1999), and thus the P2 X7 receptor 
only exists as a homomer. P2 X7 receptor has also been implicated in mediating apoptosis in 
some tissues (Surprenant et al., 1996; Di Virgilio, 2000; North, 2002).
Exogenous nucleotides modulate the functions of the adult pancreas (Loubatieres-Mariani 
and Chapal, 1988; Petit et al., 2001; Novak et al., 2002). It has been demonstrated that ATP 
stimulates insulin secretion, while adenosine inhibits insulin secretion from p cells and 
stimulates glucagon secretion from a  cells.
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The P2 X7 receptor has been recently detected in a  cells but not the other pancreatic 
endocrine cell types (Coutinho-Silva et al., 2001, 2003). In the present study, we have 
investigated the developmental expression pattern of the P2 X7 receptor. We have made use of 
specific antibodies and an immunofluorescent double labeling method to study the 
spatial-temporal expression of P2 X7 receptor in the early developing pancreas in order to find 
out its relationship with the glucagon and insulin secreting cells.
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MATERIALS AND METHODS
Tissue preparation
Please refer to the section Materials and Methods on Chapter II.
Immunofluorescence double labeling
Please refer to the section Materials and Methods on Chapter III. The primary antibodies 
used were rabbit anti-P2X7 (1:200; Roche Bioscience), goat anti-glucagon (1:50; Santa Cruz 
Biotechnology) and guinea pig anti-insulin (1:500; Inestar Stillwater).
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RESULTS
P2 X7 receptor immunoreactivity was detected in pancreatic islets at El 1 -El 8. The P2 X7 
receptor was first expressed at E ll (Fig 1A), the stage at which glucagon and insulin 
immunoreactivities were not yet detectable (also see Roberts et al., 2001). P2 X7 
receptor-immunoreactive cells were found in the islets, which appear as ovoid cell clusters in 
the pancreas. At E12, both glucagon and insulin started to express in the islets (Figs IB, 1C). 
Double immunofluorescence labeling showed that all the insulin-expressing cells were 
glucagon-positive, whereas some pancreatic cells expressed glucagon only (Fig ID). 
Insulin-expressing cells constituted only a small fraction of cells within the 
glucagon-expressing population at E l2 (Fig ID). Double labeling also showed that all the 
P2 X7 receptor-expressing cells were glucagon positive (Fig IF). Some of the 
glucagon-expressing cells, however, were P2 X7 receptor-negative (Fig IF). At this stage, a 
small number of islet cells were observed co-expressing P2 X7 receptor and insulin, whereas 
some populations expressing either P2 X7 receptor or insulin only were also identified (Fig 1J).
At E l4, expression of glucagon and insulin was detected. Unlike E l2, where all the 
insulin-expressing cells were glucagon-immunopositive, cells that express insulin but not 
glucagon were first appeared at this stage (Fig 2A-2C). All the glucagon-immunoreactive
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cells showed complete co-localization with the P2 X7 receptor (Fig 2D-2F). Similar to that 
observed at E l2, some but not all of the P2 X7 receptor-expressing cells were colocalized with 
insulin-immunopositive cells. Cells expressing either P2 X7 receptor or insulin were also 
observed.
A sharp increase in the population of insulin-expressing cells took place after E14 
(Larsson, 1998). At El 8 , when insulin-secreting p cells became the dominant endocrine cell 
type and outnumbered the glucagon-immunoreactive cells (Fig 3A-3B), the glucagon-positive 
and insulin-positive cells were completely segregated (Fig 3C). The P2 X7 receptor was 
expressed in the glucagon-expressing islet cells, indicated by colocalization of P2 X7 receptor 
and glucagon (Fig 3D-3F). Glucagon-positive, P2 X7 receptor negative cells, though present, 
were very rare (Fig 3F). At this stage, none of the insulin-expressing cells were P2 X7 
receptor-immunopositive (Fig 3G-3I).
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DISCUSSION
The current experiments used a double immunohistochemical method to examine the 
expression of ATP-gated P2 X7 receptor in glucagon and insulin expressing cells during early 
development in the rat pancreas. Glucagon and insulin are secreted hormonal peptides as well 
as common markers for a cells and p cells respectively in both adult and embryonic islets in 
pancreas. Surprisingly, we found that the P2 X7 receptor, which has previously been shown to 
be expressed specifically in glucagon-expressing cells in postnatal as well as in adult pancreas 
(Coutinho-Silva et al., 2001), was detected as early as at E ll ,  the stage at which pancreatic 
cells are still glucagon- and insulin-negative. The early appearance of P2 X7 
immunoreactivity prior to glucagon expression indicates that expression of the P2 X7 receptor 
does not require the presence of glucagon. Whether or not the P2 X7 receptor participates in 
regulation of glucagon expression, however, is not known. Subsequent expression of the 
P2 X7 receptor was shown to be largely associated with glucagon-positive cells but some 
insulin staining cells also expressed P2 X7 receptors. Eventually, P2 X7 receptor expression 
was only detected in mature a  cells containing glucagon (Coutinho-Silva et al., 2001). It has 
been shown that the early islet cell population (before El 4-El 5) consists of glucagon-positive 
cells and glucagon/insulin-coexpressing cells (Larsson, 1998). Our present study and also 
other reports (Herrera et al., 1991; Teitelman et al., 1993; Larsson, 1998) show that all insulin
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expressing cells prior to E l4 belong to the glucagon/insulin-coexpressing cell subpopulation. 
Our results also show that the P2 X7 receptor was expressed in both glucagon-positive and 
glucagon/insulin-coexpressing cells. In view of the finding in the adult pancreas that the 
P2 X7 receptor was restricted to mature a  cells that secrete glucagon only (Coutinho et al., 2001, 
2003), the expression of the P2 X7 receptor in glucagon/insulin expressing cells appears to be 
novel. It is however known that while the glucagon-positive cells will give rise to the mature 
a  cells, the glucagon/insulin expressing cells will not give rise to any of the mature a- or 
P-cells (Herrera, 2000), which are thought to be eliminated by apoptosis (Larsson, 1998). 
Whether the P2 X7 receptor is involved in the elimination of the glucagon/insulin expressing 
cells through apoptosis needs further investigation, but the finding that the P2 X7 receptor are 
not found in all of the glucagon/insulin expressing cells and are observed in glucagon-positive 
cells indicates that the involvement of the P2 X7 receptor in the pancreatic cell death is highly 
unlikely.
Previous studies demonstrated the first appearance of ultrastructurally recognizable p 
cells with a characteristic of insulin-positive and glucagon-negative immunoreactivity at 
E14-E15 (Larsson, 1998). Our present study also found that the insulin-positive and 
glucagon-negative cells first appeared at E l4.
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In summary, we have shown the expression of the P2 X7 receptor early in the embryonic 
pancreas even before expression of hormone peptides, suggesting that expression of P2 X7 
receptor did not depend on the presence of glucagon. Subsequent expression was detected in 
islet cells expressing different endocrine markers. Thus the P2 X7 receptor appears to be one 
of the earliest markers during islet cell development. Besides, transient expression of P2 X7 
receptors in the glucagon and insulin co-expressing cells offers additional insight into whether 
ATP is involved during pancreatic development, in addition to its role in modulating insulin 
secretion.
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FIGURES & LEGENDS
Figure 1 Immunohistochemistry of P2X7 receptor, glucagon and insulin in islets of the 
E ll-E l 2 pancreas. (A) P2X7 receptor-immunoreactive cells (red) are expressed in clusters in 
E ll  pancreas. (B) Immunoreactivity of glucagon-expressing cells (red); (C)
insulin-expressing cells (green), and (D) colocalization of glucagon and insulin (yellow). 
(E-G) Double labeling of glucagon and P2X7 receptor. (E) Glucagon expression (red) and (F) 
P2X7 receptor expression (green). (G) Colocalization of glucagon and P2X7 receptor 
(yellow). (H) P2X7 receptor expression (red); (I) insulin expression (green) and (J) 
colocalization of P2X7 receptor and insulin (yellow). Scale bar = 100pm (A, E-J) and 114pm 
(B-D).
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Figure 2 Immunohistochemistry of P2 X7 receptor, glucagon and insulin in islets of the E l4 
pancreas. (A) Immunoreactivity of glucagon-expressing cells (red), (B) insulin-expressing 
cells (green). (C) Colocalization of glucagon- and insulin-expressing cells (yellow). (D) 
P2 X 7 receptor immunoreactive cells (red). (E) Glucagon-expressing cells (green) and (F) 
colocalization of glucagon and P2 X7 receptor (yellow). (G) P2 X7 immunostaining (red), (H) 
insulin immunostaining (green). (I) Colocalization of P2 X7 receptor (yellow). Scale bar = 
1 0 0 pm.
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Figure 3 Immunohistochemistry of P2 X7 receptor, glucagon and insulin in islets of the E l 8 
pancreas. (A) Immunoreactivity of glucagon-expressing cells (red), (B) insulin-expressing 
cells (green), and (C) colocalization of glucagon and insulin (yellow); (D) P2 X7 receptor 
immunoreactive cells (red), (E) glucagon and insulin expressing cells (green), and (F) 
colocalization of P2 X7 and glucagon (yellow); (G) P2 X7 immunoreactive cells (red), (H) 
Insulin expressing cells (green) and (I) colocalization of P2 X7 and insulin (yellow). Scale bar 
= 1 0 0 pm.
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Chapter VII. General Discussion and Conclusion
VII. 1 Introduction
Fundamental questions in developmental biology concern (1) what genes are expressed; 
(2) where and when they are expressed and turned off; (3) the regulatory programs that govern 
the gene expression; (4) and ultimately, why they are expressed. The vast majority of events 
take place in embryos, with many genes expressed in a dynamic sequential manner, making 
development a complex and highly integrated process. ATP has an intracellular role in energy 
storage and release, as well as extracellular roles in mediating wide ranges of physiological 
activities (see review Abbracchio and Burnstock, 1998; Burnstock, 2002b). Extracellular 
activities of ATP and related nucleotides (ADP, UTP and UDP) are mediated by activation of 
two families of P2 receptors, the ionotropic P2X receptors and the metabotropic P2 Y receptors 
(Abbracchio and Burnstock, 1994). Cloning of over 50 P2 receptor subtypes in different 
species for the past decade (Burnstock, 2003a) has increased our knowledge of the P2 
receptor-mediated signaling. It is expected that purinergic signaling pathways would be 
involved in embryonic development (see Burnstock, 2001.
During development of the early mammalian embryos, the process of gastrulation
determines the embryonic body axis and, in addition, generates three distinctive germ layers,
namely ectoderm, mesoderm and endoderm. There are two types of ectodermal tissues, the
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neuroectoderm and the surface ectoderm. While the neuroectoderm gives rise to tissues of 
both the central and peripheral nervous system, the surface ectoderm will form the skin. 
Mesoderm gives rise to several types of tissues, such as musculo-skeletal, cardiovascular and 
urogenital tissues. Endoderm gives rise mainly to the tissues of the viscera, including those 
of the digestive and respiratory systems. The results of the present study have demonstrated 
that P2 receptors are widely expressed throughout the three germ layers during development. 
The spatial-temporal expression pattern of the P2 receptors in each germ layer, together with 
the possible roles during development, will be discussed below.
VII. 2 P2 receptors in ectoderm-derived tissues
Nervous system
Activation of P2X receptors involves depolarization of plasma membrane and activation 
of voltage-dependent Ca2+ influx, resulting in an increase in intracellular free Ca2+ 
concentration. In addition, during early development changes in intracellular Ca2+ can alter 
growth cone motility and the rate of neurite outgrowth (Mattson and Kater, 1987), neural 
migration (Komuro and Rakic, 1996) and neural phenotype (Marty et al., 1996). Therefore, 
we investigated the expression pattern of P2X receptors during embryonic neurogenesis. 
Surprisingly, the P2 X2 , P2 X4  and P2X6 receptors, which are widely distributed in adult brains 
(see Burnstock, 2003b), were absent in early embryonic neural tube. It was the homomeric
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P2 X3 receptor that showed early expression in embryonic branchiomotor/visceromotor 
(BM/VM) neurons in the neural tube as well as in cranial ganglia. As development proceeded, 
the P2 X3 receptor was detected in the facial motor nucleus in the hindbrain, which raised the 
question of whether the cranial motor neurons showing P2 X3 -immunoreactivity were the facial 
branchiomotor neurons. The spatial-temporal expression pattern of P2 X3 receptors in the 
cranial motor neurons suggested that it might be involved in neurite outgrowth. Both 
ap-meATP and ATP, agonists to the P2 X3 receptor, showed significant inhibition of neurite 
extension. UTP did not mimic the inhibitory effect of ATP; therefore, it is unlikely that P2 Y2  
and P2 Y4  receptors were involved, even though these receptors were expressed in the 
embryonic spinal nerves. The stability of ap-meATP also ruled out the possibility of an 
adenosine-mediated response. ATP has been shown to inhibit NCAM-expressing neurites 
(Skladchikova et al., 1999). Our results showed that the embryonic cranial motor axons 
expressed NCAM, and the ATP-mediated inhibitory effects on NCAM-expressing axons 
further indicated that ATP might interact with NCAM in the process of axon outgrowth in 
embryonic cranial motor neurons, most likely via P2 X3 receptor. The process of axon 
guidance appears to be very complex, involving different types of signaling molecules acting 
in concert to direct pathfinding (Tessier-Lavigne and Goodman, 1996). Our results 
demonstrated that ATP has an inhibitory effect on neurite outgrowth from cranial neural tube. 
However, no experiments were carried out to see if ATP had any effect on axon guidance.
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Several questions arise: does the inhibitory effect of ATP reflect the rejection of cranial motor 
axons to particular tissues from the environment that release ATP? What is the source of ATP 
surrounding the neural tube? Is this inhibitory effect due to a reduction in length of BM/VM 
axons? Identifying the in vivo source of ATP together with the use of specific markers for 
different types of motor axons will be crucial in uncovering the role of purinergic signaling in 
embryonic axon pathfinding.
The expression of P2 X3 receptor was also prominent in a number of neural crest-derived 
tissues, including trigeminal, facioacoustic, glossopharyngeal-vagal, dorsal root and 
sympathetic ganglia, mesencephalic trigeminal nucleus. Enteric neurons in the adult guinea 
pig also show P3 X3 receptor expression (Van Nassauw, et al., 2002; see Burnstock, 2003b). 
Other neural-crest derived tissues which are non-neural, such as melanocytes, dermal bones of 
skull, odontoblasts and the pharyngeal arches cartilages, all show absence of P2 X3 receptor 
expression throughout life. It seems that the onset of P2 X3 receptor expression begins after 
the migrating neural crest cells arrive at their presumptive destination and are committed into a 
neural fate. P2 X3 receptor-deficient mice showed an impaired response towards 
inflammatory pain (Cockayne et al., 2000) and peristalsis (Bian et al., 2003), whereas loss or 
atrophy of neurons was never reported in the transgenic model, suggesting that P2 X3 receptor 
expression is important for the function, but not the survival of neurons.
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The P2 X2 and receptor expression was detected in the nucleus tractus solitarius in E l4 rat 
brain. Results from double labeling experiments indicated that the P2 X2 receptor was 
largely, if not entirely, colocalized with the P2 X3 receptor. It is very likely that the two 
receptors formed P2 X2 /3  heteromers in the nucleus tractus solitarius. In contrast, the nodose 
and the dorsal root ganglia showed an incomplete colocalization of P2 X2  and P2 X3 receptors. 
It is known that the P2 X2 /3  heteromers differ from the homomeric P2 X2  and P2 X3 receptors in 
the response towards ATP, especially in the aspects of desensitization (Liu et al., 2001, 
Koshimizu et al., 2002). The variable extent of involvement between the P2 X2 and P2 X3 in 
the formation of the P2 X2 /3  heteromers may thus contribute to different effects of 
ATP-mediated activities.
The P2 X7 receptor was expressed in the rat hypothalamus from E l4 onwards, slightly 
earlier than the appearance of the functional glutamate receptor in the embryonic hypothalamus 
(at E l5) (van den Pol et al., 1995). Sperlagh et al. (2002) demonstrated that ATP regulates
glutamate release via activation of P2 X7 receptors, and excessive glutamate release altered the
2+  •  •  •  • • •Ca homeostasis, resulting in activation of apoptosis-related gene (e.g caspase) (see review Le
Feuvre et al., 2002). In vitro studies on the embryonic hippocampal neurons also showed that 
glutamate release upon reactive oxygen species induced activation of glutamate receptor
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(NMDA receptor), which then activated caspases and in turn triggered apoptosis (Ishikawa et 
al., 1999). Given that ATP-mediated apoptosis involved activation of P2 X7 receptor (see 
review Le Feuvre et al., 2002), it seems likely that the activation of P2 X7 receptor is also 
involved in cell death during neurogenesis, but this possibility awaits further investigation.
The P2 X4 , P2 X5 and P2X6 receptors were not detected in the developing brain until the 
late embryonic period, between E18-P1. P2X6 receptor expression was shown in the lateral 
hypothalamus of PI brain. P2X6 receptors have been implicated in hormone release from 
axon terminals as well as recycling of the granular vesicles and microvesicles in the adult 
hypothalamo-neurohypophysial system (Loesch and Bumstock, 2001). P2 X4  and P2 X5 
receptors were both detected in the subventricular zone (SVZ) of the embryonic striatum. 
The SVZ was previously demonstrated to be a site of postnatal neurogenesis (Conover and 
Allen, 2002). P2 X4  and P2 X5 receptors labeled two different types of cells in the SVZ; the 
round-shaped, cytoplasmic-stained, P2 X4  receptor immunoreactive cells, and the 
pyramidal-shaped, nuclear and cytoplasmic-stained, P2 X5 receptor immunoreactive cells. 
Doetsch et al. (1999) and Laywell et al. (2000) showed that the subventricular (SV) astrocytes 
are the neural stem cells that give rise to both neurons and glia. Other results suggest that it is 
the ependymal cells that generate multipotent neurospheres (Johansson et al., 1999). It would 
be interesting to use double-labeling to examine the identity of the P2Xs
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receptor-immunoreactive cells in the SVZ to see if they are SV astrocytes or ependymal cells. 
P2 X4  receptor-immunoreactive cells, however, resemble migrating neuroblasts rather than the 
morphologically distinctive astrocytes or ependymal cells. The P2Xi receptor, according to 
our result, was not expressed before P I 6 . It has been demonstrated previously that P2Xi 
receptors are expressed in the adult rat cerebellum (Loesch and Bumstock, 1998; Florenzano et 
al., 2 0 0 2 ) and upregulation of the receptor was observed in the precerebellar neurons that 
survived after cerebellar injury (Florenzano et al., 2002). It is not clear whether the 
upregulation is important for post-injured cell survival or a consequence of axotomy. 
Although P2Xi receptor expression was unlikely to be involved in embryonic neurogenesis, its 
potential role in either cell survival or regeneration after injury would be worth investigating.
In addition, the P2X receptor involvement in embryonic neurogenesis, G-protein coupled 
P2Y receptor expression was also detected in the embryonic nervous system. We have 
observed an early expression of P2 Y2  and P2 Y4  receptors in the ventral neural tube. The 
P2 Y2 receptor was expressed in the spinal motor neurons and the ventrally migrating motor 
axons. The P2 Y4  receptors, however, were only found in the spinal motor neurons. Absence 
of inhibitory effects by UTP suggested that ATP-induced effects were not mediated by P2 Y2 or 
P2 Y4  receptors. Nevertheless, the distinct expression pattern of P2 X3 , P2 Y2  and P2 Y4  
receptors in the ventral neural tube raises the question of whether there is any interaction
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between ATP signaling and the well known ventral-patteming signals such as Sonic Hedgehog 
(Shh) and Pax 6  (Goulding et al., 1993; Mansouri et al., 1996; Dodd et al., 1998, Litingtung 
and Chiang, 2000). Among the P2Y receptor examined, the P2 Y4  receptor appeared to be the 
dominant receptor in the developing brain. Although the exact function of the P2 Y4  receptor 
during neurogenesis was unknown, the transient expression (at least in the medulla) suggests a 
role during development.
Taken together, our results suggest that ATP is involved during neurogenesis in both 
prenatal and postnatal animals. While the P2 X2 , P2 X4  and P2X6 receptors are dominant in the 
neonatal as well as adult brain, P2 X3 receptors appeared to play a more important role during 
embryonic neurogenesis. Despite a transient and dynamic expression of P2 X3 receptors in the 
embryonic brain especially in the motor neurons, the early expression in the cranial sensory 
ganglia persists after birth. Nevertheless, purinergic signaling via P2X receptor activation 
appears to be complex and fine-tuned, for each of the receptors are expressed in a 
spatial-temporal manner.
The present study also showed distinct localization of P2 X2  and P2Y1 receptors in the 
notochord and the floor plate, respectively. The notochord is situated just beneath the neural 
tube, while the floor plate is at the ventral midline. Although the notochord and the floor
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plate were not considered to be neuronal structures, they are known to exert major effects on 
neurogenesis (Placzek, 1995; Bronner-Fraser and Fraser, 1997). Both the notochord and the 
floor plate secrete Shh, which is a powerful signaling molecule involved in ventral patterning 
of the neural tube (Goulding et al., 1993; Dodd et al., 1998, Litingtung and Chiang, 2000). 
Shh first secretes from the notochord and then from the floor plate. Shh regulates one of the 
transcription factors Pax 6 gene, and both of them act in a concentration dependent manner in 
promoting the differentiation of the neurons in the ventral neural tube to become motor 
neurons. This is the first report demonstrating P2 receptor expression in the notochord and 
floor plate. It would be interesting to look at the interaction between the Shh, Pax and 
purinergic signaling.
VII.3 P2 receptors in mesoderm-derived tissues 
VIL3.a Somites and skeletal muscles
Following gastrulation, the paraxial mesodermal tissues on either side of the embryos in a 
position lateral to the neural tube segregate from the rest of the mesoderm and form the 
well-defined tissue blocks, the somites. Shortly after it has formed, each somite undergoes a 
mesenchyme-to-epithelial transition, and the epithelialized somite becomes partitioned into 
presumptive sclerotome (ventromedial) and dermomyotome (dorsolateral) regions, in a 
rostral-caudal direction. The dermomyotome will give rise to myotome (forming skeletal
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muscle) and the dermatome (forming dermis).
Although the P2Yi, P2 Y2 and P2 Y4  receptors in our study were all expressed early in the 
myotome and later in the developing skeletal muscle, their fate appeared to be quite different. 
Whereas P2 Y4  receptor expression was sustained in postnatal skeletal muscle, the P2Yj and 
P2 Y2 receptors were no longer expressed. Instead, P2Yi receptor was located in the smooth 
muscle of the blood vessels and P2 Y2 receptors appeared to be expressed in satellite cells. 
Neonatal satellite cells showed a concentration-dependent proliferation upon UTP treatment 
(Ryten et al., 2002), suggesting that P2 Y2 receptor activation by UTP was likely to participate 
in satellite cell proliferation, which is very important in the response to muscle damage. It is 
equally possible that UTP (and possibly ADP via P2Yi receptors) are also involved in 
proliferation during embryonic myogenesis. The present results suggest future studies of the 
interaction between extracellular nucleotides and myogenic signaling molecules such as Pax 3, 
MyoD and Myf5 (Tajbakhsh et al., 1997; Buckingham, 2001; Chi and Epstein, 2002; 
Buckingham et al., 2002).
Choi et al (2002) showed a colocalization of P2Yi receptor with the acetylcholine 
receptor. In the present study, however, colocalization of P2Y receptor subtypes with 
acetylcholine receptors in the neuromuscular junction was not observed. It may be that the
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difference in the antibodies used in the two studies accounts for the discrepancy. We used a 
commercial rat-specific antibody, while the one used by Choi et al (2002) was prepared against 
chick receptor. The P2Yi receptor expression in our study was downregulated in the 
embryonic skeletal muscle as development proceeded, which was in agreement with a 
downregulation of chick P2Yi receptor mRNA transcript in embryonic skeletal muscle 
reported by Meyer et al. (1999a).
In addition to expression studies, functional studies also showed that upon ATP treatment, 
the isolated skeletal muscle cells from mouse embryos demonstrated P2X receptor-like 
responses (Collet et al., 2002). The response to ATP was developmentally regulated, as the 
amplitude of responses was decreased during early postnatal stages. The responses were 
completely lost in adult skeletal muscle cells, indicating that the ATP-induced responses were 
stage-specific. Altogether, the dynamic expression of P2Yi, P2 Y2 and P2 Y4 receptors in 
somites and in the developing skeletal muscle, the transient expression of the P2 X5 receptor in 
the embryonic skeletal muscle tissue and its role in inducing satellite cell differentiation (Ryten 
et al., 2001; 2002), strongly suggests that ATP is involved in regulation of skeletal muscle 
development as well as regeneration.
VII. 3. b Heart
218
Chapter VII General discussion and conclusion
The heart originates from paired cardiac mesodermal primordia which fuse in the midline 
to produce a primitive heart tube (Yutzey and Bader, 1995). The heart tube then undergoes a 
series of remodeling steps, including looping, trabeculation, septation, and development of 
spiral outflow tracts (Larsen, 1998). Extracellular ATP and adenosine are known to have 
powerful actions on cardiomyocytes (Olsson and Pearson, 1990; Ralevic and Bumstock, 1991; 
Pelleg and Belardinelli, 1998; Vassort, 2001). Previous studies showed that subtypes of PI 
adenosine receptors were expressed in the embryonic cardiomyocytes (Hofman et al., 1997; 
Zhao and Rivkees, 2001; Zhao et al., 2002). It was therefore interesting to investigate if 
subtypes of P2 receptor were also expressed in particular stages of heart development. The 
present results showed that P2 X2  and P2Yi, P2 Y2 , and P2 Y4 receptors were expressed in the 
myocardium at E l2, the stage at which trabeculation and septation are in progress (Franco et 
al., 1998). Studies on Ca2+ influx, together with RT-PCR and immunocytochemistry, have 
identified particular subtypes of P2X (P2 X2 , P2 X4 , P2 X7) and P2Y (P2Yi, P2 Y2 , P2 Y4 , P2Y6) 
receptors in embryonic cardiomyocytes at E l4, followed by P2Xi, P2 X3 and P2 X5 receptors at 
E l 8 . Identification of P2 X7 receptor in the cardiomyocytes appears to be novel. Although 
P2Y receptor-mediated responses were observed in the cardiomyocytes at both E l4 and E l 8 , 
immunohistochemical studies showed that the P2Yi, P2 Y2 , P2 Y4  receptor subtypes, while 
widely expressed throughout the myocardium, gradually became restricted to the trabeculated 
myocardium but not to the compact myocardium. Differences in the proliferation capacity
219
Chapter VII General discussion and conclusion
between the compact layer and the trabeculated layer of the myocardium (Sedmera et al., 2000) 
may provide a clue to the functional role of P2Y receptor activation. Trabeculations are 
important in enhancing contractility (Challice and Viragh, 1973) and in coordinating 
intraventricular conduction (de Jong et al., 1992). However, preliminary results have shown 
that treatment of cultured embryonic cardiomyocytes with ATP, ADP, UTP and UDP did not 
affect cell proliferation (unpublished data). P2X receptors are expressed in embryonic as well 
as adult cardiomyocytes. Persistent expression of P2X receptors did not necessarily reflect 
the absence of dynamic expression patterns. In situ labeling of the P2X receptors in the 
embryonic hearts during development should further be examined. It is possible that P2X 
receptors regulate particular physiological activities which are important in embryonic as well 
as in adult cardiomyocytes (Pelleg and Belardinelli, 1998).
VII.4 P2 receptors in endodermal-derived tissues 
Pancreas
We have shown in the present study that one of the P2X receptors, the P2 X7 receptor, was 
expressed in developing endodermal tissue, the embryonic pancreas. The study was focused 
on the endocrine tissues, i.e. the islets of Langerhans. The major hormones present are insulin 
secreted from p cells, somatostatin from 8 cells and glucagon from a cells. Previously, our 
group has demonstrated the expression of P2 X7 receptor to be restricted to a cells raising the
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question of whether P2 X7 receptor expression depends upon the presence of glucagon. The 
present results showed that i) the possibility of glucagon-driven P2 X7 receptor expression was 
ruled out; ii) P2 X7 receptor expression was not limited to glucagon-expressing cells during 
early development; and iii) colocalization of P2 X7 receptor with insulin was transient. It is 
reasonable to speculate that the P2 X7 and glucagon positive cells (insulin negative) at both E l2 
and E l4 would give rise to a cells, whereas the insulin-positive and P2 X7 negative (also 
glucagon negative) cells would give rise to p cells. Given that the early islet cells are all 
glucagon-positive (at E l2), two additional types of cells were identified which were the 
glucagons/insulin/P2X7 receptor coexpressing cells (i.e P2 X7 receptor-positive) and 
glucagons/insulin coexpressing cells (i.e. P2 X7 receptor-negative). Information is missing 
regarding to the identity of these cells, although these multihormonal cells would not give rise 
to either mature a or p cells and appeared to be eliminated in later development (Larsson, 1998; 
Herrera, 2000). The possibility of P2 X7 receptor control of glucagon-release appears to be 
unlikely, and previous studies have shown that glucagon release is regulated by adenosine, 
while insulin secretion is stimulated by ATP via P2Y receptor-mediated pathway 
(Loubatieres-Mariani and Chapal, 1988; Loubatieres-Mariani et al., 1997). Previous studies 
on P2 X7 receptor-deficient mice did not report any pancreatic-related abnormalities (Labasi et 
al., 2002; Ke et al., 2003). Further studies using in vitro culture systems would be an 
appropriate approach, together with the application of ATP or manipulation of P2 X7 receptor
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expression (either overexpressed receptor transcripts, or suppressed transcripts by means of 
RNA interference techniques) to examine the roles of P2X7-mediated signaling. Coutinho et 
al (2003) have demonstrated the expression of the P2 Y4 receptor in both a  and P cells in adult 
pancreas. Examination on the P2 Y4  receptor expression in the developing pancreas will 
probably provide a more complete picture about how ATP regulates the development of 
pancreatic islets.
VII.5 Concluding Remarks
In conclusion, our study has demonstrated for the first time the widespread expression 
pattern of P2X and P2Y receptor subtypes during rat embryonic development. The 
expression pattern of P2 receptor subtypes was not restricted to a particular tissue or system but 
included all the three germ layers. Dynamic and transient expression for particular receptors 
was observed in different tissues (for example, the P2 X3 receptor in cranial motor neurons; the 
P2 X2 receptor in notochord; the P2 X7 receptor in pancreatic insulin-expressing cells; the P2Y1 
receptor in the floor plate; the P2 Y4  receptor in the brainstem; the P2Xs, P2Yi, P2 Y2  and P2 Y4  
receptors in somites in developing skeletal muscle; and the P2Yi, P2 Y2 and P2 Y4  receptors in 
the compact layer of myocardium). It appears that ATP acting on P2X and P2Y receptor 
subtypes regulates organogenesis during embryonic development.
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Table 1: Prim er sequence for P2X and P2Y receptors in RT-PCR analysis
Receptor Prim er sequence (5’ to 3’) Prim er
position
Product 
length (bp)
P2Xi forward GAAGTGTGATCTGGACTGGCACGT 776-801 452
P2Xi reverse GCGTCAAGTCCGGATCTCGACTAA 1203-1231
P2 X2 forward GAATCAGAGTGCAACCCCAA 826-845 357
P2 X2  reverse TCACAGGCCATCTACTTGAG 1183-1164
P2 X3 forward TGGCGTTCTGGGTATTAAGATCGG 708-731 440
P2 X3 reverse CAGTGGCCTGGTCACTGGCGA 1126-1147
P2 X4  forward GAGGCATCATGGGTATCCAGATCAAG 749-774 447
P2 X4  reverse G AGCGGGGT GG A AAT GTAACTTTAG 1170-1195
P2 X 5 forward GCCGAAAGCTTCACCATTTCCATAA 553-577 418
P2 X5 reverse CCTACGGC ATCCGCTTT GAT GT G ATAG 944-970
P2X6 forward AAAGACTGGTCAGTGTGTGGCGTTC 444-468 520
P2X6 reverse T GCCTGCCC AGT G AC AAG AAT GT C A A 938-963
P2 X7 forward GTGCCATTCTGACCAGGGTTGTATAAA 384-410 354
P2 X7 reverse GCC ACCTCT GTAAAGTT CTCTCCG ATT 711-737
P2Yi forward ACGTCAGATGAGTACCTGCG 1235-1254 289
P2 Y 1 reverse CCCTGTCGTTGAAATCACAC 1504-1523
P2 Y2 forward CTGGTCCGCTTTGCCCGAGATG 1417-1438 311
P2 Y2 reverse TATCCTGAGTCCCTGCCAAATGAGA 1703-1727
P2 Y4 forward TGTTCCACCTGGCATTGTCAG 1586-1586 294
P2 Y4  reverse AAAGATTGGGCACGAGGCAG 1840-1859
P2Y6 forward TGCTTGGGTGGTATGTGGAGTC 868-889 339
P2Y6 reverse CAATAGTCGAAGGACGGAAAGGT 1184-1206
Shibuya et al (1999); Bailey et al. (2000, 2001)
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Table 2: Peptide sequence for raising the polyclonal antibodies against P2X
and P2Y receptor subtypes
Receptor antibody Peptide position Amino acid sequence
Roche Antibodies
Rabbit-anti-rat P2Xi 385-399 ATS STLGLQENMRTS
Rabbit-anti-rat P2 X2 458-472 QQDSTSTDPKGLAQL
Rabbit-anti-rat P2 X3 383-397 VEKQSTDSGAYSIGH
Rabbit-anti-rat P2 X4 374-388 YVEDYEQGLSGEMNQ
Rabbit-anti-rat P2 X5 437-451 RENAIVNVKQSQILH
Rabbit-anti-rat P2X6 357-371 EAGFYWRTKYEEARA
Rabbit-anti-rat P2 X7 555-569 TWRFVSQDMADFAIL
Alomone antibodies
Rabbit-anti-rat P2 Y 1 242-258 RALIYKDLDN SPLRRKS
Rabbit-anti-rat P2 Y2 227-244 KPAY GTTGLPRAKRKSVR
Rabbit-anti-rat P2 Y4 337-350 HEESISRWADTHQD
Rabbit-anti-rat P2 X7 576-595 KIRKEFPKTQGQYSGFKYPY
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